

T cell exhaustion

Nature Immunology

12, 492-499

DOI: [10.1038/ni.2035](https://doi.org/10.1038/ni.2035)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions. <i>Journal of Immunology</i> , 2008, 181, 7660-7669.	0.4	181
2	Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load. <i>Immunity</i> , 2011, 35, 285-298.	6.6	141
3	Next-generation leukemia immunotherapy. <i>Blood</i> , 2011, 118, 2951-2959.	0.6	65
4	Understand memory, design better vaccines. <i>Nature Immunology</i> , 2011, 12, 463-465.	7.0	43
5	Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8+ T cells during cytomegalovirus infection. <i>Immunologic Research</i> , 2011, 51, 195-204.	1.3	33
6	PD-1 co-stimulation contributes to ligand-induced T cell receptor downmodulation on CD8 ⁺ T cells. <i>EMBO Molecular Medicine</i> , 2011, 3, 581-592.	3.3	234
7	An MHC Class Ib-Restricted CD8+ T Cell Response to Lymphocytic Choriomeningitis Virus. <i>Journal of Immunology</i> , 2011, 187, 6463-6472.	0.4	7
8	Late Interleukin-6 Escalates T Follicular Helper Cell Responses and Controls a Chronic Viral Infection. <i>Science</i> , 2011, 334, 825-829.	6.0	302
9	Manipulation of Costimulatory Molecules by Intracellular Pathogens: Veni, Vidi, Vici!!. <i>PLoS Pathogens</i> , 2012, 8, e1002676.	2.1	62
10	PD-L1-Expressing Dendritic Cells Contribute to Viral Resistance during Acute HSV-1 Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	17
11	Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-22.	3.3	33
12	CD28 ligation increases macrophage suppression of T-cell proliferation. <i>Cellular and Molecular Immunology</i> , 2012, 9, 341-349.	4.8	8
14	Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression. <i>Clinical Cancer Research</i> , 2012, 18, 1925-1935.	3.2	94
15	Therapeutic Blockade of Transforming Growth Factor Beta Fails To Promote Clearance of a Persistent Viral Infection. <i>Journal of Virology</i> , 2012, 86, 7060-7071.	1.5	37
16	Deconvolving heterogeneity in the CD8+ T-cell response to HIV. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 38-43.	1.5	1
17	Memory T cells and their exhaustive differentiation in allograft tolerance and rejection. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 15-19.	0.8	18
18	A Novel Role for Type 1 Angiotensin Receptors on T Lymphocytes to Limit Target Organ Damage in Hypertension. <i>Circulation Research</i> , 2012, 110, 1604-1617.	2.0	109
19	Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral Infection. <i>Journal of Virology</i> , 2012, 86, 8161-8170.	1.5	233

#	ARTICLE	IF	CITATIONS
20	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. <i>Journal of Experimental Medicine</i> , 2012, 209, 2113-2126.	4.2	130
21	A molecular profile of T-cell exhaustion in cancer. <i>Oncolmmunology</i> , 2012, 1, 369-371.	2.1	6
22	Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection. <i>Journal of Experimental Medicine</i> , 2012, 209, 1481-1492.	4.2	79
23	Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3389-3398.	0.9	19
26	FOXO3 Regulates the CD8 T Cell Response to a Chronic Viral Infection. <i>Journal of Virology</i> , 2012, 86, 9025-9034.	1.5	40
27	State-of-the-Art Monitoring of Cytomegalovirus-Specific Cell-Mediated Immunity After Organ Transplant: A Primer for the Clinician. <i>Clinical Infectious Diseases</i> , 2012, 55, 1678-1689.	2.9	128
28	Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. <i>Nature Immunology</i> , 2012, 13, 188-195.	7.0	438
29	Self-boosting vaccines and their implications for herd immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20154-20159.	3.3	18
30	Differential Roles for RIG-I-like Receptors and Nucleic Acid-Sensing TLR Pathways in Controlling a Chronic Viral Infection. <i>Journal of Immunology</i> , 2012, 188, 4432-4440.	0.4	26
31	CD8 T Cells Recruited Early in Mouse Polyomavirus Infection Undergo Exhaustion. <i>Journal of Immunology</i> , 2012, 188, 4340-4348.	0.4	21
32	CD8 T cell memory: it takes all kinds. <i>Frontiers in Immunology</i> , 2012, 3, 353.	2.2	13
33	Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	78
34	Defective CD8 T Cell Responses in Aged Mice Are Due to Quantitative and Qualitative Changes in Virus-Specific Precursors. <i>Journal of Immunology</i> , 2012, 188, 1933-1941.	0.4	126
35	Cell-Intrinsic Abrogation of TGF- β 2 Signaling Delays but Does Not Prevent Dysfunction of Self/Tumor-Specific CD8 T Cells in a Murine Model of Autochthonous Prostate Cancer. <i>Journal of Immunology</i> , 2012, 189, 3936-3946.	0.4	22
36	Inhibitory Receptors on Lymphocytes: Insights from Infections. <i>Journal of Immunology</i> , 2012, 188, 2957-2965.	0.4	145
37	Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. <i>Blood</i> , 2012, 119, 5758-5768.	0.6	156
38	Therapeutic vaccination against chronic hepatitis C virus infection. <i>Antiviral Research</i> , 2012, 96, 36-50.	1.9	26
39	Role of the PD-1 Pathway in the Immune Response. <i>American Journal of Transplantation</i> , 2012, 12, 2575-2587.	2.6	348

#	ARTICLE	IF	CITATIONS
40	Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory. <i>Immunity</i> , 2012, 37, 1130-1144.	6.6	480
41	Interleukin-27: Balancing Protective and Pathological Immunity. <i>Immunity</i> , 2012, 37, 960-969.	6.6	231
42	Infected CD8 ⁺ dendritic cells are the predominant source of IL-10 during establishment of persistent viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14116-14121.	3.3	48
43	Gone baby gone—but how?. <i>Blood</i> , 2012, 120, 4664-4666.	0.6	0
44	Telomeres and immune competency. <i>Current Opinion in Immunology</i> , 2012, 24, 470-475.	2.4	62
45	Modulation of MHC Binding by Lateral Association of TCR and Coreceptor. <i>Biophysical Journal</i> , 2012, 103, 1890-1898.	0.2	9
46	Progenitor and Terminal Subsets of CD8 ⁺ T Cells Cooperate to Contain Chronic Viral Infection. <i>Science</i> , 2012, 338, 1220-1225.	6.0	760
47	A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. <i>Critical Care</i> , 2012, 16, R112.	2.5	187
48	A rapidly progressing lymphocyte exhaustion after severe sepsis. <i>Critical Care</i> , 2012, 16, 140.	2.5	27
49	Th2 responses in schistosomiasis. <i>Seminars in Immunopathology</i> , 2012, 34, 863-871.	2.8	99
50	T cell exhaustion in protozoan disease. <i>Trends in Parasitology</i> , 2012, 28, 377-384.	1.5	71
51	Proinflammatory Characteristics of SMAC/DIABLO-Induced Cell Death in Antitumor Therapy. <i>Cancer Research</i> , 2012, 72, 1342-1352.	0.4	32
52	Thinking inside the box: how T cell inhibitory receptors signal. <i>Nature Medicine</i> , 2012, 18, 1338-1339.	15.2	9
53	SAM-pointed domain ETS factor mediates epithelial cell intrinsic innate immune signaling during airway mucous metaplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16630-16635.	3.3	45
54	Memory T cell inflation: understanding cause and effect. <i>Trends in Immunology</i> , 2012, 33, 84-90.	2.9	140
55	T cells in helminth infection: the regulators and the regulated. <i>Trends in Immunology</i> , 2012, 33, 181-189.	2.9	166
56	The three main stumbling blocks for anticancer T cells. <i>Trends in Immunology</i> , 2012, 33, 364-372.	2.9	127
57	Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8 ⁺ T Cell Exhaustion and Chronic Viral Infection. <i>Cell Host and Microbe</i> , 2012, 11, 631-642.	5.1	140

#	ARTICLE	IF	CITATIONS
58	Tim-3, a negative regulator of anti-tumor immunity. <i>Current Opinion in Immunology</i> , 2012, 24, 213-216.	2.4	175
59	Peroxiredoxin II Regulates Effector and Secondary Memory CD8 ⁺ T Cell Responses. <i>Journal of Virology</i> , 2012, 86, 13629-13641.	1.5	12
60	Transcriptional control of effector and memory CD8 ⁺ T cell differentiation. <i>Nature Reviews Immunology</i> , 2012, 12, 749-761.	10.6	1,203
61	Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral Immunity. <i>Immunity</i> , 2012, 37, 158-170.	6.6	817
62	Antigen amount dictates CD8 ⁺ T cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell. <i>European Journal of Immunology</i> , 2012, 42, 2290-2304.	1.6	51
63	CD8 ⁺ T cell exhaustion due to persistent antigen: Quantity not quality?. <i>European Journal of Immunology</i> , 2012, 42, 2285-2289.	1.6	14
64	Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection. <i>Veterinary Research</i> , 2012, 43, 45.	1.1	27
65	Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. <i>BMC Cancer</i> , 2012, 12, 580.	1.1	24
66	Inflammatory events during murine squamous cell carcinoma development. <i>Journal of Inflammation</i> , 2012, 9, 46.	1.5	29
67	Mouse models of sarcomas: critical tools in our understanding of the pathobiology. <i>Clinical Sarcoma Research</i> , 2012, 2, 20.	2.3	19
68	Anti-tumor immunity: Myeloid leukocytes control the immune landscape. <i>Cellular Immunology</i> , 2012, 278, 21-26.	1.4	19
69	Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. <i>Mathematical Modelling of Natural Phenomena</i> , 2012, 7, 78-104.	0.9	43
70	Combating chronic T-cell exhaustion. <i>Immunotherapy</i> , 2012, 4, 557-560.	1.0	2
71	Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 143, 637-645.	0.6	257
72	Immunology of hepatitis C virus infections. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 391-400.	1.0	21
73	Cytokine production and dysregulation in HIV pathogenesis: Lessons for development of therapeutics and vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 181-191.	3.2	61
74	Sustained Rap1 activation in autoantigen-specific T lymphocytes attenuates experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2012, 250, 35-43.	1.1	7
75	IL-7 and IL-15 do not synergize during CD8 T cell recall response against an obligate intracellular parasite. <i>Microbes and Infection</i> , 2012, 14, 1160-1168.	1.0	8

#	ARTICLE	IF	CITATIONS
76	Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. <i>Nature Medicine</i> , 2012, 18, 1394-1400.	15.2	303
77	Graduate Theses and Dissertations. , 2012, , 63-79.		13
78	Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing. <i>Molecular Therapy</i> , 2012, 20, 1242-1250.	3.7	107
79	Traitement par lymphoth�rapie adoptive des infections virales chez les patients transplant�s : de r�elles raisons d'esp�rer. <i>Revue Francophone Des Laboratoires</i> , 2012, 2012, 83-92.	0.0	0
80	Diagnostic performance of multiplex cytokine and chemokine assay for tuberculosis. <i>Tuberculosis</i> , 2012, 92, 513-520.	0.8	38
81	T cell responses in hepatitis C: the good, the bad and the unconventional. <i>Gut</i> , 2012, 61, 1226-1234.	6.1	126
82	Downregulation of the AU-Rich RNA-Binding Protein ZFP36 in Chronic HBV Patients: Implications for Anti-Inflammatory Therapy. <i>PLoS ONE</i> , 2012, 7, e33356.	1.1	5
83	Apoptosis - an Ubiquitous T cell Immunomodulator. <i>Journal of Clinical & Cellular Immunology</i> , 2012, 01, 2.	1.5	13
84	The immunological life cycle of tuberculosis. <i>Nature Reviews Immunology</i> , 2012, 12, 581-591.	10.6	481
85	Reduced tumor antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2012, 42, 662-671.	1.6	17
86	CD4 ⁺ T cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. <i>European Journal of Immunology</i> , 2012, 42, 1755-1766.	1.6	31
87	Expanding roles for CD4 ⁺ T cells in immunity to viruses. <i>Nature Reviews Immunology</i> , 2012, 12, 136-148.	10.6	691
88	Role of PD-1 in HIV Pathogenesis and as Target for Therapy. <i>Current HIV/AIDS Reports</i> , 2012, 9, 81-90.	1.1	127
89	Living in the liver: hepatic infections. <i>Nature Reviews Immunology</i> , 2012, 12, 201-213.	10.6	451
90	Immune checkpoints in central nervous system autoimmunity. <i>Immunological Reviews</i> , 2012, 248, 122-139.	2.8	90
91	CD8 T cell defect of TNF-� and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. <i>Virology</i> , 2012, 429, 163-170.	1.1	26
92	Immune Reconstitution in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 13-20.	1.2	23
93	EVER2 Deficiency is Associated with Mild T-cell Abnormalities. <i>Journal of Clinical Immunology</i> , 2013, 33, 14-21.	2.0	38

#	ARTICLE	IF	CITATIONS
94	Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. <i>AIDS Research and Therapy</i> , 2013, 10, 18.	0.7	18
95	Killer T cells find meaningful encounters through iMATEs. <i>Nature Immunology</i> , 2013, 14, 533-534.	7.0	2
96	Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 207-235.	0.9	84
97	Using EAE to better understand principles of immune function and autoimmune pathology. <i>Journal of Autoimmunity</i> , 2013, 45, 31-39.	3.0	212
98	Combination Checkpoint Blockade "Taking Melanoma Immunotherapy to the Next Level. <i>New England Journal of Medicine</i> , 2013, 369, 187-189.	13.9	65
99	Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation. <i>Journal of Gastroenterology</i> , 2013, 48, 728-737.	2.3	13
100	The great balancing act: regulation and fate of antiviral T cell interactions. <i>Immunological Reviews</i> , 2013, 255, 110-124.	2.8	19
101	Generating protective immunity against genital herpes. <i>Trends in Immunology</i> , 2013, 34, 487-494.	2.9	43
102	Immune targeting of PD-1hi expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. <i>Virology</i> , 2013, 447, 274-284.	1.1	15
103	Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus. <i>Virology</i> , 2013, 442, 114-121.	1.1	25
104	Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C. <i>Clinical and Experimental Immunology</i> , 2013, 174, 172-178.	1.1	30
105	Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. <i>Nature Immunology</i> , 2013, 14, 1173-1182.	7.0	509
106	Role of T cell immunity in hepatitis C virus infections. <i>Current Opinion in Virology</i> , 2013, 3, 461-467.	2.6	28
107	Prospects for Treatment of Latent HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 46-56.	2.3	77
108	Bypassing T cell 'exhaustion'. <i>Nature Immunology</i> , 2013, 14, 1114-1116.	7.0	2
109	Regulation of immunopathogenesis during Plasmodium and Toxoplasma infections: more parallels than distinctions?. <i>Trends in Parasitology</i> , 2013, 29, 593-602.	1.5	29
110	Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings. <i>Cancer Research</i> , 2013, 73, 3545-3554.	0.4	17
111	Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. <i>Nature Reviews Immunology</i> , 2013, 13, 862-874.	10.6	1,819

#	ARTICLE	IF	CITATIONS
112	An Interferon Paradox. <i>Science</i> , 2013, 340, 155-156.	6.0	55
113	Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo. <i>Clinical Immunology</i> , 2013, 149, 450-463.	1.4	38
114	Containing "The Great Houdini" of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. <i>Drug Resistance Updates</i> , 2013, 16, 60-67.	6.5	15
115	Rapid Deletion and Inactivation of CTLs upon Recognition of a Number of Target Cells over a Critical Threshold. <i>Journal of Immunology</i> , 2013, 191, 3534-3544.	0.4	15
116	Programmed Death 1-Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function. <i>Journal of Immunology</i> , 2013, 191, 5542-5550.	0.4	158
117	Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. <i>Journal of Immunology</i> , 2013, 191, 4121-4129.	0.4	87
118	Regulation of the Development of the Hepatic B Cell Compartment during <i>Schistosoma mansoni</i> Infection. <i>Journal of Immunology</i> , 2013, 191, 4202-4210.	0.4	12
119	Primer on tumor immunology and cancer immunotherapy. , 2013, 1, 12.		63
120	Cytotoxic response persists in subjects treated for tuberculosis decades ago. <i>BMC Infectious Diseases</i> , 2013, 13, 573.	1.3	2
121	Cytomegalovirus contributes partly to uraemia-associated premature immunological ageing of the T cell compartment. <i>Clinical and Experimental Immunology</i> , 2013, 174, 424-432.	1.1	36
122	The contextual role of TNFR family members in CD8 ⁺ T cell control of viral infections. <i>Immunological Reviews</i> , 2013, 255, 125-148.	2.8	77
123	A Breath of Fresh Aire. <i>Immunity</i> , 2013, 39, 427-429.	6.6	4
124	Immune Escape. , 2013, , 149-164.		1
125	High-Dimensional Analysis of Human CD8+ T Cell Phenotype, Function, and Antigen Specificity. <i>Current Topics in Microbiology and Immunology</i> , 2013, 377, 61-84.	0.7	11
126	Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis. <i>European Journal of Immunology</i> , 2013, 43, 2194-2205.	1.6	37
127	An Altered Maturation and Adhesion Phenotype of Dendritic Cells in Diseased Individuals Compared to Asymptomatic Carriers of Human T Cell Leukemia Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1273-1285.	0.5	13
128	T cell vaccinology: Exploring the known unknowns. <i>Vaccine</i> , 2013, 31, 297-305.	1.7	27
129	NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. <i>Virology</i> , 2013, 435, 37-45.	1.1	67

#	ARTICLE	IF	CITATIONS
130	Anti-viral CD8 T cells and the cytokines that they love. <i>Virology</i> , 2013, 435, 157-169.	1.1	104
131	Memory T Cell Subsets, Migration Patterns, and Tissue Residence. <i>Annual Review of Immunology</i> , 2013, 31, 137-161.	9.5	668
132	Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation. <i>Cell Stem Cell</i> , 2013, 12, 114-126.	5.2	327
133	T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 214-221.	2.4	576
134	Shaping of NK Cell Responses by the Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2013, 6, 135-146.	3.1	52
135	Acute aerobic exercise in humans increases cytokine expression in CD27 ^{hi} but not CD27 ^{lo} CD8 ⁺ T-cells. <i>Brain, Behavior, and Immunity</i> , 2013, 27, 54-62.	2.0	27
136	Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. <i>Hepatology</i> , 2013, 57, 13-22.	3.6	43
137	PD-1 Dependent Exhaustion of CD8 ⁺ T Cells Drives Chronic Malaria. <i>Cell Reports</i> , 2013, 5, 1204-1213.	2.9	147
138	Using epigenetics to define vaccine-induced memory T cells. <i>Current Opinion in Virology</i> , 2013, 3, 371-376.	2.6	17
139	Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly(I:C) containing liposomes, in aqueous or oil-based formulations. <i>Vaccine</i> , 2013, 31, 1012-1018.	1.7	22
140	Immune gene expression profiles in swine inguinal lymph nodes with different viral loads of porcine circovirus type 2. <i>Veterinary Microbiology</i> , 2013, 162, 519-529.	0.8	7
141	Mechanistic basis of immunotherapies for type 1 diabetes mellitus. <i>Translational Research</i> , 2013, 161, 217-229.	2.2	21
142	Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. <i>Journal of Leukocyte Biology</i> , 2013, 93, 825-836.	1.5	66
143	Parasite-Derived Arginase Influences Secondary Anti- <i>Leishmania</i> Immunity by Regulating Programmed Cell Death-1-Mediated CD4 ⁺ T Cell Exhaustion. <i>Journal of Immunology</i> , 2013, 190, 3380-3389.	0.4	55
144	Molecular mechanisms of T cell co-stimulation and co-inhibition. <i>Nature Reviews Immunology</i> , 2013, 13, 227-242.	10.6	2,382
145	Persistent antigen at vaccination sites induces tumor-specific CD8 ⁺ T cell sequestration, dysfunction and deletion. <i>Nature Medicine</i> , 2013, 19, 465-472.	15.2	400
146	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. <i>Nature Reviews Cancer</i> , 2013, 13, 365-376.	12.8	242
147	Antigen depots: T cell traps?. <i>Nature Medicine</i> , 2013, 19, 397-398.	15.2	5

#	ARTICLE	IF	CITATIONS
148	Understanding immunosenescence to improve responses to vaccines. <i>Nature Immunology</i> , 2013, 14, 428-436.	7.0	616
149	Immune checkpoint blockade immunotherapy to activate anti-tumour T cell immunity. <i>British Journal of Haematology</i> , 2013, 162, 313-325.	1.2	102
150	Networking at the Level of Host Immunity: Immune Cell Interactions during Persistent Viral Infections. <i>Cell Host and Microbe</i> , 2013, 13, 652-664.	5.1	79
151	T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. <i>Nature Immunology</i> , 2013, 14, 603-610.	7.0	228
152	T cell exhaustion: a means or an end?. <i>Nature Immunology</i> , 2013, 14, 531-533.	7.0	14
153	Tracking antigen-specific CD4 ⁺ T cells throughout the course of chronic <i>Leishmania major</i> infection in resistant mice. <i>European Journal of Immunology</i> , 2013, 43, 427-438.	1.6	29
154	The Tumor Immunoenvironment. , 2013, , .		4
155	Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. <i>Nature Medicine</i> , 2013, 19, 859-868.	15.2	409
156	T-cell responses in hepatitis B and C virus infection: similarities and differences. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-8.	3.0	70
157	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	2.0	11
158	T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 441-456.	1.5	11
159	An Attenuated <i>Listeria monocytogenes</i> Vector Primes More Potent Simian Immunodeficiency Virus-Specific Mucosal Immunity than DNA Vaccines in Mice. <i>Journal of Virology</i> , 2013, 87, 4751-4755.	1.5	9
160	Anti-leukemia T cells in AML. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1200-1204.	1.4	4
161	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <i>Expert Review of Vaccines</i> , 2013, 12, 1325-1340.	2.0	5
162	CD4 T-cell immunotherapy for chronic viral infections and cancer. <i>Immunotherapy</i> , 2013, 5, 975-987.	1.0	52
163	Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 435.	2.2	23
164	Th2 Cell-Intrinsic Hypo-Responsiveness Determines Susceptibility to Helminth Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003215.	2.1	54
165	The Systemic Immune State of Super-shedder Mice Is Characterized by a Unique Neutrophil-dependent Blunting of TH1 Responses. <i>PLoS Pathogens</i> , 2013, 9, e1003408.	2.1	29

#	ARTICLE	IF	CITATIONS
166	Clonal Exhaustion as a Mechanism to Protect Against Severe Immunopathology and Death from an Overwhelming CD8 T Cell Response. <i>Frontiers in Immunology</i> , 2013, 4, 475.	2.2	83
167	Reactive oxygen species delay control of lymphocytic choriomeningitis virus. <i>Cell Death and Differentiation</i> , 2013, 20, 649-658.	5.0	44
168	IL-21 Restricts Virus-driven Treg Cell Expansion in Chronic LCMV Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003362.	2.1	67
169	CD4 T Cell Responses in Latent and Chronic Viral Infections. <i>Frontiers in Immunology</i> , 2013, 4, 105.	2.2	19
170	Characteristics of tertiary lymphoid structures in primary cancers. <i>Oncolmmunology</i> , 2013, 2, e26836.	2.1	103
171	PC61 (Anti-CD25) Treatment Inhibits Influenza A Virus-Expanded Regulatory T Cells and Severe Lung Pathology during a Subsequent Heterologous Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2013, 87, 12636-12647.	1.5	15
172	Memory T cells in transplantation â€“ progress and challenges. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 387-392.	0.8	27
173	Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion. <i>Interface Focus</i> , 2013, 3, 20130010.	1.5	46
174	FoxO1 Controls Effector-to-Memory Transition and Maintenance of Functional CD8 T Cell Memory. <i>Journal of Immunology</i> , 2013, 191, 187-199.	0.4	76
175	Strength of PD-1 signaling differentially affects T-cell effector functions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2480-9.	3.3	242
176	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1021-1034.	3.2	458
177	Lessons learned and concepts formed from study of the pathogenesis of the two negative-strand viruses lymphocytic choriomeningitis and influenza. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4180-4183.	3.3	32
178	CD8+Memory T Cells Appear Exhausted within Hours of Acute Virus Infection. <i>Journal of Immunology</i> , 2013, 191, 4211-4222.	0.4	16
179	The Janus Head of T Cell Aging â€“ Autoimmunity and Immunodeficiency. <i>Frontiers in Immunology</i> , 2013, 4, 131.	2.2	107
180	Blockade of programmed death receptorâ€“1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirusâ€“specific T cells. <i>Transplant Infectious Disease</i> , 2013, 15, 79-89.	0.7	28
181	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20200-20205.	3.3	185
182	Persistent Enteric Murine Norovirus Infection Is Associated with Functionally Suboptimal Virus-Specific CD8 T Cell Responses. <i>Journal of Virology</i> , 2013, 87, 7015-7031.	1.5	79
183	The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8 ⁺ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15019-15024.	3.3	78

#	ARTICLE	IF	CITATIONS
184	Donor CD8 ⁺ T Cells Prevent Toxoplasma gondii De-Encystation but Fail To Rescue the Exhausted Endogenous CD8 ⁺ T Cell Population. <i>Infection and Immunity</i> , 2013, 81, 3414-3425.	1.0	28
185	Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell-Mediated Killing. <i>Journal of Immunology</i> , 2013, 190, 5874-5881.	0.4	140
186	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 2604-2615.	3.9	245
187	Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers. <i>Clinical Cancer Research</i> , 2013, 19, 5351-5360.	3.2	176
188	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. <i>Journal of Experimental Medicine</i> , 2013, 210, 757-774.	4.2	211
189	Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies. <i>Frontiers in Immunology</i> , 2013, 4, 221.	2.2	37
190	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. <i>Frontiers in Immunology</i> , 2013, 4, 363.	2.2	70
191	Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice. <i>Journal of Immunology</i> , 2013, 191, 1753-1764.	0.4	64
192	Constitutively CD40-Activated B Cells Regulate CD8 T Cell Inflammatory Response by IL-10 Induction. <i>Journal of Immunology</i> , 2013, 190, 3189-3196.	0.4	8
193	Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than Exhaustion of Human CD8 ⁺ T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 455.	2.2	202
194	Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension. <i>Respirology</i> , 2013, 18, 1271-1277.	1.3	30
195	Infection and Cancer: Reevaluation of the Hygiene Hypothesis. <i>Clinical Cancer Research</i> , 2013, 19, 2834-2841.	3.2	57
196	Predominance of activated, clonally expanded T helper type 17 cells within the CD4 ⁺ T cell population in psoriatic lesions. <i>Clinical and Experimental Immunology</i> , 2013, 173, 38-46.	1.1	22
197	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. <i>International Journal of Cancer</i> , 2013, 133, 2895-2902.	2.3	49
198	CMV Infection in the Donor and Increased Kidney Graft Loss: Impact of Full HLA-I Mismatch and Posttransplantation CD8 ⁺ Cell Reduction. <i>American Journal of Transplantation</i> , 2013, 13, 2119-2129.	2.6	28
199	Genetic disruption of CD8 ⁺ Treg activity enhances the immune response to viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 21089-21094.	3.3	41
200	Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells. <i>Journal of Immunology</i> , 2013, 191, 540-544.	0.4	143
201	The Depletion of NK Cells Prevents T Cell Exhaustion to Efficiently Control Disseminating Virus Infection. <i>Journal of Immunology</i> , 2013, 190, 641-649.	0.4	112

#	ARTICLE	IF	CITATIONS
202	Reversal of Global CD4+ Subset Dysfunction Is Associated with Spontaneous Clinical Resolution of Pulmonary Sarcoidosis. <i>Journal of Immunology</i> , 2013, 190, 5446-5453.	0.4	78
203	Chronic Exposure to <i>Plasmodium falciparum</i> Is Associated with Phenotypic Evidence of B and T Cell Exhaustion. <i>Journal of Immunology</i> , 2013, 190, 1038-1047.	0.4	261
204	Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. <i>Clinical Cancer Research</i> , 2013, 19, 5626-5635.	3.2	381
205	A New Model for CD8+ T Cell Memory Inflation Based upon a Recombinant Adenoviral Vector. <i>Journal of Immunology</i> , 2013, 190, 4162-4174.	0.4	41
206	Inhibiting the inhibitors. <i>Oncolmmunology</i> , 2013, 2, e26535.	2.1	15
207	FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1282-90.	3.3	34
208	Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. <i>Blood</i> , 2013, 122, 1399-1410.	0.6	74
209	Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. <i>Blood</i> , 2013, 121, 604-613.	0.6	85
210	T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. <i>Blood</i> , 2013, 121, 1612-1621.	0.6	422
211	Exhausting T cells in CLL. <i>Blood</i> , 2013, 121, 1485-1486.	0.6	26
212	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 4129-4139.	0.6	537
213	Kinetics of Homeostatic Proliferation and Thymopoiesis after rATG Induction Therapy in Kidney Transplant Patients. <i>Transplantation</i> , 2013, 96, 904-913.	0.5	36
214	T Cell Replicative Senescence in Human Aging. <i>Current Pharmaceutical Design</i> , 2013, 19, 1680-1698.	0.9	176
215	Next-generation-sequencing-spectratyping reveals public T-cell receptor repertoires in pediatric very severe aplastic anemia and identifies a α chain CDR3 sequence associated with hepatitis-induced pathogenesis. <i>Haematologica</i> , 2013, 98, 1388-1396.	1.7	29
216	Immunomodulatory effects of polysaccharopeptide in immunosuppressed mice induced by cyclophosphamide. <i>Molecular Medicine Reports</i> , 2013, 8, 669-675.	1.1	17
217	<i>In Vitro</i> Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function. <i>Journal of Visualized Experiments</i> , 2013, , e50821.	0.2	4
218	Complementary Role of HCV and HIV in T-Cell Activation and Exhaustion in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2013, 8, e59302.	1.1	59
219	Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity. <i>International Journal of Nanomedicine</i> , 2013, 8, 2543.	3.3	36

#	ARTICLE	IF	CITATIONS
221	A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2013, 8, e63818.	1.1	204
222	CD4+ T-Cell Help Is Required for Effective CD8+ T Cell-Mediated Resolution of Acute Viral Hepatitis in Mice. <i>PLoS ONE</i> , 2014, 9, e86348.	1.1	28
223	Patients with Tuberculosis Disease Have Mycobacterium tuberculosis-Specific CD8 T Cells with a Pro-Apoptotic Phenotype and Impaired Proliferative Capacity, Which Is Not Restored following Treatment. <i>PLoS ONE</i> , 2014, 9, e94949.	1.1	44
224	Intact Dendritic Cell Pathogen-Recognition Receptor Functions Associate with Chronic Hepatitis C Treatment-Induced Viral Clearance. <i>PLoS ONE</i> , 2014, 9, e102605.	1.1	5
226	Attenuated <i>Listeria monocytogenes</i> : a powerful and versatile vector for the future of tumor immunotherapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 4, 51.	1.8	112
227	Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. <i>Frontiers in Immunology</i> , 2014, 5, 265.	2.2	14
228	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2246-2259.	3.9	892
229	Adaptive immune response during hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 3418.	1.4	57
230	Immune Response to Viruses: Cell-Mediated Immunity. , 2014, , .		2
231	Out of the bitter came forth sweet. <i>Oncolmmunology</i> , 2014, 3, e27399.	2.1	15
232	Mucosal-associated Invariant T-Cell Function Is Modulated by Programmed Death-1 Signaling in Patients with Active Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 329-339.	2.5	140
233	Understanding anti-leukemia responses to donor lymphocyte infusion. <i>Oncolmmunology</i> , 2014, 3, e28187.	2.1	18
234	Role of SFB in autoimmune arthritis. <i>Gut Microbes</i> , 2014, 5, 259-264.	4.3	15
235	Type I Interferon Signaling Enhances CD8 ⁺ T Cell Effector Function and Differentiation during Murine Gammaherpesvirus 68 Infection. <i>Journal of Virology</i> , 2014, 88, 14040-14049.	1.5	35
236	Depressive symptoms post hip fracture in older adults are associated with phenotypic and functional alterations in T cells. <i>Immunity and Ageing</i> , 2014, 11, 25.	1.8	18
237	The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1587-1597.	0.4	45
238	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. , 2014, 2, 33.		52
239	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 665-674.	1.5	73

#	ARTICLE	IF	CITATIONS
240	Tissue-Resident Exhausted Effector Memory CD8+ T Cells Accumulate in the Retina during Chronic Experimental Autoimmune Uveoretinitis. <i>Journal of Immunology</i> , 2014, 192, 4541-4550.	0.4	33
241	Tim-3 Directly Enhances CD8 T Cell Responses to Acute <i>Listeria monocytogenes</i> Infection. <i>Journal of Immunology</i> , 2014, 192, 3133-3142.	0.4	76
242	Programmed Death-1 Impairs Secondary Effector Lung CD8+ T Cells during Respiratory Virus Reinfection. <i>Journal of Immunology</i> , 2014, 193, 5108-5117.	0.4	39
243	T-bet: Eomes Balance, Effector Function, and Proliferation of Cytomegalovirus-Specific CD8+ T Cells during Primary Infection Differentiates the Capacity for Durable Immune Control. <i>Journal of Immunology</i> , 2014, 193, 5709-5722.	0.4	27
244	Type I interferon is a therapeutic target for virus-induced lethal vascular damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8925-8930.	3.3	56
245	IRF4 and BATF are critical for CD8+ T-cell function following infection with LCMV. <i>Cell Death and Differentiation</i> , 2014, 21, 1050-1060.	5.0	72
246	Malarial liver parasites awaken in culture. <i>Nature Medicine</i> , 2014, 20, 237-239.	15.2	8
247	A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing. <i>Journal of Hepatology</i> , 2014, 61, S34-S44.	1.8	70
248	Chronic Parasitic Infection Maintains High Frequencies of Short-Lived Ly6C+CD4+ Effector T Cells That Are Required for Protection against Re-infection. <i>PLoS Pathogens</i> , 2014, 10, e1004538.	2.1	79
249	Novel Aspects of the Liver Microenvironment in Hepatocellular Carcinoma Pathogenesis and Development. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9422-9458.	1.8	73
250	Chronic hepatitis B virus in young adults: the need for new approaches to management. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1045-1053.	2.0	6
251	Impairment of T Cell Function in Parasitic Infections. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2567.	1.3	80
252	Follicular Helper T Cells Promote Liver Pathology in Mice during <i>Schistosoma japonicum</i> Infection. <i>PLoS Pathogens</i> , 2014, 10, e1004097.	2.1	42
253	Infection of Adult Thymus with Murine Retrovirus Induces Virus-Specific Central Tolerance That Prevents Functional Memory CD8+ T Cell Differentiation. <i>PLoS Pathogens</i> , 2014, 10, e1003937.	2.1	6
254	Malaria drives T cells to exhaustion. <i>Frontiers in Microbiology</i> , 2014, 5, 249.	1.5	70
255	Restoring the balance: immunotherapeutic combinations for autoimmune disease. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 503-513.	1.2	84
256	AAV8 Induces Tolerance in Murine Muscle as a Result of Poor APC Transduction, T Cell Exhaustion, and Minimal MHC I Upregulation on Target Cells. <i>Molecular Therapy</i> , 2014, 22, 28-41.	3.7	50
257	Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 570-575.	0.9	23

#	ARTICLE	IF	CITATIONS
258	Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC. <i>Journal of Immunology</i> , 2014, 193, 5033-5043.	0.4	22
259	Detection of self-reactive CD8 ⁺ T cells with an anergic phenotype in healthy individuals. <i>Science</i> , 2014, 346, 1536-1540.	6.0	162
260	Dysfunctional HIV-Specific CD8+ T Cell Proliferation Is Associated with Increased Caspase-8 Activity and Mediated by Necroptosis. <i>Immunity</i> , 2014, 41, 1001-1012.	6.6	60
261	Increased expression of TIGIT on CD4 ⁺ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. <i>Journal of Cellular Biochemistry</i> , 2014, 115, n/a-n/a.	1.2	24
262	Expansion of Dysfunctional Tim-3 ⁺ Expressing Effector Memory CD8+ T Cells during Simian Immunodeficiency Virus Infection in Rhesus Macaques. <i>Journal of Immunology</i> , 2014, 193, 5576-5583.	0.4	23
263	Hepatitis B virus-specific T cell responses during IFN α administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment. <i>Journal of Viral Hepatitis</i> , 2014, 21, 633-641.	1.0	13
264	The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection. <i>Immunity</i> , 2014, 41, 802-814.	6.6	294
265	The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. <i>Cancer Cell</i> , 2014, 26, 923-937.	7.7	851
266	Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis. <i>Seminars in Immunology</i> , 2014, 26, 578-587.	2.7	60
267	Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. <i>Nature</i> , 2014, 515, 572-576.	13.7	1,010
268	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	13.7	1,705
269	Perforin: A Key Pore-Forming Protein for Immune Control of Viruses and Cancer. <i>Sub-Cellular Biochemistry</i> , 2014, 80, 197-220.	1.0	47
270	Antitumor CD8 ⁺ T cells in hepatocellular carcinoma: Present but exhausted. <i>Hepatology</i> , 2014, 59, 1232-1234.	3.6	17
271	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <i>Nature Communications</i> , 2014, 5, 5241.	5.8	780
272	Antigen-Dependent Integration of Opposing Proximal TCR-Signaling Cascades Determines the Functional Fate of T Lymphocytes. <i>Journal of Immunology</i> , 2014, 192, 2109-2119.	0.4	27
273	Persistent inflammation and T cell exhaustion in severe sepsis in the elderly. <i>Critical Care</i> , 2014, 18, R130.	2.5	85
274	Animal models for viral infection and cell exhaustion. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 492-499.	1.5	5
275	B-cell exhaustion in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 472-477.	1.5	89

#	ARTICLE	IF	CITATIONS
276	Anti-TCR mAb Induces Peripheral Tolerance to Alloantigens and Delays Islet Allograft Rejection in Autoimmune Diabetic NOD Mice. <i>Transplantation</i> , 2014, 97, 1216-1224.	0.5	6
277	Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load. <i>Aids</i> , 2014, 28, 2007-2021.	1.0	17
278	MicroRNA modulation of key targets associated with T cell exhaustion in HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 464-471.	1.5	19
279	T-cell aging in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 93-100.	2.0	123
280	Transcriptional regulation and T cell exhaustion. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 459-463.	1.5	17
281	Distinctive features of CD4+ T cell dysfunction in chronic viral infections. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 446-451.	1.5	41
282	IL-10: Achieving Balance During Persistent Viral Infection. <i>Current Topics in Microbiology and Immunology</i> , 2014, 380, 129-144.	0.7	33
283	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. <i>Frontiers in Immunology</i> , 2014, 5, 206.	2.2	108
284	The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion. <i>Journal of Immunology</i> , 2014, 193, 1836-1846.	0.4	20
285	The Liver and Immune Tolerance. , 2014, , 79-94.		2
286	Immunity to Cytomegalovirus in Early Life. <i>Frontiers in Immunology</i> , 2014, 5, 552.	2.2	47
287	The Many Unknowns Concerning the Bioenergetics of Exhaustion and Senescence during Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2014, 5, 468.	2.2	17
288	Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2014, 4, 107.	1.3	62
289	Adaptations of Natural Killer Cells to Self-MHC Class I. <i>Frontiers in Immunology</i> , 2014, 5, 349.	2.2	25
290	Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12145-12150.	3.3	34
291	Exposure of human astrocytes to leukotriene C4 promotes a CX3CL1/fractalkine-mediated transmigration of HIV-1-infected CD4+ T cells across an in vitro blood-brain barrier model. <i>Virology</i> , 2014, 454-455, 128-138.	1.1	22
292	Second-line chemotherapy for patients with oesophagogastric adenocarcinoma. <i>Lancet Oncology</i> , The, 2014, 15, 8-10.	5.1	27
293	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 69-77.	5.1	518

#	ARTICLE	IF	CITATIONS
294	Liver Environment and HCV Replication Affect Human T-Cell Phenotype and Expression of Inhibitory Receptors. <i>Gastroenterology</i> , 2014, 146, 550-561.	0.6	82
295	Anti-PD1 antibody: a new approach to treatment of lymphomas. <i>Lancet Oncology</i> , The, 2014, 15, 7-8.	5.1	36
296	Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2014, 62, 23-30.	1.0	4
297	Reactivation of human polyomaviruses in immunocompromised states. <i>Journal of NeuroVirology</i> , 2014, 20, 1-8.	1.0	23
298	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. <i>Critical Care</i> , 2014, 18, R3.	2.5	236
299	Balance lost: T cell immunity in progressive HBV infection. <i>Hepatology International</i> , 2014, 8, 7-9.	1.9	3
300	CD4 ⁺ T Cells: Guardians of the Phagosome. <i>Clinical Microbiology Reviews</i> , 2014, 27, 200-213.	5.7	78
301	Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?. <i>Reviews in Medical Virology</i> , 2014, 24, 125-138.	3.9	16
302	Primary Human Cytomegalovirus Infection Induces the Expansion of Virus-Specific Activated and Atypical Memory B Cells. <i>Journal of Infectious Diseases</i> , 2014, 210, 1275-1285.	1.9	29
303	High-Dimensional Single Cell Analysis. <i>Current Topics in Microbiology and Immunology</i> , 2014, , .	0.7	4
304	MACPF/CDC Proteins - Agents of Defence, Attack and Invasion. <i>Sub-Cellular Biochemistry</i> , 2014, , .	1.0	9
305	Protective CD4 T Cells Targeting Cryptic Epitopes of <i>Mycobacterium tuberculosis</i> Resist Infection-Driven Terminal Differentiation. <i>Journal of Immunology</i> , 2014, 192, 3247-3258.	0.4	69
306	Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape. <i>Cancer Immunology Research</i> , 2014, 2, 393-398.	1.6	278
307	Progress in tuberculosis vaccine development and host-directed therapiesâ€”a state of the art review. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 301-320.	5.2	195
308	Induction of T-cell memory by a dendritic cell vaccine: a computational model. <i>Bioinformatics</i> , 2014, 30, 1884-1891.	1.8	35
309	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. <i>Methods in Molecular Biology</i> , 2014, 1102, 287-324.	0.4	78
310	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. <i>Trends in Immunology</i> , 2014, 35, 51-60.	2.9	513
311	Differentiation of Antigen-Specific T Cells with Limited Functional Capacity during <i>Mycobacterium tuberculosis</i> Infection. <i>Infection and Immunity</i> , 2014, 82, 132-139.	1.0	20

#	ARTICLE	IF	CITATIONS
312	Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. <i>Endocrine-Related Cancer</i> , 2014, 21, 505-516.	1.6	37
313	Increased Antitumor Effects Using IL-2 with Anti- $\text{TGF-}\beta^2$ Reveals Competition between Mouse NK and CD8 T Cells. <i>Journal of Immunology</i> , 2014, 193, 1709-1716.	0.4	39
314	Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein. <i>Trends in Molecular Medicine</i> , 2014, 20, 675-684.	3.5	24
315	Impact of sepsis on CD4 T cell immunity. <i>Journal of Leukocyte Biology</i> , 2014, 96, 767-777.	1.5	128
316	Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. <i>Journal of Hepatology</i> , 2014, 61, 1212-1219.	1.8	234
317	T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. <i>Hepatology</i> , 2014, 60, 1531-1540.	3.6	64
318	Orchestration of pulmonary T cell immunity during <i>Mycobacterium tuberculosis</i> infection: Immunity interruptus. <i>Seminars in Immunology</i> , 2014, 26, 559-577.	2.7	53
319	Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege. <i>Clinical Cancer Research</i> , 2014, 20, 5620-5629.	3.2	91
320	Getting older can be exhausting. <i>Critical Care</i> , 2014, 18, 465.	2.5	2
321	Tsc1 promotes the differentiation of memory CD8 ⁺ T cells via orchestrating the transcriptional and metabolic programs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14858-14863.	3.3	64
322	Immunization-Induced <i>Anaplasma marginale</i> -Specific T-Lymphocyte Responses Impaired by <i>A. marginale</i> Infection Are Restored after Eliminating Infection with Tetracycline. <i>Vaccine Journal</i> , 2014, 21, 1369-1375.	3.2	9
323	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <i>Nature Reviews Immunology</i> , 2014, 14, 768-774.	10.6	248
324	Neuropeptides as neuroprotective agents: Oxytocin a forefront developmental player in the mammalian brain. <i>Progress in Neurobiology</i> , 2014, 123, 37-78.	2.8	44
325	Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. <i>Journal of Experimental Medicine</i> , 2014, 211, 2047-2059.	4.2	85
326	A divergent approach to the synthesis of iGb3 sugar and lipid analogues via a lactosyl 2-azido-sphingosine intermediate. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 2729-2736.	1.5	11
327	Transforming Growth Factor β^2 -Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression. <i>Immunity</i> , 2014, 41, 427-439.	6.6	100
328	Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion. <i>Journal of Immunology</i> , 2014, 193, 1525-1530.	0.4	149
329	Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance. <i>Journal of Hepatology</i> , 2014, 61, 459-461.	1.8	8

#	ARTICLE	IF	CITATIONS
330	Differential Impact of PD-1 and/or Interleukin-10 Blockade on HIV-1-Specific CD4 T Cell and Antigen-Presenting Cell Functions. <i>Journal of Virology</i> , 2014, 88, 2508-2518.	1.5	58
331	Innate immune cell networking in hepatitis C virus infection. <i>Journal of Leukocyte Biology</i> , 2014, 96, 757-766.	1.5	36
332	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	3.2	17
333	Mitochondria Are Gate-keepers of T Cell Function by Producing the ATP That Drives Purinergic Signaling. <i>Journal of Biological Chemistry</i> , 2014, 289, 25936-25945.	1.6	86
334	Revisiting Thymic Positive Selection and the Mature T Cell Repertoire for Antigen. <i>Immunity</i> , 2014, 41, 181-190.	6.6	76
335	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. <i>Journal of Experimental Medicine</i> , 2014, 211, 1905-1918.	4.2	182
336	B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 859-867.	2.0	13
337	Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection. <i>Immunity</i> , 2014, 40, 289-302.	6.6	418
338	Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 655-661.	2.0	50
339	B Cell Depletion Curtails CD4+ T Cell Memory and Reduces Protection against Disseminating Virus Infection. <i>Journal of Immunology</i> , 2014, 192, 1597-1608.	0.4	52
340	Functional dynamics of Foxp3 ⁺ regulatory T cells in mice and humans. <i>Immunological Reviews</i> , 2014, 259, 140-158.	2.8	49
341	Augmented Replicative Capacity of the Boosting Antigen Improves the Protective Efficacy of Heterologous Prime-Boost Vaccine Regimens. <i>Journal of Virology</i> , 2014, 88, 6243-6254.	1.5	10
342	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 4262-4273.	3.2	339
343	Immune control and failure in HCV infection—tipping the balance. <i>Journal of Leukocyte Biology</i> , 2014, 96, 535-548.	1.5	53
344	Regulation of T cell responses by the receptor molecule Tim-3. <i>Immunologic Research</i> , 2014, 59, 56-65.	1.3	73
345	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. <i>Journal of Translational Medicine</i> , 2014, 12, 97.	1.8	69
346	Chronic thoracic spinal cord injury impairs CD8+ T-cell function by up-regulating programmed cell death-1 expression. <i>Journal of Neuroinflammation</i> , 2014, 11, 65.	3.1	41
347	Adaptive response in hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 305-313.	1.0	35

#	ARTICLE	IF	CITATIONS
348	Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. <i>Acta Pharmaceutica Sinica B</i> , 2014, 4, 248-257.	5.7	48
349	Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. <i>Nature Communications</i> , 2014, 5, 4741.	5.8	147
350	Enrichment of LAG-3, but not PD-1, on Double Negative T Cells at the Female Genital Tract. <i>American Journal of Reproductive Immunology</i> , 2014, 72, 534-540.	1.2	3
351	Cellular immune response in patients with chronic hepatitis B virus infection. <i>Microbial Pathogenesis</i> , 2014, 74, 59-62.	1.3	23
352	Up-regulated expression of PD-1 and its ligands during acute Classical Swine Fever virus infection in swine. <i>Research in Veterinary Science</i> , 2014, 97, 251-256.	0.9	14
353	Postnatal Acquisition of Primary Rhesus Cytomegalovirus Infection is Associated With Prolonged Virus Shedding and Impaired CD4+ T Lymphocyte Function. <i>Journal of Infectious Diseases</i> , 2014, 210, 1090-1099.	1.9	17
354	Transplantation tolerance and its outcome during infections and inflammation. <i>Immunological Reviews</i> , 2014, 258, 80-101.	2.8	26
355	Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 872-879.e7.	1.5	110
356	Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance. <i>Immunotherapy</i> , 2014, 6, 637-653.	1.0	8
357	Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 410-422.	1.6	322
358	Epigenetic Manipulation Restores Functions of Defective CD8+ T Cells From Chronic Viral Infection. <i>Molecular Therapy</i> , 2014, 22, 1698-1706.	3.7	72
359	A Fox of a different color: FoxA1 programs a new regulatory T cell subset. <i>Nature Medicine</i> , 2014, 20, 236-237.	15.2	4
360	Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity. <i>Immunity</i> , 2014, 40, 949-960.	6.6	191
361	MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 77-89.	2.7	101
362	Costimulatory TNFR family members in control of viral infection: Outstanding questions. <i>Seminars in Immunology</i> , 2014, 26, 210-219.	2.7	23
363	PD-1/SHP-2 negatively regulate Tc1/Th1 phenotypic responses and activation of T cells in the tumor microenvironment. , 2014, 2, .		1
364	Ninety-Day Survival Rate of Patients with Sepsis Relates to Programmed Cell Death 1 Genetic Polymorphism rs11568821. <i>Journal of Investigative Medicine</i> , 2014, 62, 638-643.	0.7	21
365	Development of an IFN- γ ; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	5

#	ARTICLE	IF	CITATIONS
366	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 717-724.	0.6	53
367	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. <i>Blood</i> , 2014, 123, 1412-1421.	0.6	78
368	Reversing CD8+ T-cell exhaustion with DLI. <i>Blood</i> , 2014, 123, 1289-1290.	0.6	4
369	Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. <i>Cancer Science</i> , 2015, 106, 672-686.	1.7	61
370	Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1786-1800.	1.9	29
371	Regulation of T cell function by microRNA-720. <i>Scientific Reports</i> , 2015, 5, 12159.	1.6	20
372	Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. <i>Scientific Reports</i> , 2015, 5, 15659.	1.6	132
373	Metabolic dysfunction in lymphocytes promotes postoperative morbidity. <i>Clinical Science</i> , 2015, 129, 423-437.	1.8	28
374	Perturbation of the normal immune system in patients with CLL. <i>Blood</i> , 2015, 126, 573-581.	0.6	290
375	Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. <i>Scientific Reports</i> , 2015, 5, 15907.	1.6	69
376	Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. <i>EMBO Journal</i> , 2015, 34, 2042-2058.	3.5	100
377	Understanding Immune Checkpoint Inhibitors for Effective Patient Care. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 709-717.	0.3	17
378	T cells from patients with Candida sepsis display a suppressive immunophenotype. <i>Critical Care</i> , 2016, 20, 15.	2.5	100
379	Profiling B and T cell immune responses to co-infection of <i>Mycobacterium tuberculosis</i> and hookworm in humans. <i>Infectious Diseases of Poverty</i> , 2015, 4, 20.	1.5	8
380	T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi, Kenya. <i>Clinical and Experimental Immunology</i> , 2015, 181, 451-456.	1.1	9
381	Genomic alterations underlying immune privilege in malignant lymphomas. <i>Current Opinion in Hematology</i> , 2015, 22, 343-354.	1.2	18
382	Tumor-Infiltrating Lymphocyte Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 450-464.	1.0	45
383	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. <i>Aids</i> , 2015, 29, 1911-1915.	1.0	14

#	ARTICLE	IF	CITATIONS
384	T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation. <i>Transplantation</i> , 2015, 99, 1995-2003.	0.5	10
385	The Evolving Roles of Memory Immune Cells in Transplantation. <i>Transplantation</i> , 2015, 99, 2029-2037.	0.5	15
386	Secretion, blood levels and cutaneous expression of <scp>TL</scp>1A in psoriasis patients. <i>Apmis</i> , 2015, 123, 547-555.	0.9	9
387	Adoptive T Cell Immunotherapy For Cancer. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0004.	0.4	187
388	Characterization of the HCMV-Specific CD4 T Cell Responses that Are Associated with Protective Immunity. <i>Viruses</i> , 2015, 7, 4414-4437.	1.5	21
389	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , 2015, 6, 270.	2.2	27
390	Inhibitory Receptors Beyond T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2015, 6, 310.	2.2	188
391	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. <i>OncoTargets and Therapy</i> , 2015, 8, 929.	1.0	27
392	Current and future prophylactic vaccines for hepatitis C virus. <i>Vaccine (Auckland, N Z)</i> , 2015, , 31.	1.7	8
393	TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 2046-2058.	3.9	603
394	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2015, 6, 7-17.	0.1	82
395	Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. <i>Vaccines</i> , 2015, 3, 771-802.	2.1	11
396	PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis. <i>PLoS ONE</i> , 2015, 10, e0128523.	1.1	39
397	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. <i>PLoS ONE</i> , 2015, 10, e0136476.	1.1	59
398	Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo. <i>PLoS ONE</i> , 2015, 10, e0144375.	1.1	25
399	Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. <i>PLoS ONE</i> , 2015, 10, e0144767.	1.1	16
400	IRF4 Regulates the Ratio of T-Bet to Eomesodermin in CD8+ T Cells Responding to Persistent LCMV Infection. <i>PLoS ONE</i> , 2015, 10, e0144826.	1.1	16
401	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. <i>PLoS Pathogens</i> , 2015, 11, e1005270.	2.1	41

#	ARTICLE	IF	CITATIONS
402	TIGIT predominantly regulates the immune response via regulatory T cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4053-4062.	3.9	470
403	Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	21
404	Cell-Mediated Defense against Infection. , 2015, , 50-69.e6.		3
405	Preserving HIV-specific T cell responses. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 55-60.	1.5	20
406	Regulation of immunopathology in hepatitis B virus infection. <i>Nature Medicine</i> , 2015, 21, 548-549.	15.2	3
407	Converting smooth muscle cells to macrophage-like cells with KLF4 in atherosclerotic plaques. <i>Nature Medicine</i> , 2015, 21, 549-551.	15.2	20
408	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
409	Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2015, 212, 1125-1137.	4.2	368
410	Costimulation Immunotherapy in Infectious Diseases. , 2015, , 83-129.		10
411	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. <i>Current Oncology Reports</i> , 2015, 17, 30.	1.8	9
412	Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable. <i>Journal of Hepatology</i> , 2015, 63, 13-19.	1.8	16
413	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model. <i>Blood</i> , 2015, 126, 212-221.	0.6	111
414	PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 620-630.	1.6	84
415	A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates. <i>Science Translational Medicine</i> , 2015, 7, 289ra82.	5.8	130
416	Mature Cystic Fibrosis Airway Neutrophils Suppress T Cell Function: Evidence for a Role of Arginase 1 but Not Programmed Death-Ligand 1. <i>Journal of Immunology</i> , 2015, 194, 5520-5528.	0.4	60
417	Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism. <i>Journal of Immunology</i> , 2015, 194, 5789-5800.	0.4	104
418	NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection. <i>Journal of Leukocyte Biology</i> , 2015, 98, 153-162.	1.5	59
419	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. <i>Vaccine</i> , 2015, 33, B21-B28.	1.7	28

#	ARTICLE	IF	CITATIONS
420	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. <i>Onc Immunology</i> , 2015, 4, e965570.	2.1	189
421	Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. <i>Scientific Reports</i> , 2015, 5, 10276.	1.6	88
422	Id3 Controls Cell Death of 2B4+ Virus-Specific CD8+ T Cells in Chronic Viral Infection. <i>Journal of Immunology</i> , 2015, 195, 2103-2114.	0.4	15
423	Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. <i>Aging Cell</i> , 2015, 14, 945-956.	3.0	94
424	Neurocognitive decline in HIV patients is associated with ongoing T cell activation in the cerebrospinal fluid. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 906-919.	1.7	40
426	CD8 T Cell Exhaustion, Suppressed Gamma Interferon Production, and Delayed Memory Response Induced by Chronic <i>Brucella melitensis</i> Infection. <i>Infection and Immunity</i> , 2015, 83, 4759-4771.	1.0	44
427	A Critical Role of IL-21-Induced BATF in Sustaining CD8-T-Cell-Mediated Chronic Viral Control. <i>Cell Reports</i> , 2015, 13, 1118-1124.	2.9	105
428	Feeding an army: The metabolism of T cells in activation, anergy, and exhaustion. <i>Molecular Immunology</i> , 2015, 68, 492-496.	1.0	65
429	T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. <i>Journal of Hematology and Oncology</i> , 2015, 8, 93.	6.9	127
430	T Cell Fate in the Tumor Microenvironment. <i>Cancer Drug Discovery and Development</i> , 2015, , 53-74.	0.2	0
431	Imaging CD8+T cells during diverse viral infections. <i>Intravital</i> , 2015, 4, e1055425.	2.0	2
432	T cell exhaustion during persistent viral infections. <i>Virology</i> , 2015, 479-480, 180-193.	1.1	251
433	The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells. <i>Immunity</i> , 2015, 42, 265-278.	6.6	555
434	Suppression of Fcγ3-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection. <i>Immunity</i> , 2015, 42, 379-390.	6.6	58
435	Immune-mediated antitumor effect by type 2 diabetes drug, metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1809-1814.	3.3	450
436	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <i>Journal of Experimental Medicine</i> , 2015, 212, 139-148.	4.2	836
437	Altered Phenotype and Functionality of Varicella Zoster Virus-Specific Cellular Immunity in Individuals With Active Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 600-612.	1.9	62
438	Manipulating IL-10 signalling blockade for better immunotherapy. <i>Cellular Immunology</i> , 2015, 293, 126-129.	1.4	77

#	ARTICLE	IF	CITATIONS
439	Cellular Energy Metabolism in T-Lymphocytes. <i>International Reviews of Immunology</i> , 2015, 34, 34-49.	1.5	21
440	Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. <i>Immunology and Cell Biology</i> , 2015, 93, 634-640.	1.0	30
441	CD4 ⁺ T Cell Hyporesponsiveness after Repeated Exposure to <i>Schistosoma mansoni</i> Larvae Is Dependent upon Interleukin-10. <i>Infection and Immunity</i> , 2015, 83, 1418-1430.	1.0	22
442	IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. <i>Cancer Research</i> , 2015, 75, 1635-1644.	0.4	145
443	Increased frequency of late-â€senescent T cells lacking CD127 in chronic hepatitis C disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 466-474.	1.7	17
444	Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. , 2015, 3, 2.		93
445	Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 459-462.	1.3	1
446	Resistance to hepatitis C virus: potential genetic and immunological determinants. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 451-460.	4.6	17
447	Biomarkers for glioma immunotherapy: the next generation. <i>Journal of Neuro-Oncology</i> , 2015, 123, 359-372.	1.4	23
448	Type 1 Diabetes Mellitus. , 2015, , 99-113.		0
449	Characterization of CD8+ T Cell Differentiation following SIV ^{nef} Vaccination by Transcription Factor Expression Profiling. <i>PLoS Pathogens</i> , 2015, 11, e1004740.	2.1	13
450	Quiescence of Memory CD8+ T Cells Is Mediated by Regulatory T Cells through Inhibitory Receptor CTLA-4. <i>Immunity</i> , 2015, 42, 1116-1129.	6.6	79
451	Nivolumab: targeting PD-1 to bolster antitumor immunity. <i>Future Oncology</i> , 2015, 11, 1307-1326.	1.1	158
452	Immunopathology of multiple sclerosis. <i>Nature Reviews Immunology</i> , 2015, 15, 545-558.	10.6	1,642
453	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. <i>Journal of Immunology</i> , 2015, 195, 1054-1063.	0.4	34
454	Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8+ T Cell Hyporesponsiveness to Alloantigen. <i>Journal of Immunology</i> , 2015, 195, 1838-1848.	0.4	13
455	PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. <i>Nature Communications</i> , 2015, 6, 6692.	5.8	834
456	Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. <i>Tuberculosis</i> , 2015, 95, 267-274.	0.8	104

#	ARTICLE	IF	CITATIONS
457	PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. <i>Blood Cancer Journal</i> , 2015, 5, e330-e330.	2.8	124
458	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015, 151, 1206.	2.0	385
459	Cancer Immunity: Lessons From Infectious Diseases. <i>Journal of Infectious Diseases</i> , 2015, 212, S67-S73.	1.9	35
460	Low Frequency of Circulating CD8+ T Stem Cell Memory Cells in Chronic Chagasic Patients with Severe Forms of the Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3432.	1.3	67
461	CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1257-1268.	1.6	241
462	IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 360-366.	1.0	13
463	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	4.0	158
464	Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. <i>Virology</i> , 2015, 484, 153-162.	1.1	9
465	T-cell exhaustion in the tumor microenvironment. <i>Cell Death and Disease</i> , 2015, 6, e1792-e1792.	2.7	743
466	CD4 T Cells Mediate Both Positive and Negative Regulation of the Immune Response to HIV Infection: Complex Role of T Follicular Helper Cells and Regulatory T Cells in Pathogenesis. <i>Frontiers in Immunology</i> , 2014, 5, 681.	2.2	29
467	mTOR Links Environmental Signals to T Cell Fate Decisions. <i>Frontiers in Immunology</i> , 2014, 5, 686.	2.2	60
468	Enhanced CD8 T Cell Responses through GITR-Mediated Costimulation Resolve Chronic Viral Infection. <i>PLoS Pathogens</i> , 2015, 11, e1004675.	2.1	21
469	Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion. <i>Journal of Immunology</i> , 2015, 195, 116-125.	0.4	48
470	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. <i>Drug Discovery Today</i> , 2015, 20, 1127-1134.	3.2	27
471	Feto-maternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy. <i>Placenta</i> , 2015, 36, 1153-1160.	0.7	32
472	Molecular and cellular insights into T cell exhaustion. <i>Nature Reviews Immunology</i> , 2015, 15, 486-499.	10.6	3,159
473	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. <i>ACS Nano</i> , 2015, 9, 6861-6871.	7.3	119
474	Estimating the In Vivo Killing Efficacy of Cytotoxic T Lymphocytes across Different Peptide-MHC Complex Densities. <i>PLoS Computational Biology</i> , 2015, 11, e1004178.	1.5	13

#	ARTICLE	IF	CITATIONS
475	A Jekyll and Hyde Profile: Type 1 Interferon Signaling Plays a Prominent Role in the Initiation and Maintenance of a Persistent Virus Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, S31-S36.	1.9	13
476	T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. <i>Nature</i> , 2015, 523, 612-616.	13.7	535
477	GITR Intrinsically Sustains Early Type 1 and Late Follicular Helper CD4 T Cell Accumulation to Control a Chronic Viral Infection. <i>PLoS Pathogens</i> , 2015, 11, e1004517.	2.1	35
478	Tetramer Enrichment Reveals the Presence of Phenotypically Diverse Hepatitis C Virus-Specific CD8 ⁺ T Cells in Chronic Infection. <i>Journal of Virology</i> , 2015, 89, 25-34.	1.5	20
479	Programmed Cell Death 1 and Helios Distinguish TCR- α^{hi} Double-Negative (CD4 ⁺ CD8 ⁺) T Cells That Derive from Self-Reactive CD8 T Cells. <i>Journal of Immunology</i> , 2015, 194, 4207-4214.	0.4	53
480	Functional restoration of exhausted CD4 ⁺ and CD8 ⁺ T cells in chronic viral infection by vinegar-processed flos of <i>Daphne genkwa</i> . <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2015, 39, 25-37.	0.7	12
481	Murine lung cancer induces generalized T-cell exhaustion. <i>Journal of Surgical Research</i> , 2015, 195, 541-549.	0.8	25
482	Functional Exhaustion Limits CD4 ⁺ and CD8 ⁺ T-Cell Responses to Congenital Cytomegalovirus Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 484-494.	1.9	48
483	PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCR α^{hi} mAb therapy. <i>Diabetologia</i> , 2015, 58, 1309-1318.	2.9	3
484	Mutational escape of CD8 ⁺ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections. <i>Medical Microbiology and Immunology</i> , 2015, 204, 29-38.	2.6	41
485	Adjuvants and lymphoma risk as part of the ASIA spectrum. <i>Immunologic Research</i> , 2015, 61, 79-89.	1.3	19
487	Engineering T Cells to Functionally Cure HIV-1 Infection. <i>Molecular Therapy</i> , 2015, 23, 1149-1159.	3.7	43
488	Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. <i>Retrovirology</i> , 2015, 12, 14.	0.9	119
489	PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8 ⁺ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8 ⁺ T Cells. <i>Journal of Immunology</i> , 2015, 194, 5801-5811.	0.4	170
490	Linking the Aryl Hydrocarbon Receptor with Altered DNA Methylation Patterns and Developmentally Induced Aberrant Antiviral CD8 ⁺ T Cell Responses. <i>Journal of Immunology</i> , 2015, 194, 4446-4457.	0.4	51
491	Overcoming T cell exhaustion in infection and cancer. <i>Trends in Immunology</i> , 2015, 36, 265-276.	2.9	856
492	Cutting Edge: Identification of Autoreactive CD4 ⁺ and CD8 ⁺ T Cell Subsets Resistant to PD-1 Pathway Blockade. <i>Journal of Immunology</i> , 2015, 194, 3551-3555.	0.4	46
493	Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. <i>Nature Medicine</i> , 2015, 21, 327-334.	15.2	129

#	ARTICLE	IF	CITATIONS
494	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	13.7	1,955
495	Interfering with Immunity: Detrimental Role of Type I IFNs during Infection. <i>Journal of Immunology</i> , 2015, 194, 2455-2465.	0.4	72
496	Haematological malignancies: at the forefront of immunotherapeutic innovation. <i>Nature Reviews Cancer</i> , 2015, 15, 201-215.	12.8	63
497	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
498	T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. <i>Cell Death and Disease</i> , 2015, 6, e1694-e1694.	2.7	276
499	Immunological considerations in in utero hematopoietic stem cell transplantation (IUHCT). <i>Frontiers in Pharmacology</i> , 2015, 5, 282.	1.6	9
500	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. <i>Nature Medicine</i> , 2015, 21, 581-590.	15.2	1,304
501	PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 203-211.	0.6	158
502	T-cell exhaustion in allograft rejection and tolerance. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 37-42.	0.8	34
503	Modeling the Specific CD4+ T Cell Response against a Tumor Neoantigen. <i>Journal of Immunology</i> , 2015, 194, 3501-3512.	0.4	9
504	The Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1752-1762.	0.3	86
505	Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions. <i>Journal of Immunotherapy</i> , 2015, 38, 96-106.	1.2	171
506	Global transcriptional characterization of CD8+ T cell memory. <i>Seminars in Immunology</i> , 2015, 27, 4-9.	2.7	12
507	Innate and Adaptive Immune Regulation During Chronic Viral Infections. <i>Annual Review of Virology</i> , 2015, 2, 573-597.	3.0	110
508	Suppression of T cell responses in the tumor microenvironment. <i>Vaccine</i> , 2015, 33, 7393-7400.	1.7	46
509	Regulation of HBV-specific CD8+ T cell-mediated inflammation is diversified in different clinical presentations of HBV infection. <i>Journal of Microbiology</i> , 2015, 53, 718-724.	1.3	24
510	The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. <i>Immunity</i> , 2015, 43, 690-702.	6.6	252
511	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22

#	ARTICLE	IF	CITATIONS
512	Acute Viral Respiratory Infection Rapidly Induces a CD8+ T Cell Exhaustion-like Phenotype. <i>Journal of Immunology</i> , 2015, 195, 4319-4330.	0.4	26
513	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 513-526.	1.5	24
514	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , 2015, 3, 1344-1355.	1.6	285
515	Inhibitory Receptor Expression on CD8+ T Cells Is Linked to Functional Responses against <i>Trypanosoma cruzi</i> Antigens in Chronic Chagasic Patients. <i>Journal of Immunology</i> , 2015, 195, 3748-3758.	0.4	62
516	Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. <i>Cell</i> , 2015, 163, 160-173.	13.5	304
517	Functional classification of memory CD8+ T cells by CX3CR1 expression. <i>Nature Communications</i> , 2015, 6, 8306.	5.8	231
518	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.	2.1	87
519	DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift. <i>Vaccine</i> , 2015, 33, 2922-2929.	1.7	10
520	Poor functional immune recovery in aged HIV-1-infected patients following successful treatment with antiretroviral therapy. <i>Human Immunology</i> , 2015, 76, 701-710.	1.2	7
521	New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5191-5197.	3.2	29
522	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. <i>Cancer Immunology Research</i> , 2015, 3, 1269-1278.	1.6	84
523	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <i>Structure</i> , 2015, 23, 2341-2348.	1.6	399
524	Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1072-1078.	0.6	9
525	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. <i>Immunotherapy</i> , 2015, 7, 777-792.	1.0	18
526	Heteroclitic Peptides Increase Proliferation and Reduce Evidence of Human Immunodeficiency Virus-Specific CD8 ⁺ T Cell Dysfunction. <i>Viral Immunology</i> , 2015, 28, 455-463.	0.6	7
527	Memory programming in CD8+ T-cell differentiation is intrinsic and is not determined by CD4 help. <i>Nature Communications</i> , 2015, 6, 7994.	5.8	14
528	Natural Killer Cells in Viral Hepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 578-588.	2.3	69
529	Mutation of the ER retention receptor KDELR1 leads to cell-intrinsic lymphopenia and a failure to control chronic viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5706-14.	3.3	11

#	ARTICLE	IF	CITATIONS
530	T Follicular Helper Cell-Dependent Clearance of a Persistent Virus Infection Requires T Cell Expression of the Histone Demethylase UTX. <i>Immunity</i> , 2015, 43, 703-714.	6.6	76
531	A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. <i>Stem Cell Reports</i> , 2015, 5, 597-608.	2.3	61
532	Patients with idiopathic recurrent miscarriage show higher levels of DR+ activated T-cells that are less responsive to mitogens. <i>Journal of Reproductive Immunology</i> , 2015, 112, 82-87.	0.8	17
533	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the <scp>TCL</scp> 1 transgenic mouse model. <i>British Journal of Haematology</i> , 2015, 170, 515-522.	1.2	38
534	Salmonella induces PD-L1 expression in B cells. <i>Immunology Letters</i> , 2015, 167, 131-140.	1.1	19
535	Kupffer Cells Support Hepatitis B Virus-Mediated CD8+ T Cell Exhaustion via Hepatitis B Core Antigen-TLR2 Interactions in Mice. <i>Journal of Immunology</i> , 2015, 195, 3100-3109.	0.4	93
536	Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. <i>Cell</i> , 2015, 162, 1217-1228.	13.5	1,044
537	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , 2015, 162, 1229-1241.	13.5	2,158
538	Loss of Immunization-Induced Epitope-Specific CD4 T-Cell Response following <i>Anaplasma marginale</i> Infection Requires Presence of the T-Cell Epitope on the Pathogen and Is Not Associated with an Increase in Lymphocytes Expressing Known Regulatory Cell Phenotypes. <i>Vaccine Journal</i> , 2015, 22, 742-753.	3.2	2
539	Emerging immune checkpoints for cancer therapy. <i>Acta Oncologica</i> , 2015, 54, 1706-1713.	0.8	40
540	The characteristics of NK cells in <i>Schistosoma japonicum</i> -infected mouse spleens. <i>Parasitology Research</i> , 2015, 114, 4371-4379.	0.6	8
541	Activation and Exhaustion of Adaptive Immune Cells in Hepatitis B Infection. <i>Viral Immunology</i> , 2015, 28, 348-353.	0.6	13
542	Immune Memory and Exhaustion: Clinically Relevant Lessons from the LCMV Model. <i>Advances in Experimental Medicine and Biology</i> , 2015, 850, 137-152.	0.8	49
544	The Immune Fulcrum. <i>Progress in Molecular Biology and Translational Science</i> , 2015, 136, 217-243.	0.9	24
545	The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis. <i>Clinics in Chest Medicine</i> , 2015, 36, 561-568.	0.8	50
546	Elevated expression of T-bet in mycobacterial antigen-specific CD4+ T cells from patients with tuberculosis. <i>Cellular Immunology</i> , 2015, 298, 1-8.	1.4	5
547	Salmonella impairs CD8 T cell response through PD-1: PD-L axis. <i>Immunobiology</i> , 2015, 220, 1369-1380.	0.8	21
548	ZAP-70, CTLA-4 and proximal T cell receptor signaling in cows infected with <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> . <i>Veterinary Immunology and Immunopathology</i> , 2015, 167, 15-21.	0.5	18

#	ARTICLE	IF	CITATIONS
549	Innovative Medicine. , 2015, , .		17
550	T cell exhaustion and Interleukin 2 downregulation. Cytokine, 2015, 71, 339-347.	1.4	45
551	Natural history of chronic hepatitis B virus infection. Medical Microbiology and Immunology, 2015, 204, 5-10.	2.6	46
552	Transcriptional profiles reveal a stepwise developmental program of memory CD8+ T cell differentiation. Vaccine, 2015, 33, 914-923.	1.7	29
553	Novel immunotherapies for hematologic malignancies. Immunological Reviews, 2015, 263, 90-105.	2.8	44
554	Clinical blockade of PD1 and LAG3 " potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	10.6	524
555	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. , 2015, 148, 132-153.		50
556	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015, 21, 24-33.	3.5	628
557	Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection. Mucosal Immunology, 2015, 8, 746-759.	2.7	45
558	OX40- and CD27-Mediated Costimulation Synergizes with Anti"PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence. Journal of Immunology, 2015, 194, 125-133.	0.4	65
559	Peptide" MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development. Expert Review of Vaccines, 2015, 14, 69-84.	2.0	11
560	T cell"based targeted immunotherapies for patients with multiple myeloma. International Journal of Cancer, 2015, 136, 1751-1768.	2.3	10
561	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. Journal of Hepatology, 2015, 62, 31-40.	1.8	50
562	Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response. Blood Advances, 2016, 1, 208-218.	2.5	9
563	Immune Responses to Viral Infection. , 0, , 321-350.		1
564	Recent advances in understanding Type 1 Diabetes. F1000Research, 2016, 5, 110.	0.8	22
565	Flow Cytometric Characterization of Antigen-Specific T Cells Based on RNA and Its Advantages in Detecting Infections and Immunological Disorders. Critical Reviews in Immunology, 2016, 36, 359-378.	1.0	3
566	Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biology and Medicine, 2016, 13, 171-193.	1.4	98

#	ARTICLE	IF	CITATIONS
567	Immune Checkpoint Blockade Therapy: Merits and Demerits. <i>Journal of Clinical & Experimental Dermatology Research</i> , 2016, 7, .	0.1	0
568	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3447-3452.	3.9	439
569	PD-1 marks dysfunctional regulatory T cells in malignant gliomas. <i>JCI Insight</i> , 2016, 1, .	2.3	182
570	Tandem CAR T cells targeting HER2 and IL13R α 2 mitigate tumor antigen escape. <i>Journal of Clinical Investigation</i> , 2016, 126, 3036-3052.	3.9	515
571	The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. <i>Oncotarget</i> , 2016, 7, 7913-7924.	0.8	107
572	Effector, Memory, and Dysfunctional CD8 ⁺ T Cell Fates in the Antitumor Immune Response. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	186
573	Enhanced Anti-Tumor Efficacy through a Combination of Integrin α 6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. <i>Theranostics</i> , 2016, 6, 627-637.	4.6	92
574	Patterns of Infection. , 2016, , 81-94.		1
575	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016, 4, 27.	2.1	35
576	Harnessing the immune system to improve cancer therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 261-261.	0.7	225
577	New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for Influenza. <i>Frontiers in Immunology</i> , 2016, 7, 136.	2.2	42
578	mTOR Regulation of Lymphoid Cells in Immunity to Pathogens. <i>Frontiers in Immunology</i> , 2016, 7, 180.	2.2	38
579	Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4 ⁺ and CD8 ⁺ T Cells. <i>Frontiers in Immunology</i> , 2016, 7, 221.	2.2	20
580	Recognition and Regulation of T Cells by NK Cells. <i>Frontiers in Immunology</i> , 2016, 7, 251.	2.2	139
581	Changes in Follicular CD4 ⁺ T Helper Cells as a Marker for Evaluating Disease Progression in the Competition between HIV and Host Immunity. <i>Frontiers in Immunology</i> , 2016, 7, 474.	2.2	10
582	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
583	Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. <i>Frontiers in Immunology</i> , 2016, 7, 577.	2.2	18
584	Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2016, 7, 609.	2.2	120

#	ARTICLE	IF	CITATIONS
585	Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection. <i>Frontiers in Microbiology</i> , 2016, 7, 2111.	1.5	149
586	NF- κ B Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 84.	1.4	88
587	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
588	Activation, Impaired Tumor Necrosis Factor- α Production, and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Scrub Typhus. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004832.	1.3	24
589	Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. <i>PLoS ONE</i> , 2016, 11, e0158262.	1.1	20
590	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0167091.	1.1	38
591	A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. <i>PLoS Pathogens</i> , 2016, 12, e1005486.	2.1	18
592	Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. <i>Oncotarget</i> , 2016, 7, 23282-23299.	0.8	81
593	Transition of T Cells from Effector to Memory Phase. , 2016, , 353-362.		2
594	Adaptive Immunity. , 2016, , 57-69.		9
595	Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5101-5116.	1.0	27
596	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	0.8	76
597	Antigen–specific impairment of adoptive T–cell therapy against cancer: players, mechanisms, solutions and a hypothesis. <i>Immunological Reviews</i> , 2016, 272, 169-182.	2.8	11
598	Continuous Effector CD8 + T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population. <i>Immunity</i> , 2016, 45, 159-171.	6.6	75
599	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
600	Schistosome Soluble Egg Antigen Decreases<i>Mycobacterium tuberculosis</i>–Specific CD4⁺T-Cell Effector Function With Concomitant Arrest of Macrophage Phago-Lysosome Maturation. <i>Journal of Infectious Diseases</i> , 2016, 214, 479-488.	1.9	21
601	An adaptive immune response driven by mature, antigen–experienced <sc>T</sc> and <sc>B</sc> cells within the microenvironment of oral squamous cell carcinoma. <i>International Journal of Cancer</i> , 2016, 138, 2952-2962.	2.3	22
602	Alemtuzumab as Antirejection Therapy. <i>Transplantation Direct</i> , 2016, 2, e83.	0.8	15

#	ARTICLE	IF	CITATIONS
603	Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. <i>Onc Immunology</i> , 2016, 5, e1196308.	2.1	41
604	Expression of PD-1/LAG-3 and cytokine production by CD4 ⁺ T cells during infection with <i>Plasmodium</i> parasites. <i>Microbiology and Immunology</i> , 2016, 60, 121-131.	0.7	23
605	CD8 ⁺ T cells with distinct cytokine-producing features and low cytotoxic activity in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. <i>Clinical and Experimental Allergy</i> , 2016, 46, 1162-1175.	1.4	43
606	Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 109-119.	0.5	57
607	CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade. <i>Molecular Medicine Reports</i> , 2016, 14, 1107-1116.	1.1	28
608	Molecular Profile of Tumor-Specific CD8 ⁺ T Cell Hypofunction in a Transplantable Murine Cancer Model. <i>Journal of Immunology</i> , 2016, 197, 1477-1488.	0.4	42
609	Reversing T Cell Dysfunction for Tumor Immunotherapy. , 2016, , 109-128.		0
610	Cardiomyocytes display low mitochondrial priming and are highly resistant toward cytotoxic T cell killing. <i>European Journal of Immunology</i> , 2016, 46, 1415-1426.	1.6	6
611	The current status of checkpoint inhibitors in metastatic bladder cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 629-635.	1.7	11
612	CD57 ⁺ CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 1102-1112.	2.6	98
613	Immune Exhaustion and Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 1953-1957.	2.6	45
614	Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 ⁺ and CD8 ⁺ T-cell responses in older adults positively correlates with response size. <i>Scientific Reports</i> , 2016, 6, 19227.	1.6	44
615	The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. <i>Scientific Reports</i> , 2016, 6, 19740.	1.6	157
616	The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. <i>Science Immunology</i> , 2016, 1, .	5.6	415
617	Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7R β . <i>Journal of Neuroinflammation</i> , 2016, 13, 302.	3.1	8
618	NKp30 ⁺ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 38778.	1.6	16
619	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8425-E8432.	3.3	54
620	Dynamic Changes in Chromatin Accessibility Occur in CD8 ⁺ T Cells Responding to Viral Infection. <i>Immunity</i> , 2016, 45, 1327-1340.	6.6	231

#	ARTICLE	IF	CITATIONS
621	IL-10 Induces T Cell Exhaustion During Transplantation of Virus Infected Hearts. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 1171-1181.	1.1	10
622	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. <i>Molecular Therapy</i> , 2016, 24, 1135-1149.	3.7	281
623	Tumor Immunology. <i>Methods in Molecular Biology</i> , 2016, , .	0.4	2
624	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. <i>Melanoma Management</i> , 2016, 3, 137-147.	0.1	1
626	PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. <i>Immunity</i> , 2016, 44, 1190-1203.	6.6	116
627	LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 119-127.	0.4	23
628	Emerging Role and Characterization of Immunometabolism: Relevance to HIV Pathogenesis, Serious Non-AIDS Events, and a Cure. <i>Journal of Immunology</i> , 2016, 196, 4437-4444.	0.4	39
629	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1746-1756.	1.9	45
630	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	6.0	3,421
631	In Vitro Generation of Antigen-Specific T Cells from Induced Pluripotent Stem Cells of Antigen-Specific T Cell Origin. <i>Methods in Molecular Biology</i> , 2016, 1393, 67-73.	0.4	16
632	Embracing rejection: Immunologic trends in brain metastasis. <i>Oncolmmunology</i> , 2016, 5, e1172153.	2.1	33
633	CD1d-restricted peripheral T cell lymphoma in mice and humans. <i>Journal of Experimental Medicine</i> , 2016, 213, 841-857.	4.2	19
634	CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets. <i>Vaccine</i> , 2016, 34, 3109-3118.	1.7	6
635	Memory CD8 + T Cells: Innate-Like Sensors and Orchestrators of Protection. <i>Trends in Immunology</i> , 2016, 37, 375-385.	2.9	31
636	Unique human immune signature of Ebola virus disease in Guinea. <i>Nature</i> , 2016, 533, 100-104.	13.7	170
637	The "cancer immunogram" <i>Science</i> , 2016, 352, 658-660.	6.0	655
638	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , 2016, 28, 373-382.	1.8	143
639	Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103 ⁺ dendritic cells in late-stage ovarian cancer. <i>Oncolmmunology</i> , 2016, 5, e1185583.	2.1	36

#	ARTICLE	IF	CITATIONS
640	Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2863-2873.	1.8	137
641	Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. <i>Structure</i> , 2016, 24, 1719-1728.	1.6	86
642	Cooperation of PD-1 and LAG-3 Contributes to T-Cell Exhaustion in <i>Anaplasma marginale</i> -Infected Cattle. <i>Infection and Immunity</i> , 2016, 84, 2779-2790.	1.0	39
643	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. <i>Journal of Virology</i> , 2016, 90, 8934-8946.	1.5	69
644	Restoring anti-oncogene Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential. <i>Immunotherapy</i> , 2016, 8, 1219-1232.	1.0	22
645	T cell exhaustion and immune-mediated disease—the potential for therapeutic exhaustion. <i>Current Opinion in Immunology</i> , 2016, 43, 74-80.	2.4	66
646	Tumor-infiltrating Tim-3 ⁺ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. <i>Oncotarget</i> , 2016, 5, e1200778.	2.1	47
647	Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 179-193.	0.1	0
648	Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. <i>Journal of Leukocyte Biology</i> , 2016, 100, 1239-1254.	1.5	163
649	Antigen dynamics govern the induction of CD4 ⁺ T cell tolerance during autoimmunity. <i>Journal of Autoimmunity</i> , 2016, 72, 84-94.	3.0	4
650	Follicular CXCR5-expressing CD8 ⁺ T cells curtail chronic viral infection. <i>Nature</i> , 2016, 537, 412-416.	13.7	514
653	Molecular Programming of Tumor-Infiltrating CD8 ⁺ T Cells and IL15 Resistance. <i>Cancer Immunology Research</i> , 2016, 4, 799-811.	1.6	25
654	The untold story of IFN- β in cancer biology. <i>Cytokine and Growth Factor Reviews</i> , 2016, 31, 73-81.	3.2	125
655	Characterization of age-associated exhausted CD8 ⁺ T cells defined by increased expression of Tim-3 and PD-1. <i>Aging Cell</i> , 2016, 15, 291-300.	3.0	95
656	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	2.7	56
657	Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity. <i>Molecular Therapy</i> , 2016, 24, 1444-1455.	3.7	22
658	Cellular senescence impact on immune cell fate and function. <i>Aging Cell</i> , 2016, 15, 400-406.	3.0	104
659	Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization. <i>Vaccine</i> , 2016, 34, 4955-4963.	1.7	22

#	ARTICLE	IF	CITATIONS
660	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	2
661	A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage <i>Plasmodium</i> Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens. Journal of Immunology, 2016, 197, 2748-2761.	0.4	13
662	T cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. Immunology and Cell Biology, 2016, 94, 935-942.	1.0	29
663	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. Journal of Immunology, 2016, 197, 2532-2540.	0.4	110
664	T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity, 2016, 45, 415-427.	6.6	721
665	Interleukin-2 reverses CD8+ T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clinical and Experimental Immunology, 2016, 186, 106-114.	1.1	26
666	T lymphocyte immunophenotypes in the cerebrospinal fluid of dogs with visceral leishmaniasis. Veterinary Parasitology, 2016, 232, 12-20.	0.7	5
667	Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1451-1463.	2.0	21
668	Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis. European Journal of Immunology, 2016, 46, 2812-2821.	1.6	31
669	Self-reactivity as the necessary cost of maintaining a diverse memory T-cell repertoire. Pathogens and Disease, 2016, 74, ftw092.	0.8	9
670	Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management. Hepatology International, 2016, 10, 871-882.	1.9	11
671	Immune regulation in chronic hepatitis C virus infection. Scandinavian Journal of Gastroenterology, 2016, 51, 1387-1397.	0.6	17
672	High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. Journal of Experimental Medicine, 2016, 213, 1819-1834.	4.2	137
673	Role of CD4+ T Cells in the Pathophysiology of Multiple Sclerosis. , 2016, , 41-69.		10
674	Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8+ T Cells in the Same Host. Cell Reports, 2016, 16, 1243-1252.	2.9	176
675	MicroRNA-491 regulates the proliferation and apoptosis of CD8+ T cells. Scientific Reports, 2016, 6, 30923.	1.6	34
676	Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Science Immunology, 2016, 1, .	5.6	169
677	Menin Plays a Critical Role in the Regulation of the Antigen-Specific CD8+ T Cell Response upon <i>Listeria</i> Infection. Journal of Immunology, 2016, 197, 4079-4089.	0.4	9

#	ARTICLE	IF	CITATIONS
678	Scramblase TMEM16F terminates T cell receptor signaling to restrict T cell exhaustion. <i>Journal of Experimental Medicine</i> , 2016, 213, 2759-2772.	4.2	25
679	Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. <i>Science Translational Medicine</i> , 2016, 8, 332ra46.	5.8	64
680	Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines. <i>Molecular Brain</i> , 2016, 9, 88.	1.3	21
681	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. <i>Trends in Molecular Medicine</i> , 2016, 22, 1000-1011.	3.5	60
682	Naïve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β 2 immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	1.6	36
683	Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways. <i>Scientific Reports</i> , 2016, 6, 33869.	1.6	13
684	PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7231-E7239.	3.3	38
685	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
686	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. <i>Journal of Immunotherapy</i> , 2016, 39, 306-315.	1.2	10
687	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. <i>International Immunopharmacology</i> , 2016, 38, 81-89.	1.7	44
688	Progress in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	6
689	Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 349-367.	1.0	38
690	Phase I study with ONCOS-102 for the treatment of solid tumors " an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17.		155
691	T-cell therapies for HIV: Preclinical successes and current clinical strategies. <i>Cytotherapy</i> , 2016, 18, 931-942.	0.3	36
694	Adoptive Cellular Therapy (ACT) for Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 169-239.	0.8	14
695	Regulation of immunity during visceral Leishmania infection. <i>Parasites and Vectors</i> , 2016, 9, 118.	1.0	188
696	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
697	Functional role of mucosal-associated invariant T cells in HIV infection. <i>Journal of Leukocyte Biology</i> , 2016, 100, 305-314.	1.5	40

#	ARTICLE	IF	CITATIONS
698	T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection. <i>Virology Journal</i> , 2016, 13, 14.	1.4	4
699	Molecular and genetic inflammation networks in major human diseases. <i>Molecular BioSystems</i> , 2016, 12, 2318-2341.	2.9	49
700	TCR-contacting residues orientation and HLA-DRÎ²* binding preference determine long-lasting protective immunity against malaria. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 654-660.	1.0	7
701	Modulation of innate immunity in the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1261-1268.	2.0	63
702	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 1112-1121.	0.8	513
703	Th2 Cell Responses in Immunity and Inflammation Following Helminth Infection. , 2016, , 53-72.		1
704	Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. <i>Vaccine</i> , 2016, 34, 923-932.	1.7	48
705	Persistent Infections and Immunity in Ruminants to Arthropod-Borne Bacteria in the Family Anaplasmataceae. <i>Annual Review of Animal Biosciences</i> , 2016, 4, 177-197.	3.6	29
706	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3057-3066.	3.2	217
707	Tumour-infiltrating lymphocytes in melanoma prognosis andÂcancerÂimmunotherapy. <i>Pathology</i> , 2016, 48, 177-187.	0.3	210
708	Immune Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 59-90.	0.8	1
709	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. <i>Cell Metabolism</i> , 2016, 23, 63-76.	7.2	291
711	The Microbiome, Systemic Immune Function, and Allotransplantation. <i>Clinical Microbiology Reviews</i> , 2016, 29, 191-199.	5.7	39
712	An Odyssey to Viral Pathogenesis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 1-19.	9.6	2
713	Airway CD8⁺ T Cells Are Associated with Lung Injury during Infant Viral Respiratory Tract Infection. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 822-830.	1.4	49
714	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	0.6	1,644
715	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016, 165, 35-44.	13.5	2,437
716	<i>Fasciola hepatica</i> tegumental antigens induce anergicÂcâ€like TÂcells via dendritic cells in a mannose receptorÂdependent manner. <i>European Journal of Immunology</i> , 2016, 46, 1180-1192.	1.6	49

#	ARTICLE	IF	CITATIONS
717	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <i>International Immunology</i> , 2016, 28, 383-391.	1.8	223
718	Checkpoint inhibitors in Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2016, 96, 335-343.	1.1	14
719	Editorial: Cytokines in inflammation, aging, cancer and obesity. <i>Cytokine</i> , 2016, 82, 1-3.	1.4	8
720	Immune-surveillance through exhausted effector T-cells. <i>Current Opinion in Virology</i> , 2016, 16, 49-54.	2.6	42
721	The Anatomy of a Career in Science. <i>DNA and Cell Biology</i> , 2016, 35, 109-117.	0.9	0
722	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. <i>Immunity</i> , 2016, 44, 274-286.	6.6	144
723	Hepatitis B Virus Immunopathogenesis. <i>Molecular and Translational Medicine</i> , 2016, , 79-93.	0.4	0
724	Antigen-Encoding Bone Marrow Terminates Islet-Directed Memory CD8+ T-Cell Responses to Alleviate Islet Transplant Rejection. <i>Diabetes</i> , 2016, 65, 1328-1340.	0.3	16
725	Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. <i>Immunotherapy</i> , 2016, 8, 211-221.	1.0	18
726	Cytokines and persistent viral infections. <i>Cytokine</i> , 2016, 82, 4-15.	1.4	33
727	Immunodominant Dengue Virus-Specific CD8 ⁺ T Cell Responses Are Associated with a Memory PD-1 ⁺ Phenotype. <i>Journal of Virology</i> , 2016, 90, 4771-4779.	1.5	71
728	<i>MAF</i> drives CD8 ⁺ T-cell exhaustion. <i>OncotImmunology</i> , 2016, 5, e1082707.	2.1	3
729	Memory T cells in organ transplantation: progress and challenges. <i>Nature Reviews Nephrology</i> , 2016, 12, 339-347.	4.1	49
730	Tumor-necrosis factor impairs CD4+ T cell-mediated immunological control in chronic viral infection. <i>Nature Immunology</i> , 2016, 17, 593-603.	7.0	75
731	<i>Leishmania</i> -encoded orthologs of macrophage migration inhibitory factor regulate host immunity to promote parasite persistence. <i>FASEB Journal</i> , 2016, 30, 2249-2265.	0.2	25
732	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8 ⁺ T Cell Response by Selection of Altered Epitope Processing. <i>Journal of Virology</i> , 2016, 90, 33-42.	1.5	16
733	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
734	CD4+ and CD8+ T Cell Activation in Children with Hepatitis C. <i>Journal of Pediatrics</i> , 2016, 170, 142-148.e1.	0.9	11

#	ARTICLE	IF	CITATIONS
735	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Annals of Oncology</i> , 2016, 27, 559-574.	0.6	749
736	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 797-804.	2.0	20
737	New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2016, 51, 324-332.	1.3	29
738	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. <i>Oncolmmunology</i> , 2016, 5, e1062969.	2.1	27
739	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 389-397.	1.1	14
740	Apoptotic Epitope-Specific CD8 T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 674-683.	1.9	8
741	Dibromoacetic Acid Induces Thymocyte Apoptosis by Blocking Cell Cycle Progression, Increasing Intracellular Calcium, and the Fas/FasL Pathway in Vitro. <i>Toxicologic Pathology</i> , 2016, 44, 88-97.	0.9	2
742	Reprogramming away from the exhausted T cell state. <i>Seminars in Immunology</i> , 2016, 28, 35-44.	2.7	25
743	Persistent Simian Immunodeficiency Virus Infection Drives Differentiation, Aberrant Accumulation, and Latent Infection of Germinal Center Follicular T Helper Cells. <i>Journal of Virology</i> , 2016, 90, 1578-1587.	1.5	67
744	Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. <i>Journal of Infectious Diseases</i> , 2016, 213, 14-22.	1.9	69
745	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- κ B. <i>Cancer Research</i> , 2016, 76, 239-250.	0.4	84
746	CD4 T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 807-818.	0.6	129
747	PDL1 Regulation by p53 via miR-34. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	475
748	Mitochondrial Dysfunction, Depleted Purinergic Signaling, and Defective T Cell Vigilance and Immune Defense. <i>Journal of Infectious Diseases</i> , 2016, 213, 456-464.	1.9	39
749	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2016, 24, 175-183.	3.7	26
750	Dysregulation of Antiviral Function of CD8 T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1/PD-L1 Axis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 642-651.	2.5	106
751	Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. <i>Leukemia</i> , 2016, 30, 570-579.	3.3	102
752	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , 2016, 17, 95-103.	7.0	310

#	ARTICLE	IF	CITATIONS
753	Bovine Immunoinhibitory Receptors Contribute to Suppression of Mycobacterium avium subsp. paratuberculosis-Specific T-Cell Responses. <i>Infection and Immunity</i> , 2016, 84, 77-89.	1.0	38
754	Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. <i>Journal of Hepatology</i> , 2016, 64, 539-546.	1.8	37
755	Role of vitamin D in cytotoxic T lymphocyte immunity to pathogens and cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 132-145.	2.7	65
756	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 628-634.	0.6	24
757	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. <i>Leukemia and Lymphoma</i> , 2016, 57, 563-571.	0.6	34
758	T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 61-71.	1.6	152
759	Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. <i>Cellular and Molecular Immunology</i> , 2017, 14, 529-545.	4.8	30
760	Accelerated telomere shortening in peripheral blood lymphocytes after occupational polychlorinated biphenyls exposure. <i>Archives of Toxicology</i> , 2017, 91, 289-300.	1.9	48
761	Immune regulation of canine tumour and macrophage PD-L1 expression. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 534-549.	0.8	56
762	CD8+ T Cells That Coexpress ROR γ t and T-bet Are Functionally Impaired and Expand in Patients with Distal Bile Duct Cancer. <i>Journal of Immunology</i> , 2017, 198, 1729-1739.	0.4	27
763	Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. <i>Nature Medicine</i> , 2017, 23, 242-249.	15.2	179
764	Humanized Mice Reproduce Acute and Persistent Human Adenovirus Infection. <i>Journal of Infectious Diseases</i> , 2017, 215, 70-79.	1.9	15
765	Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. <i>Scientific Reports</i> , 2017, 7, 40354.	1.6	65
767	The chronicles of T-cell exhaustion. <i>Nature</i> , 2017, 543, 190-191.	13.7	24
768	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. <i>Nature Communications</i> , 2017, 8, 14572.	5.8	279
769	Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression. <i>Journal of Immunology</i> , 2017, 198, 2979-2988.	0.4	44
770	Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response <i>in vivo</i> by counteracting angiogenic gene expressions. <i>Clinical and Experimental Immunology</i> , 2017, 189, 21-35.	1.1	19
771	Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. <i>Cell Discovery</i> , 2017, 3, 17004.	3.1	147

#	ARTICLE	IF	CITATIONS
772	Armed Oncolytic Adenovirusâ€“Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Cancer Research</i> , 2017, 77, 2040-2051.	0.4	170
773	Gene expression markers of Tumor Infiltrating Leukocytes. , 2017, 5, 18.		572
774	CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. <i>Blood</i> , 2017, 129, 1166-1176.	0.6	143
775	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
776	Reactivation of dormant anti-tumor immunity â€“ a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
777	Activation and exhaustion of antigen-specific CD8 + T cells occur in different splenic compartments during infection with <i>Plasmodium berghei</i> . <i>Parasitology International</i> , 2017, 66, 227-235.	0.6	5
778	The Principles of Engineering Immune Cells to Treat Cancer. <i>Cell</i> , 2017, 168, 724-740.	13.5	844
779	Timâ€“3 and its role in regulating antiâ€“tumor immunity. <i>Immunological Reviews</i> , 2017, 276, 97-111.	2.8	599
780	Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients. <i>Journal of Immunology</i> , 2017, 198, 3170-3180.	0.4	43
781	Monocytes, Macrophages, and Osteoclasts in Osteosarcoma. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 396-405.	0.7	57
782	Second- and third-generation drugs for immuno-oncology treatmentâ€“The more the better?. <i>European Journal of Cancer</i> , 2017, 74, 55-72.	1.3	204
783	Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-Î±. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 523-535.	2.0	76
784	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 41-54.	3.3	55
785	Equine Arteritis Virus Has Specific Tropism for Stromal Cells and CD8⁺T and CD21⁺B Lymphocytes but Not for Glandular Epithelium at the Primary Site of Persistent Infection in the Stallion Reproductive Tract. <i>Journal of Virology</i> , 2017, 91, .	1.5	18
786	Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection. <i>Journal of Zhejiang University: Science B</i> , 2017, 18, 277-288.	1.3	47
787	Elevated T cell activation score is associated with improved survival of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 689-696.	1.1	49
788	Integrative Analysis Identifies a Novel AXLâ€“PI3 Kinaseâ€“PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.	3.2	91
789	Chronic viral hepatitis and its association with liver cancer. <i>Biological Chemistry</i> , 2017, 398, 817-837.	1.2	77

#	ARTICLE	IF	CITATIONS
790	Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons. <i>Gastroenterology</i> , 2017, 153, 566-578.e5.	0.6	22
791	Human Tumor Antigens Yesterday, Today, and Tomorrow. <i>Cancer Immunology Research</i> , 2017, 5, 347-354.	1.6	94
792	An Immune Atlas of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2017, 169, 736-749.e18.	13.5	751
793	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1725-1733.	1.9	196
794	Overcoming CD8+ T-Cell Exhaustion in Viral Hepatitis: Lessons from the Mouse Model and Clinical Perspectives. <i>Digestive Diseases</i> , 2017, 35, 334-338.	0.8	28
795	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
796	The Path to Cancer and Back. <i>Transplantation</i> , 2017, 101, 910-915.	0.5	23
797	Co-Signaling Molecules in Maternal-Fetal Immunity. <i>Trends in Molecular Medicine</i> , 2017, 23, 46-58.	3.5	50
798	Alloantigen gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8 + regulatory T cells. <i>Journal of Hepatology</i> , 2017, 66, 765-777.	1.8	25
799	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017, 52, 71-81.	3.4	437
800	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. <i>Journal of Leukocyte Biology</i> , 2017, 102, 601-615.	1.5	39
801	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. <i>Journal of Infectious Diseases</i> , 2017, 215, S160-S171.	1.9	24
802	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. <i>Protein and Cell</i> , 2017, 8, 861-877.	4.8	53
803	Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis. <i>Clinical Immunology</i> , 2017, 184, 54-62.	1.4	40
804	miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. <i>Biochemical and Biophysical Research Communications</i> , 2017, 488, 425-431.	1.0	133
805	Protective and Pathological Immunity during Central Nervous System Infections. <i>Immunity</i> , 2017, 46, 891-909.	6.6	123
806	De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. <i>Cell</i> , 2017, 170, 142-157.e19.	13.5	536
807	A tightly regulated IL-22 response maintains immune functions and homeostasis in systemic viral infection. <i>Scientific Reports</i> , 2017, 7, 3857.	1.6	12

#	ARTICLE	IF	CITATIONS
808	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2017, 153, 1107-1119.e10.	0.6	309
809	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
810	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. <i>Molecular Therapy</i> , 2017, 25, 1917-1932.	3.7	50
811	Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1479-1487.	0.5	32
812	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. <i>Journal of Biomedical Science</i> , 2017, 24, 35.	2.6	88
813	The molecular signature of murine T cell homeostatic proliferation reveals both inflammatory and immune inhibition patterns. <i>Journal of Autoimmunity</i> , 2017, 82, 47-61.	3.0	21
814	Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. <i>Cancer Immunology Research</i> , 2017, 5, 535-546.	1.6	108
815	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. <i>Cancer Immunology Research</i> , 2017, 5, 560-570.	1.6	10
816	Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN- γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 355-363.	1.3	44
817	Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. <i>Journal of Immunology</i> , 2017, 199, 604-612.	0.4	33
818	Retinoic Acid Regulates Immune Responses by Promoting IL-22 and Modulating S100 Proteins in Viral Hepatitis. <i>Journal of Immunology</i> , 2017, 198, 3448-3460.	0.4	24
819	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. <i>International Immunopharmacology</i> , 2017, 46, 210-219.	1.7	102
820	Regulatory and Exhausted T Cell Responses to AAV Capsid. <i>Human Gene Therapy</i> , 2017, 28, 338-349.	1.4	35
821	Quantitative, Phenotypical, and Functional Characterization of Cellular Immunity in Children and Adolescents With Down Syndrome. <i>Journal of Infectious Diseases</i> , 2017, 215, 1619-1628.	1.9	37
822	The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the immunoreactive microenvironment of colorectal carcinoma. <i>Histopathology</i> , 2017, 71, 366-374.	1.6	20
823	Role of TIM-3 in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1079-1083.	1.2	20
824	Aging increases cell-to-cell transcriptional variability upon immune stimulation. <i>Science</i> , 2017, 355, 1433-1436.	6.0	265
825	Obesity-associated digestive cancers: A review of mechanisms and interventions. <i>Tumor Biology</i> , 2017, 39, 101042831769502.	0.8	26

#	ARTICLE	IF	CITATIONS
826	Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1. <i>Molecular BioSystems</i> , 2017, 13, 892-900.	2.9	35
827	Frequency and functional characterization of exhausted CD8 ⁺ T cells in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2017, 98, 622-631.	1.1	44
828	Successful and Maladaptive T Cell Aging. <i>Immunity</i> , 2017, 46, 364-378.	6.6	250
829	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 76, 152-166.	1.3	82
830	Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. <i>Oncotmmunology</i> , 2017, 6, e1261779.	2.1	235
831	Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients. <i>International Immunopharmacology</i> , 2017, 43, 210-218.	1.7	52
832	Epigenetic Modification Mediates the Increase of LAG-3+ T Cells in Chronic Osteomyelitis. <i>Inflammation</i> , 2017, 40, 414-421.	1.7	7
833	T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. <i>Trends in Immunology</i> , 2017, 38, 104-115.	2.9	105
834	Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy. <i>Human Gene Therapy</i> , 2017, 28, 328-337.	1.4	85
835	PD-1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. <i>EMBO Molecular Medicine</i> , 2017, 9, 167-180.	3.3	172
836	Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. <i>Vaccine</i> , 2017, 35, 1-9.	1.7	14
837	The promise of chimeric antigen receptor T cells (CARs) in leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 13-26.	1.2	17
838	T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. <i>Haematologica</i> , 2017, 102, 562-572.	1.7	121
839	Barriers to HIV remission research in low- and middle-income countries. <i>Journal of the International AIDS Society</i> , 2017, 20, 21521.	1.2	16
840	Immune cells and autoantibodies in pulmonary arterial hypertension. <i>Acta Biochimica Et Biophysica Sinica</i> , 2017, 49, 1047-1057.	0.9	28
841	Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation. <i>Experimental and Molecular Medicine</i> , 2017, 49, e382-e382.	3.2	27
842	Gene editing in T cell therapy. <i>Journal of Genetics and Genomics</i> , 2017, 44, 415-422.	1.7	15
843	Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 1644-1655.	2.9	70

#	ARTICLE	IF	CITATIONS
844	Hollow MnO ₂ as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. <i>Nature Communications</i> , 2017, 8, 902.	5.8	1,124
845	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. <i>Science China Life Sciences</i> , 2017, 60, 1058-1064.	2.3	19
846	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. <i>Cellular Immunology</i> , 2017, 322, 1-14.	1.4	114
847	CTLA-4+PD-1 ^{hi} Memory CD4 ⁺ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques. <i>Immunity</i> , 2017, 47, 776-788.e5.	6.6	139
848	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
849	Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3. <i>Scientific Reports</i> , 2017, 7, 13579.	1.6	8
850	Alloimmune Responses of Humanized Mice to Human Pluripotent Stem Cell Therapeutics. <i>Cell Reports</i> , 2017, 20, 1978-1990.	2.9	31
851	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. <i>Clinical Cancer Research</i> , 2017, 23, 6165-6177.	3.2	249
852	Antigen-Presenting Intratumoral B Cells Affect CD4 ⁺ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 898-907.	1.6	184
853	KLRG1 expression identifies short-lived Foxp3 ⁺ T _{reg} effector cells with functional plasticity in islets of NOD mice. <i>Autoimmunity</i> , 2017, 50, 354-362.	1.2	26
854	Molecular-Targeted Immunotherapeutic Strategy for Melanoma <i>via</i> Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. <i>ACS Nano</i> , 2017, 11, 9536-9549.	7.3	268
855	The chromatin accessibility signature of human immune aging stems from CD8 ⁺ T cells. <i>Journal of Experimental Medicine</i> , 2017, 214, 3123-3144.	4.2	150
856	Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1487-1494.	0.2	33
857	Enhancing tumor specific immune responses by transcutaneous vaccination. <i>Expert Review of Vaccines</i> , 2017, 16, 1079-1094.	2.0	14
858	Immunological memory to blood-stage malaria infection is controlled by the histamine releasing factor (HRF) of the parasite. <i>Scientific Reports</i> , 2017, 7, 9129.	1.6	9
859	Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 474-483.	1.1	12
860	The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8 ⁺ T-cell Function. <i>Cancer Immunology Research</i> , 2017, 5, 920-928.	1.6	3
861	IRF9 Prevents CD8 ⁺ T Cell Exhaustion in an Extrinsic Manner during Acute Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	30

#	ARTICLE	IF	CITATIONS
862	The promise of 4-1BB (CD137) mediated immunomodulation and immunotherapy for viral diseases. <i>Future Virology</i> , 2017, 12, 361-372.	0.9	3
863	Predict disease progression from T cell phenotypes in northern pig-tailed macaques (<i>Macaca</i>) Tj ETQq1 1 0.784314 rgBT /Over	2.0	12
864	Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. <i>Trends in Cancer</i> , 2017, 3, 583-592.	3.8	151
865	Adoptive transfer of murine T cells expressing a chimeric PD-1 Δ p10 receptor as an immunotherapy for lymphoma. <i>Immunology</i> , 2017, 152, 472-483.	2.0	19
866	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. <i>International Journal of Cancer</i> , 2017, 141, 1891-1900.	2.3	23
867	Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways. <i>Life Sciences</i> , 2017, 185, 53-62.	2.0	55
868	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gamma delta T-cells. <i>Scientific Reports</i> , 2017, 7, 5509.	1.6	44
869	Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e111-e114.	0.5	67
870	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
871	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. <i>ESMO Open</i> , 2017, 2, e000213.	2.0	248
872	Programmed death 1 is highly expressed on CD8 ⁺ CD57 ⁺ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. <i>Immunology</i> , 2017, 152, 660-676.	2.0	37
873	WC1 ⁺ T cells from cattle naturally infected with <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> respond differentially to stimulation with PPD-J. <i>Veterinary Immunology and Immunopathology</i> , 2017, 190, 57-64.	0.5	5
874	Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. <i>Molecular Therapy</i> , 2017, 25, 2452-2465.	3.7	229
875	HIV-1 Infection Is Associated with Depletion and Functional Impairment of <i>Mycobacterium tuberculosis</i> -Specific CD4 T Cells in Individuals with Latent Tuberculosis Infection. <i>Journal of Immunology</i> , 2017, 199, 2069-2080.	0.4	51
876	A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 790-803.	1.6	38
877	Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B. <i>Medicine (United States)</i> , 2017, 96, e5275.	0.4	29
878	Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4 ⁺ CXCR5 ⁺ PD-1 ⁺ Cells, With Relative Preservation of Recall Antigen-Specific Responses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 72-80.	0.9	5
879	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17

#	ARTICLE	IF	CITATIONS
880	HIV-Infected Children Have Elevated Levels of PD-1+ Memory CD4 T Cells With Low Proliferative Capacity and High Inflammatory Cytokine Effector Functions. <i>Journal of Infectious Diseases</i> , 2017, 216, 641-650.	1.9	31
881	Anti-TCR β mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice. <i>Endocrinology</i> , 2017, 158, 3140-3151.	1.4	6
882	Lymphocytes Negatively Regulate NK Cell Activity via Qa-1b following Viral Infection. <i>Cell Reports</i> , 2017, 21, 2528-2540.	2.9	34
883	Modulation of antitumor immunity with histone deacetylase inhibitors. <i>Immunotherapy</i> , 2017, 9, 1359-1372.	1.0	37
884	Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. <i>Clinical and Translational Immunology</i> , 2017, 6, e161.	1.7	51
885	Sustained T follicular helper cell response is essential for control of chronic viral infection. <i>Science Immunology</i> , 2017, 2, .	5.6	80
886	Purging Exhausted Virus-Specific CD8 T Cell Phenotypes by Somatic Cell Reprogramming. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, S-59-S-69.	0.5	1
887	Suppression of FIP200 and autophagy by tumor-derived lactate promotes na \tilde{A} -ve T cell apoptosis and affects tumor immunity. <i>Science Immunology</i> , 2017, 2, .	5.6	83
888	New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review. <i>Infectious Diseases and Therapy</i> , 2017, 6, 461-476.	1.8	18
889	Chronic Alcohol Consumption Promotes Diethylnitrosamine-Induced Hepatocarcinogenesis via Immune Disturbances. <i>Scientific Reports</i> , 2017, 7, 2567.	1.6	39
890	Ebola Virus Disease in Humans: Pathophysiology and Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 141-169.	0.7	31
891	Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 61.	2.0	49
892	Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7R α antibodies in NOD mice. <i>BMC Immunology</i> , 2017, 18, 18.	0.9	8
893	The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study. <i>BMC Infectious Diseases</i> , 2017, 17, 228.	1.3	13
894	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 124.	6.9	42
895	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017, 77, 1263-1280.	4.9	29
896	Endocrine dysfunction following immune checkpoint inhibitor therapy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 337-347.	1.2	18
897	Immune checkpoints in chronic obstructive pulmonary disease. <i>European Respiratory Review</i> , 2017, 26, 170045.	3.0	27

#	ARTICLE	IF	CITATIONS
898	T-cell exhaustion in tuberculosis: pitfalls and prospects. <i>Critical Reviews in Microbiology</i> , 2017, 43, 133-141.	2.7	75
899	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. <i>Oncolmmunology</i> , 2017, 6, e1249561.	2.1	252
900	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017, 215, 139-149.	1.9	32
901	“Off-the-shelf” immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes. <i>Experimental Hematology</i> , 2017, 47, 2-12.	0.2	22
902	Irreversible splenic atrophy following chronic LCMV infection is associated with compromised immunity in mice. <i>European Journal of Immunology</i> , 2017, 47, 94-106.	1.6	11
903	Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 315-324.	0.3	10
904	The safety of anti PD-1 therapeutics for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 41-53.	1.0	17
905	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
906	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 469-481.	5.5	58
907	Heterologous Immunity and Persistent Murine Cytomegalovirus Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	14
908	The life cycle of a T cell after vaccination “ where does immune ageing strike?. <i>Clinical and Experimental Immunology</i> , 2016, 187, 71-81.	1.1	39
909	Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 93-99.	0.6	40
910	Hepatic expansion of virus-specific CD8 + BTLA + T cells with regulatory properties in chronic hepatitis B virus infection. <i>Cellular Immunology</i> , 2017, 311, 36-45.	1.4	21
911	OMIP037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 175-179.	1.1	21
912	Waldenstrom’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment. , 2017, , 83-94.		0
914	Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 331-370.	0.8	16
915	Immune Checkpoint Blockade in Breast Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 383-402.	0.8	24
916	Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. <i>Oncolmmunology</i> , 2017, 6, e1336272.	2.1	17

#	ARTICLE	IF	CITATIONS
917	Marburg- and Ebolaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	4
918	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. <i>Journal of Virus Eradication</i> , 2017, 3, 236-241.	0.3	0
919	Programmed Cell Death-1/Programmed Death-ligand 1 Pathway. <i>Chinese Medical Journal</i> , 2017, 130, 986-992.	0.9	15
920	Cerebral Gluconeogenesis and Diseases. <i>Frontiers in Pharmacology</i> , 2016, 7, 521.	1.6	55
921	The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. <i>Journal of Cancer</i> , 2017, 8, 1690-1703.	1.2	17
922	Markers of T Cell Senescence in Humans. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1742.	1.8	162
923	A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2134.	1.8	55
924	Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis. <i>Journal of Fungi (Basel)</i> , 2017, 1, 14.	1.5	21
925	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1517.	1.8	69
926	Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 98.	1.8	12
927	Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. <i>Frontiers in Immunology</i> , 2017, 8, 66.	2.2	102
928	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
929	Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. <i>Frontiers in Immunology</i> , 2017, 8, 330.	2.2	44
930	Anti-Bovine Programmed Death-1 Ratâ€“Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle. <i>Frontiers in Immunology</i> , 2017, 8, 650.	2.2	21
931	NK Cell Exhaustion. <i>Frontiers in Immunology</i> , 2017, 8, 760.	2.2	221
932	Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection. <i>Frontiers in Immunology</i> , 2017, 8, 811.	2.2	10
933	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	2.2	93
934	Peripheral Autoimmune Regulator Induces Exhaustion of CD4+ and CD8+ Effector T Cells to Attenuate Autoimmune Diabetes in Non-Obese Diabetic Mice. <i>Frontiers in Immunology</i> , 2017, 8, 1128.	2.2	7

#	ARTICLE	IF	CITATIONS
935	CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity. <i>Frontiers in Immunology</i> , 2017, 8, 1152.	2.2	11
936	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1215.	2.2	80
937	Long-Lasting Graft-Derived Donor T Cells Contribute to the Pathogenesis of Chronic Graft-versus-Host Disease in Mice. <i>Frontiers in Immunology</i> , 2017, 8, 1842.	2.2	12
938	Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner. <i>Frontiers in Immunology</i> , 2017, 8, 1880.	2.2	15
939	The Different Functional Distribution of α Not Effector T Cells (Treg/Tnull) in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1900.	2.2	39
940	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918.	2.2	72
941	Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection. <i>Frontiers in Oncology</i> , 2017, 7, 147.	1.3	24
942	Local and Systemic CD4 ⁺ T Cell Exhaustion Reverses with Clinical Resolution of Pulmonary Sarcoidosis. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	24
943	IL-10: A Multifunctional Cytokine in Viral Infections. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	249
944	The current status of immunobased therapies for metastatic renal-cell carcinoma. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 83-93.	2.7	14
945	Increased PD-1 Expression and Altered T Cell Repertoire Diversity Predict Mortality in Patients with Septic Shock: A Preliminary Study. <i>PLoS ONE</i> , 2017, 12, e0169653.	1.1	30
946	Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. <i>PLoS ONE</i> , 2017, 12, e0181538.	1.1	34
947	Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. <i>PLoS ONE</i> , 2017, 12, e0182498.	1.1	41
948	Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. <i>PLoS ONE</i> , 2017, 12, e0184127.	1.1	16
949	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. <i>PLoS ONE</i> , 2017, 12, e0189697.	1.1	40
950	In vitro and in vivo antiviral activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. <i>PLoS ONE</i> , 2017, 12, e0174916.	1.1	33
951	Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. <i>PLoS ONE</i> , 2017, 12, e0171217.	1.1	16
952	Modulation of the strength and character of HIV-specific CD8+ T cell responses with heteroclitic peptides. <i>AIDS Research and Therapy</i> , 2017, 14, 41.	0.7	4

#	ARTICLE	IF	CITATIONS
953	Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 193.	1.6	14
954	Vaccination with recombinant adenovirus expressing peste des petits ruminants virus-F or -H proteins elicits T cell responses to epitopes that arises during PPRV infection. <i>Veterinary Research</i> , 2017, 48, 79.	1.1	15
955	Immunosenescence in persons with spinal cord injury in relation to urinary tract infections -a cross-sectional study-. <i>Immunity and Ageing</i> , 2017, 14, 22.	1.8	30
956	Tim-3 and PD-1 regulate CD8 ⁺ T cell function to maintain early pregnancy in mice. <i>Journal of Reproduction and Development</i> , 2017, 63, 289-294.	0.5	26
957	Physiology and Pathology of Immune Dysregulation: Regulatory T Cells and Anergy. , 2017, , .		1
958	Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 33159-33171.	0.8	96
959	Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	1.4	31
960	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <i>Oncotarget</i> , 2017, 8, 44960-44975.	0.8	82
961	Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. <i>Cancer Management and Research</i> , 2017, Volume 9, 19-27.	0.9	13
962	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <i>Oncotarget</i> , 2017, 8, 72167-72181.	0.8	221
963	PD-1 blockade restores impaired function of ex vivo expanded CD8 ⁺ T cells and enhances apoptosis in mismatch repair deficient EpCAM ⁺ PD-L1 ⁺ cancer cells. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3453-3465.	1.0	24
964	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
965	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
966	Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. <i>Oncotarget</i> , 2017, 8, 98215-98232.	0.8	30
967	Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2455-2460.	3.3	124
968	Nivolumab in the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2018, 14, 1679-1689.	1.1	3
969	CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8 ⁺ T cells to Tc1 phenotype. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 893-905.	2.0	24
970	Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma. <i>Oncolmunology</i> , 2018, 7, e1397248.	2.1	45

#	ARTICLE	IF	CITATIONS
971	MHC-mismatched mixed chimerism restores peripheral tolerance of noncross-reactive autoreactive T cells in NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2329-E2337.	3.3	5
972	Prostaglandin E ₂ Induction Suppresses the Th1 Immune Responses in Cattle with Johne's Disease. <i>Infection and Immunity</i> , 2018, 86, .	1.0	26
973	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1706-1725.	1.1	13
974	Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 1319-1327.	1.3	33
975	Foxo transcription factors in T cell biology and tumor immunity. <i>Seminars in Cancer Biology</i> , 2018, 50, 13-20.	4.3	31
976	Understanding the tumor immune microenvironment (TIME) for effective therapy. <i>Nature Medicine</i> , 2018, 24, 541-550.	15.2	3,421
977	A Dual Immunotherapy Nanoparticle Improves T _H 1 Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
978	Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. <i>European Journal of Immunology</i> , 2018, 48, 1389-1399.	1.6	17
979	NFATc1 Promotes Antitumoral Effector Functions and Memory CD8 ⁺ T-cell Differentiation during Non-Small Cell Lung Cancer Development. <i>Cancer Research</i> , 2018, 78, 3619-3633.	0.4	37
980	Memory vs memory-like: The different facets of CD8 ⁺ T _H 1 cell memory in HCV infection. <i>Immunological Reviews</i> , 2018, 283, 232-237.	2.8	5
981	Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. <i>Immunological Reviews</i> , 2018, 283, 54-76.	2.8	142
982	The function and dysfunction of memory CD8 ⁺ T cells in tumor immunity. <i>Immunological Reviews</i> , 2018, 283, 194-212.	2.8	121
983	YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells. <i>IScience</i> , 2018, 2, 105-122.	1.9	49
984	Resistance of HIV-infected macrophages to CD8 ⁺ T lymphocyte-mediated killing drives activation of the immune system. <i>Nature Immunology</i> , 2018, 19, 475-486.	7.0	105
985	TCR repertoire evolution during maintenance of CMV-specific T _H 1 cell populations. <i>Immunological Reviews</i> , 2018, 283, 113-128.	2.8	30
986	Quo Vadis? Do Immunotherapies Have a Role in Glioblastoma?. <i>Current Treatment Options in Neurology</i> , 2018, 20, 14.	0.7	22
987	Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8 ⁺ T Cells. <i>Immunity</i> , 2018, 48, 773-786.e5.	6.6	150
988	PD-1 immune checkpoint blockade promotes brain leukocyte infiltration and diminishes cyst burden in a mouse model of <i>Toxoplasma</i> infection. <i>Journal of Neuroimmunology</i> , 2018, 319, 55-62.	1.1	24

#	ARTICLE	IF	CITATIONS
989	Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. <i>Nature Communications</i> , 2018, 9, 1241.	5.8	70
990	Immune active cells with 4-1BB signal enhancement inhibit hepatitis B virus replication in noncytolytic manner. <i>Cellular Immunology</i> , 2018, 328, 79-85.	1.4	2
991	Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. <i>Scientific Reports</i> , 2018, 8, 5549.	1.6	29
992	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 114-121.	3.4	28
993	Interplay Between Metabolic Sensors and Immune Cell Signaling. <i>Experientia Supplementum</i> (2012), 2018, 109, 115-196.	0.5	2
994	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393
995	T Cell Dysfunction in Cancer. <i>Cancer Cell</i> , 2018, 33, 547-562.	7.7	787
996	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
997	The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China. <i>Medicine (United States)</i> , 2018, 97, e0276.	0.4	5
998	Inhibitory Receptor Expression on T Cells as a Marker of Disease Activity and Target to Regulate Effector Cellular Responses in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1429-1439.	2.9	11
999	PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1707112.	11.1	196
1000	Role of PD-1 during effector CD8 T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4749-4754.	3.3	327
1001	A guide to manufacturing CAR T cell therapies. <i>Current Opinion in Biotechnology</i> , 2018, 53, 164-181.	3.3	262
1002	Cellular and functional biomarkers of clinical transplant tolerance. <i>Human Immunology</i> , 2018, 79, 322-333.	1.2	10
1003	T cell dysfunction and patient age are associated with poor outcomes after mechanical circulatory support device implantation. <i>Human Immunology</i> , 2018, 79, 203-212.	1.2	10
1004	Metabolic exhaustion in infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2018, 19, 213-221.	7.0	84
1005	IFN- γ and tumor gangliosides: Implications for the tumor microenvironment. <i>Cellular Immunology</i> , 2018, 325, 33-40.	1.4	15
1006	Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review. <i>Journal of Thoracic Oncology</i> , 2018, 13, 624-635.	0.5	35

#	ARTICLE	IF	CITATIONS
1007	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. <i>Oncolmmunology</i> , 2018, 7, e1431088.	2.1	67
1008	Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. <i>Immunotherapy</i> , 2018, 10, 221-234.	1.0	7
1009	Checkpoint molecule expression by B and T cell lymphomas in dogs. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 352-360.	0.8	25
1010	Tâ€bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1. <i>European Journal of Immunology</i> , 2018, 48, 738-750.	1.6	152
1011	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018, 6, 402-408.	1.6	56
1012	MAIT cells and viruses. <i>Immunology and Cell Biology</i> , 2018, 96, 630-641.	1.0	90
1013	Tâ€cell Immunoglobulin and <sc>ITIM</sc> Domain Contributes to <sc>CD</sc>8⁺ Tâ€cell Immunosenescence. <i>Aging Cell</i> , 2018, 17, e12716.	3.0	77
1014	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1413519.	2.1	21
1015	Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival. <i>Oncolmmunology</i> , 2018, 7, e1431083.	2.1	28
1016	Clinical Development of PD-1 Blockade in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 31-35.	1.0	11
1017	Stromal PD-L1â€™Positive Regulatory T cells and PD-1â€™Positive CD8-Positive T cells Define the Response of Different Subsets of Nonâ€™Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 521-532.	0.5	119
1018	Regulatory T Cells: Their Role, Mechanism of Action, and Impact on Cancer. , 2018, , 97-113.		1
1019	Regulatory T cells constrain the <sc>TCR</sc> repertoire of antigenâ€™stimulated conventional <sc>CD</sc>4 T cells. <i>EMBO Journal</i> , 2018, 37, 398-412.	3.5	10
1020	MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. <i>Hepatology</i> , 2018, 68, 172-186.	3.6	129
1021	FOXOs in cancer immunity: Knowns and unknowns. <i>Seminars in Cancer Biology</i> , 2018, 50, 53-64.	4.3	56
1022	High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They â€™Seeâ€™ in Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 2-9.	1.6	15
1023	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Nonâ€™Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. <i>Clinical Cancer Research</i> , 2018, 24, 3857-3866.	3.2	150
1025	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	2.2	10

#	ARTICLE	IF	CITATIONS
1026	PD-L1 Independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2018, 200, 3304-3311.	0.4	6
1027	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. <i>Clinical Cancer Research</i> , 2018, 24, 2653-2664.	3.2	109
1028	Re-programming immunosurveillance in persistent non-infectious ocular inflammation. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 93-106.	7.3	10
1029	Expansion of circulating T follicular helper cells is associated with disease progression in HIV-infected individuals. <i>Journal of Infection and Public Health</i> , 2018, 11, 685-690.	1.9	7
1030	Novel targeted therapies and immunotherapy for advanced thyroid cancers. <i>Molecular Cancer</i> , 2018, 17, 51.	7.9	168
1031	Phase I clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	0.6	30
1032	Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 547-564.	1.4	18
1033	In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. <i>Oncolmmunology</i> , 2018, 7, e1424673.	2.1	27
1034	PKB/Akt-dependent regulation of inflammation in cancer. <i>Seminars in Cancer Biology</i> , 2018, 48, 62-69.	4.3	87
1035	Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model. <i>Cellular and Molecular Immunology</i> , 2018, 15, 815-826.	4.8	40
1036	The role of IL-12/23 in T cell related chronic inflammation: implications of immunodeficiency and therapeutic blockade. <i>Rheumatology</i> , 2018, 57, 246-254.	0.9	38
1037	Malnutrition in HIV-Infected Children Is an Indicator of Severe Disease with an Impaired Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 46-55.	0.5	35
1038	Hepatitis E virus ORF 1 induces proliferative and functional T cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , 2018, 38, 266-277.	1.9	18
1039	Co-inhibitory profile and cytotoxicity of CD57+PD-1 ^{hi} T cells in end-stage renal disease patients. <i>Clinical and Experimental Immunology</i> , 2018, 191, 363-372.	1.1	6
1040	Dendritic cell vaccine induces antigen-specific CD8 ⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. <i>Oncolmmunology</i> , 2018, 7, e1395124.	2.1	20
1041	CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells. <i>Cancer Research</i> , 2018, 78, 115-128.	0.4	284
1042	Decreased intra-lymphocyte cytokines measurement in septic shock patients: A proof of concept study in whole blood. <i>Cytokine</i> , 2018, 104, 78-84.	1.4	10
1043	In-vitro effect of pembrolizumab on different T regulatory cell subsets. <i>Clinical and Experimental Immunology</i> , 2018, 191, 189-197.	1.1	42

#	ARTICLE	IF	CITATIONS
1044	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. <i>Oncolimmunology</i> , 2018, 7, e1365997.	2.1	2
1045	T cells responding to <i>Trypanosoma cruzi</i> detected by membrane TNF α and CD154 in chagasic patients. <i>Immunity, Inflammation and Disease</i> , 2018, 6, 47-57.	1.3	11
1046	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407
1047	The PD α 1 and PD α L1 pathway in recurrent respiratory papillomatosis. <i>Laryngoscope</i> , 2018, 128, E27-E32.	1.1	31
1048	Rescue of T-cell function during persistent pulmonary adenoviral infection by Toll-like receptor 9 activation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 416-419.e10.	1.5	2
1049	Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. <i>Biotechnology Journal</i> , 2018, 13, 1700095.	1.8	56
1050	CD8 + T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. <i>Clinical Immunology</i> , 2018, 190, 64-73.	1.4	52
1051	Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1002-1010.	3.2	30
1052	Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors α 1, α 2, and α 3 in Lymphocytes From Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 566-577.	2.9	26
1053	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39.		7
1054	CAR-T cells and combination therapies: What's next in the immunotherapy revolution?. <i>Pharmacological Research</i> , 2018, 129, 194-203.	3.1	33
1055	Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy. <i>Journal of Immunology</i> , 2018, 200, 558-564.	0.4	11
1056	PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2018, 200, 834-846.	0.4	23
1057	Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections. <i>American Journal of Transplantation</i> , 2018, 18, 351-363.	2.6	11
1058	PD-L1. <i>Journal of Clinical Pathology</i> , 2018, 71, 189-194.	1.0	218
1059	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <i>Current Cancer Research</i> , 2018, , 1-28.	0.2	0
1060	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. <i>Translational Lung Cancer Research</i> , 2018, 8, 107-115.	1.3	40
1061	NFAT control of immune function: New Frontiers for an Abiding Trooper. <i>F1000Research</i> , 2018, 7, 260.	0.8	139

#	ARTICLE	IF	CITATIONS
1062	The Contribution of Co-signaling Pathways to Anti-malarial T Cell Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2926.	2.2	7
1063	Novel EXO-T vaccine using polyclonal CD4 ⁺ T cells armed with HER2-specific exosomes for HER2-positive breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7089-7093.	1.0	27
1064	Immune checkpoint inhibitors and radiotherapyâ€”concept and review of current literature. <i>Annals of Translational Medicine</i> , 2018, 6, 155-155.	0.7	16
1065	Interferon-Î² signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 330-336.	1.0	52
1066	Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. <i>Annals of Gastroenterology</i> , 2018, 31, 670-679.	0.4	18
1067	T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. <i>Frontiers in Immunology</i> , 2018, 9, 2569.	2.2	241
1068	Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. <i>Melanoma Management</i> , 2018, 5, MMT10.	0.1	19
1069	Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. <i>Frontiers in Immunology</i> , 2018, 9, 2531.	2.2	32
1070	Harnessing immune checkpoints for cancer therapy. <i>Immunotherapy</i> , 2018, 10, 1265-1284.	1.0	9
1071	Contribution of Dendritic Cell Responses to Sepsis-Induced Immunosuppression and to Susceptibility to Secondary Pneumonia. <i>Frontiers in Immunology</i> , 2018, 9, 2590.	2.2	52
1072	HCV-Specific T Cell Responses During and After Chronic HCV Infection. <i>Viruses</i> , 2018, 10, 645.	1.5	40
1073	Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling. <i>PLoS ONE</i> , 2018, 13, e0206232.	1.1	22
1074	Mesothelinâ€”targeted second generation CARâ€”T cells inhibit growth of mesothelinâ€”expressing tumors in vivo. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 739-747.	0.8	21
1075	Hydrogen gas restores exhausted CD8 ⁺ T cells in patients with advanced colorectal cancer to improve prognosis. <i>Oncology Reports</i> , 2019, 41, 301-311.	1.2	44
1076	CD47 Expression in Natural Killer Cells Regulates Homeostasis and Modulates Immune Response to Lymphocytic Choriomeningitis Virus. <i>Frontiers in Immunology</i> , 2018, 9, 2985.	2.2	52
1077	Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8 ⁺ T Cells and Protect Against Recurrent Ocular Herpes Simplex Infection and Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2922.	2.2	24
1078	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. <i>Frontiers in Microbiology</i> , 2018, 9, 3158.	1.5	66
1079	High Levels of Eomes Promote Exhaustion of Anti-tumor CD8 ⁺ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2981.	2.2	137

#	ARTICLE	IF	CITATIONS
1080	Human CD8+HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+Foxp3+ Cells, Suppress Immune Responses via PD-1/PD-L1 Axis. <i>Frontiers in Immunology</i> , 2018, 9, 2788.	2.2	60
1081	The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy. <i>Frontiers in Medicine</i> , 2018, 5, 337.	1.2	2
1082	Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Hepatology Communications</i> , 2018, 2, 1451-1466.	2.0	21
1083	HBcAg-induced up-regulated 4-1BB ligand on B cells contributes to B cell hyperactivation during chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2018, 91, 781-790.	2.5	4
1084	CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2737.	2.2	123
1085	T cells and cytokines in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 594-599.	2.0	27
1086	Single-cell RNA sequencing unveils an IL-10-producing helper subset that sustains humoral immunity during persistent infection. <i>Nature Communications</i> , 2018, 9, 5037.	5.8	66
1087	Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research. <i>Transplantation Direct</i> , 2018, 4, e376.	0.8	98
1088	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	6.6	639
1089	Multivariate Computational Analysis of Gamma Delta T Cell Inhibitory Receptor Signatures Reveals the Divergence of Healthy and ART-Suppressed HIV+ Aging. <i>Frontiers in Immunology</i> , 2018, 9, 2783.	2.2	29
1090	Loss of T-Cell Multifunctionality and TCR-V β 2 Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV+ Patients. <i>Frontiers in Immunology</i> , 2018, 9, 2291.	2.2	28
1091	Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics. <i>Acta Haematologica</i> , 2018, 140, 131-140.	0.7	8
1092	Not All Immune Checkpoints Are Created Equal. <i>Frontiers in Immunology</i> , 2018, 9, 1909.	2.2	114
1093	Characterization of T cell immunophenotypes in intestinal transplantation: A pilot study. <i>Transplant Immunology</i> , 2018, 51, 50-57.	0.6	5
1094	Prostaglandin E2 facilitates Hepatitis B virus replication by impairing CTL function. <i>Molecular Immunology</i> , 2018, 103, 243-250.	1.0	11
1095	IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2347.	2.2	39
1096	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
1097	Therapeutic and immunoregulatory effects of water-soluble alkaloids E2-a from <i>Sophora moorcroftiana</i> seeds as a novel potential agent against echinococcosis in experimentally protoscolex-infected mice. <i>Veterinary Research</i> , 2018, 49, 100.	1.1	15

#	ARTICLE	IF	CITATIONS
1098	Targeting Immune Checkpoint Molecules to Eliminate Latent HIV. <i>Frontiers in Immunology</i> , 2018, 9, 2339.	2.2	32
1099	TdIF1: a putative oncogene in NSCLC tumor progression. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 28.	7.1	12
1100	T Cell Senescence and Tumor Immunotherapy. , 2018, , 1-24.		0
1101	Aging, Immunosenescence, and Transplantation Tolerance. , 2018, , 1-17.		0
1102	Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor. <i>Blood</i> , 2018, 132, 1899-1910.	0.6	20
1103	Epigenetic mechanisms regulating T-cell responses. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 728-743.	1.5	100
1104	PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 1995.	2.2	68
1105	PD-1 ⁺ TIM-3 ⁺ T cells in malignant ascites predict prognosis of gastrointestinal cancer. <i>Cancer Science</i> , 2018, 109, 2986-2992.	1.7	33
1106	Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. <i>JCI Insight</i> , 2018, 3, .	2.3	165
1107	An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. <i>PLoS ONE</i> , 2018, 13, e0198158.	1.1	20
1108	Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways. <i>BioDrugs</i> , 2018, 32, 481-497.	2.2	79
1109	Rheumatic immune-related adverse events from cancer immunotherapy. <i>Nature Reviews Rheumatology</i> , 2018, 14, 569-579.	3.5	162
1110	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K ^Î inhibitors and VIP antagonists. <i>Blood Advances</i> , 2018, 2, 210-223.	2.5	87
1111	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
1112	Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis. <i>International Journal of Clinical Oncology</i> , 2018, 23, 851-859.	1.0	6
1113	Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 657-670.	3.3	14
1114	T Lymphocyte-Based Cancer Immunotherapeutics. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 201-276.	1.6	22
1115	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	89

#	ARTICLE	IF	CITATIONS
1116	The Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 63-124.	1.6	77
1117	Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals. <i>Cancer Science</i> , 2018, 109, 2383-2390.	1.7	23
1118	Protein Kinase G Induces an Immune Response in Cows Exposed to <i>Mycobacterium avium</i> Subsp. <i>paratuberculosis</i> . <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	12
1119	CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. <i>Nature Communications</i> , 2018, 9, 2561.	5.8	41
1120	PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of <i>Toxoplasma gondii</i> . <i>Infection and Immunity</i> , 2018, 86, .	1.0	14
1121	Four Color ImmunoSpot® Assays for Identification of Effector T-Cell Lineages. <i>Methods in Molecular Biology</i> , 2018, 1808, 51-62.	0.4	7
1122	Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. <i>Clinical and Experimental Medicine</i> , 2018, 18, 487-494.	1.9	15
1123	Recent advances on T-cell exhaustion in malaria infection. <i>Medical Microbiology and Immunology</i> , 2018, 207, 167-174.	2.6	5
1124	<i>Quis Custodiet Ipsos Custodes</i> ? Regulation of Cell-Mediated Immune Responses Following Viral Lung Infections. <i>Annual Review of Virology</i> , 2018, 5, 363-383.	3.0	16
1125	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	1.8	48
1126	Immunotherapy treatment: an issue for metabolic response. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 140-151.	0.4	4
1127	Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: Clinical and prognostic implications. <i>Theranostics</i> , 2018, 8, 1956-1965.	4.6	36
1128	Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. <i>International Journal of Molecular Sciences</i> , 2018, 19, 340.	1.8	157
1129	Impact of benznidazole treatment on the functional response of <i>Trypanosoma cruzi</i> antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006480.	1.3	20
1130	Mechanistic Clues to Overcome Spaceflight-Induced Immune Dysregulation. <i>Current Pathobiology Reports</i> , 2018, 6, 185-192.	1.6	7
1131	Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1943.	2.2	32
1132	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 14.	2.2	356
1133	Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 19.	2.2	20

#	ARTICLE	IF	CITATIONS
1134	Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. <i>Frontiers in Immunology</i> , 2018, 9, 219.	2.2	48
1135	Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. <i>Frontiers in Immunology</i> , 2018, 9, 276.	2.2	91
1136	Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. <i>Frontiers in Immunology</i> , 2018, 9, 339.	2.2	133
1137	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. <i>Frontiers in Immunology</i> , 2018, 9, 385.	2.2	144
1138	Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta. <i>Frontiers in Immunology</i> , 2018, 9, 446.	2.2	52
1139	Next-Generation Sequencing Analysis of the Human TCR β + T-Cell Repertoire Reveals Shifts in V β - and VJ-Usage in Memory Populations upon Aging. <i>Frontiers in Immunology</i> , 2018, 9, 448.	2.2	31
1140	PD-L1 May Mediate T-Cell Exhaustion in a Case of Early Diffuse Leishmaniasis Caused by <i>Leishmania (L.) amazonensis</i> . <i>Frontiers in Immunology</i> , 2018, 9, 1021.	2.2	23
1141	The Janus Face of Follicular T Helper Cells in Chronic Viral Infections. <i>Frontiers in Immunology</i> , 2018, 9, 1162.	2.2	19
1142	T Cell Receptor-Major Histocompatibility Complex Interaction Strength Defines Trafficking and CD103+ Memory Status of CD8 T Cells in the Brain. <i>Frontiers in Immunology</i> , 2018, 9, 1290.	2.2	25
1143	Expansion and Antitumor Cytotoxicity of T-Cells Are Augmented by Substrate-Bound CCL21 and Intercellular Adhesion Molecule 1. <i>Frontiers in Immunology</i> , 2018, 9, 1303.	2.2	18
1144	Human $\alpha\beta$ and $\gamma\delta$ T Cells in Skin Immunity and Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1304.	2.2	83
1145	T Cell Repertoire Maturation Induced by Persistent and Latent Viral Infection Is Insufficient to Induce Costimulation Blockade Resistant Organ Allograft Rejection in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1371.	2.2	3
1146	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
1147	Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 152.	1.3	30
1148	Cooperation of PD-1 and LAG-3 in the exhaustion of CD4+ and CD8+ T cells during bovine leukemia virus infection. <i>Veterinary Research</i> , 2018, 49, 50.	1.1	22
1149	The Role of Inflammatory Cytokines in Creating T Cell Exhaustion in Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 267-273.	0.7	9
1150	Dual TGF β and PD-1 blockade synergistically enhances MAGEA3-specific CD8 ⁺ T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2561-2574.	2.3	68
1151	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1984.	1.8	31

#	ARTICLE	IF	CITATIONS
1152	Epigenetic Modulation of CD8+ T Cell Function in Lentivirus Infections: A Review. <i>Viruses</i> , 2018, 10, 227.	1.5	2
1153	Regulation of Memory CD8+ T Cell Differentiation by MicroRNAs. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 2187-2198.	1.1	18
1154	T cell senescence and CAR-T cell exhaustion in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2018, 11, 91.	6.9	172
1155	A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion. <i>Immunity</i> , 2018, 49, 11-13.	6.6	12
1156	Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. <i>Cancer Research</i> , 2018, 78, 5315-5326.	0.4	44
1157	Programmed cell death-1 3' untranslated region polymorphism is associated with spontaneous clearance of hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2018, 90, 1730-1738.	2.5	11
1158	Dysfunction of Circulating Natural Killer T Cells in Patients With Scrub Typhus. <i>Journal of Infectious Diseases</i> , 2018, 218, 1813-1821.	1.9	8
1159	Impact of congenital cytomegalovirus infection on transcriptomes from archived dried blood spots in relation to long-term clinical outcome. <i>PLoS ONE</i> , 2018, 13, e0200652.	1.1	5
1160	Differentiation and Function of Follicular CD8 T Cells During Human Immunodeficiency Virus Infection. <i>Frontiers in Immunology</i> , 2018, 9, 1095.	2.2	9
1161	A peripheral blood transcriptome biomarker test to diagnose functional recovery potential in advanced heart failure. <i>Biomarkers in Medicine</i> , 2018, 12, 619-635.	0.6	10
1162	Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. <i>Journal of Hematology and Oncology</i> , 2018, 11, 1.	6.9	196
1163	Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV. <i>Journal of Infectious Diseases</i> , 2018, 218, 937-945.	1.9	15
1164	Combined Inflammation and Metabolism Biomarker Indices of Robust and Impaired Physical Function in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1353-1359.	1.3	6
1165	<i>Dermal Immunology</i> . , 2018, , 175-194.		0
1166	New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. <i>Precision Clinical Medicine</i> , 2018, 1, 21-28.	1.3	16
1167	Measuring Immunological Age: From T Cell Repertoires to Populations. , 2018, , 1-62.		4
1168	Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. <i>Cancer Management and Research</i> , 2018, Volume 10, 941-951.	0.9	45
1169	Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). <i>Oncology Letters</i> , 2018, 16, 4105-4113.	0.8	58

#	ARTICLE	IF	CITATIONS
1170	HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction. <i>Nature Communications</i> , 2018, 9, 3450.	5.8	59
1171	High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. <i>Journal of Experimental Medicine</i> , 2018, 215, 2520-2535.	4.2	250
1172	Cholestasis induced liver pathology results in dysfunctional immune responses after arenavirus infection. <i>Scientific Reports</i> , 2018, 8, 12179.	1.6	7
1173	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
1174	Current indications for transplantation: stratification of severe heart failure and shared decision-making. <i>Annals of Cardiothoracic Surgery</i> , 2018, 7, 56-66.	0.6	14
1175	Kinetics and growth mechanism of the photoinduced synthesis of silver nanoparticles stabilized with lysozyme. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 172, 10-16.	2.5	9
1176	Engineering Platforms for T Cell Modulation. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 277-362.	1.6	8
1177	T cell exhaustion implications during transplantation. <i>Immunology Letters</i> , 2018, 202, 52-58.	1.1	8
1178	Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. <i>Oral Oncology</i> , 2018, 82, 75-82.	0.8	13
1179	CD4+T Cell Subsets and Pathways to HIV Latency. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 780-789.	0.5	16
1180	Low Levels of T Cell Exhaustion in Tuberculous Lung Granulomas. <i>Infection and Immunity</i> , 2018, 86, .	1.0	34
1181	Pre-existing malignancy results in increased prevalence of distinct populations of CD4+ T cells during sepsis. <i>PLoS ONE</i> , 2018, 13, e0191065.	1.1	11
1182	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. <i>Nature Medicine</i> , 2018, 24, 994-1004.	15.2	783
1183	Cancer Immunoediting. , 2018, , 27-44.		0
1184	Cancer as a Systemic Disease That Requires a Systemic Approach. , 2018, , 79-90.		2
1185	Gut Microbiota in Brain Development and Disorders of the CNS: Therapeutic Strategies Involving Dietary Modification, Pro- and Prebiotic Intervention, and Fecal Microbiota Transplantation (FMT) Therapy. , 2018, , 517-594.		0
1186	Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 648-652.	0.3	2
1187	Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 175-189.	1.3	6

#	ARTICLE	IF	CITATIONS
1188	Prevention and treatment of relapse after stem cell transplantation by cellular therapies. Bone Marrow Transplantation, 2019, 54, 26-34.	1.3	14
1189	Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia, 2019, 33, 64-74.	3.3	212
1190	RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations. Journal of Cystic Fibrosis, 2019, 18, 194-202.	0.3	17
1191	The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. Trends in Cell Biology, 2019, 29, 31-43.	3.6	79
1192	Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?. Cancer Biology and Therapy, 2019, 20, 138-140.	1.5	14
1193	Macrophages. International Review of Cell and Molecular Biology, 2019, 342, 73-93.	1.6	135
1194	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity, 2019, 52, 144-160.	1.2	10
1195	Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 1547-1561.	1.6	66
1196	CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B. BMC Immunology, 2019, 20, 27.	0.9	90
1197	Extensive exploration of T cell heterogeneity in cancers by single cell sequencing. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 410-418.	0.7	3
1198	Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade. Journal of Immunology, 2019, 203, 1105-1110.	0.4	29
1199	LTMC: a novel statistical modeling of transcriptional expression states in single-cell RNA-Seq data. Nucleic Acids Research, 2019, 47, e111-e111.	6.5	46
1200	Immune checkpoint inhibitor-mediated myocarditis and ventricular tachycardia storm. Heart Rhythm Case Reports, 2019, 5, 497-500.	0.2	12
1201	Human Oral Epithelial Cells Impair Bacteria-Mediated Maturation of Dendritic Cells and Render T Cells Unresponsive to Stimulation. Frontiers in Immunology, 2019, 10, 1434.	2.2	20
1202	Nucleic acid vaccines for hepatitis B and C virus. Infection, Genetics and Evolution, 2019, 75, 103968.	1.0	11
1203	T cell senescence and its correlation to inflammaging process of patients with systemic lupus erythematosus. AIP Conference Proceedings, 2019, , .	0.3	0
1204	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43.	2.0	18
1205	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 1919-1928.	0.6	13

#	ARTICLE	IF	CITATIONS
1206	A long way to the battlefield: CAR T cell therapy against solid cancers. <i>Journal of Cancer</i> , 2019, 10, 3112-3123.	1.2	26
1207	Caffeine-enhanced anti-tumor immune response through decreased expression of PD1 on infiltrated cytotoxic T lymphocytes. <i>European Journal of Pharmacology</i> , 2019, 859, 172538.	1.7	15
1208	The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells. <i>Biochemistry (Moscow)</i> , 2019, 84, 695-710.	0.7	5
1209	Immunology of <i>Mycobacterium tuberculosis</i> Infections. <i>Microbiology Spectrum</i> , 2019, 7, .	1.2	152
1210	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
1211	Antiretroviral Therapy Administration in Healthy Rhesus Macaques Is Associated with Transient Shifts in Intestinal Bacterial Diversity and Modest Immunological Perturbations. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
1212	The Role of Checkpoint Inhibitors in Glioblastoma. <i>Targeted Oncology</i> , 2019, 14, 375-394.	1.7	30
1213	SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1485-1496.	1.6	34
1214	Alveolar Macrophage Dysfunction and Increased PD-1 Expression During Chronic SIV Infection of Rhesus Macaques. <i>Frontiers in Immunology</i> , 2019, 10, 1537.	2.2	15
1215	HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. <i>Scientific Reports</i> , 2019, 9, 10624.	1.6	27
1216	T Cell Dysfunction in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1719.	2.2	219
1217	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 405-416.	2.9	63
1218	Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer. <i>Cancer Research</i> , 2019, 79, 5008-5021.	0.4	34
1219	Equine arteritis virus long-term persistence is orchestrated by CD8+ T lymphocyte transcription factors, inhibitory receptors, and the CXCL16/CXCR6 axis. <i>PLoS Pathogens</i> , 2019, 15, e1007950.	2.1	20
1220	Chronic hepatitis B virus infection drives changes in systemic immune activation profile in patients coinfecting with <i>Plasmodium vivax</i> malaria. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007535.	1.3	14
1221	TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. <i>Nature</i> , 2019, 571, 265-269.	13.7	581
1222	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. <i>Cancer Discovery</i> , 2019, 9, 1192-1207.	7.7	65
1223	Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 489-504.	0.6	7

#	ARTICLE	IF	CITATIONS
1224	CXCR5+ CD8 T Cells: Protective or Pathogenic?. <i>Frontiers in Immunology</i> , 2019, 10, 1322.	2.2	44
1225	Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression. <i>Autoimmunity</i> , 2019, 52, 102-107.	1.2	0
1226	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
1227	Understanding CD8+ T Cell Immunity to <i>Trypanosoma cruzi</i> and How to Improve It. <i>Trends in Parasitology</i> , 2019, 35, 899-917.	1.5	34
1228	NK Cell-Fc Receptors Advance Tumor Immunotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1667.	1.0	17
1229	Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. <i>Nature Communications</i> , 2019, 10, 4706.	5.8	460
1230	Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. <i>Seminars in Immunology</i> , 2019, 42, 101305.	2.7	189
1231	CD8+ T Cell Responses to <i>Toxoplasma gondii</i> : Lessons from a Successful Parasite. <i>Trends in Parasitology</i> , 2019, 35, 887-898.	1.5	23
1232	Advances in T-cell co-receptor biology and cancer immunotherapy. <i>Seminars in Immunology</i> , 2019, 42, 101281.	2.7	2
1233	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. <i>Seminars in Immunology</i> , 2019, 42, 101295.	2.7	16
1234	Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. <i>Seminars in Immunology</i> , 2019, 42, 101306.	2.7	17
1235	Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments. <i>Vaccines</i> , 2019, 7, 156.	2.1	23
1236	Increasing influenza immunization rates among healthcare providers in an ambulatory-based, University Healthcare Setting†. <i>International Journal for Quality in Health Care</i> , 2019, 31, 698-703.	0.9	2
1237	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Treatment of Adults With Metastatic Brain Tumors: Executive Summary. <i>Neurosurgery</i> , 2019, 84, 550-552.	0.6	37
1238	Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. <i>PLoS Pathogens</i> , 2019, 15, e1008080.	2.1	58
1239	VEGF-A drives TOX-dependent T cell exhaustion in anti-“PD-1”resistant microsatellite stable colorectal cancers. <i>Science Immunology</i> , 2019, 4, .	5.6	148
1240	Novel Immunotherapy Combinations. <i>Current Oncology Reports</i> , 2019, 21, 96.	1.8	12
1241	PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2041-2054.	2.0	72

#	ARTICLE	IF	CITATIONS
1242	IL-10-producing T cells and their dual functions. <i>Seminars in Immunology</i> , 2019, 44, 101335.	2.7	78
1243	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. <i>Head and Neck</i> , 2019, 41, 4-18.	0.9	40
1244	Factors Affecting the Tissue Damaging Consequences of Viral Infections. <i>Frontiers in Microbiology</i> , 2019, 10, 2314.	1.5	16
1245	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019, 11, 1525.	1.7	28
1246	Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4+T cells. <i>Cell Death and Disease</i> , 2019, 10, 15.	2.7	33
1247	The Immune Checkpoint Protein Programmed Death 1 During HIV Infection in Children: Clinical Relevance and Beyond. <i>Journal of Infectious Diseases</i> , 2019, 219, 1353-1355.	1.9	0
1248	HBV-Induced Immune Imbalance in the Development of HCC. <i>Frontiers in Immunology</i> , 2019, 10, 2048.	2.2	174
1249	Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1926.	2.2	41
1250	Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics—analysis of a new mathematical model. <i>Intensive Care Medicine Experimental</i> , 2019, 7, 32.	0.9	8
1251	Antigen-specific immune decoys intercept and exhaust autoimmunity to prevent disease. <i>Biomaterials</i> , 2019, 222, 119440.	5.7	11
1252	Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumorigenesis. <i>Scientific Reports</i> , 2019, 9, 12284.	1.6	48
1253	CD4+ T-Cell Cycling in HIV-Infected Patients with the Discordant Immunologic Response to the Antiretroviral Therapy. <i>Cell and Tissue Biology</i> , 2019, 13, 55-63.	0.2	3
1254	Anti- β -cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2246-2257.	1.9	61
1255	Striking a Balance—Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation. <i>Frontiers in Immunology</i> , 2019, 10, 1595.	2.2	23
1256	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
1257	New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota. <i>Clinical and Translational Medicine</i> , 2019, 8, 23.	1.7	20
1258	Shedding light on complexity of protein-protein interactions in cancer. <i>Current Opinion in Chemical Biology</i> , 2019, 53, 75-81.	2.8	7
1259	The multifaceted immune regulation of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 613-630.	1.9	123

#	ARTICLE	IF	CITATIONS
1260	HIV Infection Is Associated With Downregulation of BTLA Expression on Mycobacterium tuberculosis-Specific CD4 T Cells in Active Tuberculosis Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1983.	2.2	9
1261	The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like. <i>Frontiers in Immunology</i> , 2019, 10, 2251.	2.2	48
1262	Modulation of the inflammatory tumor microenvironment: a new approach for photothermal-synergized cancer immunotherapy. <i>Nanomedicine</i> , 2019, 14, 2101-2104.	1.7	5
1263	IL-2 Restores T-Cell Dysfunction Induced by Persistent Mycobacterium tuberculosis Antigen Stimulation. <i>Frontiers in Immunology</i> , 2019, 10, 2350.	2.2	31
1264	Pro-Cellular Exhaustion Markers are Associated with Splenic Microarchitecture Disorganization and Parasite Load in Dogs with Visceral Leishmaniasis. <i>Scientific Reports</i> , 2019, 9, 12962.	1.6	11
1265	Defining "T cell exhaustion". <i>Nature Reviews Immunology</i> , 2019, 19, 665-674.	10.6	879
1266	Endogenous n-3 Polyunsaturated Fatty Acids Are Beneficial to Dampen CD8+ T Cell-Mediated Inflammatory Response upon the Viral Infection in Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4510.	1.8	15
1267	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4654.	1.8	29
1268	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. <i>Molecular Aspects of Medicine</i> , 2019, 70, 117-126.	2.7	41
1269	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. <i>Cancer Microenvironment</i> , 2019, 12, 119-132.	3.1	46
1270	Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. <i>Immunology Letters</i> , 2019, 216, 43-50.	1.1	21
1271	TIM-3 as a marker of exhaustion in CD8+ T cells of active chronic hepatitis B patients. <i>Microbial Pathogenesis</i> , 2019, 128, 323-328.	1.3	28
1272	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 501.	1.8	39
1273	Combined treatment with HMG1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice. , 2019, 7, 21.		11
1274	Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 1635-1645.	0.4	42
1275	Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge. <i>PLoS ONE</i> , 2019, 14, e0210252.	1.1	32
1276	Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 231-244.	1.5	71
1277	CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. <i>Annual Review of Immunology</i> , 2019, 37, 457-495.	9.5	1,143

#	ARTICLE	IF	CITATIONS
1278	Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4+ memory T cells. <i>Nature Communications</i> , 2019, 10, 2263.	5.8	57
1279	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. <i>Advances in Cancer Research</i> , 2019, 144, 193-261.	1.9	19
1280	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , 2019, 71, 673-684.	1.8	25
1281	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. <i>Journal of Cancer</i> , 2019, 10, 1764-1771.	1.2	11
1282	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 6570-6580.	3.2	83
1283	Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. <i>Nature Communications</i> , 2019, 10, 2681.	5.8	69
1284	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 2128-2149.	4.2	160
1285	Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 14113-14118.	3.3	157
1286	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. <i>Oncotmunology</i> , 2019, 8, e1633235.	2.1	70
1288	Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1273-1286.	2.0	5
1289	Chimeric antigen receptor T cell therapy for multiple myeloma. <i>Inflammation and Regeneration</i> , 2019, 39, 10.	1.5	8
1290	TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 731-741.	1.8	193
1291	Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1393-1405.	1.6	24
1292	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 603-613.	13.9	584
1293	CD45RA+CCR7 ^{hi} CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
1294	<i>Helicobacter pylori</i> Deregulates T and B Cell Signaling to Trigger Immune Evasion. <i>Current Topics in Microbiology and Immunology</i> , 2019, 421, 229-265.	0.7	23
1295	CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo. <i>PLoS Pathogens</i> , 2019, 15, e1007748.	2.1	57
1296	PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis. <i>Frontiers in Immunology</i> , 2019, 10, 783.	2.2	33

#	ARTICLE	IF	CITATIONS
1297	The Clinical Significance of Programmed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Nontuberculous Mycobacteria-Lung Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 736.	1.0	21
1298	Exhausted and Senescent T Cells at the Maternal-Fetal Interface in Preterm and Term Labor. <i>Journal of Immunology Research</i> , 2019, 2019, 1-16.	0.9	44
1299	Proteomic Profiling Unravels a Key Role of Specific Macrophage Subtypes in Sporadic Inclusion Body Myositis. <i>Frontiers in Immunology</i> , 2019, 10, 1040.	2.2	17
1300	Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1034.	2.2	39
1301	Dependence of CD8 T Cell Response upon Antigen Load During Primary Infection. <i>Bulletin of Mathematical Biology</i> , 2019, 81, 2553-2568.	0.9	7
1302	The Evolving Role of CD8+CD28 ^{hi} Immunosenescent T Cells in Cancer Immunology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2810.	1.8	105
1303	Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. <i>BMC Infectious Diseases</i> , 2019, 19, 433.	1.3	8
1304	Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNF α Blocker Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 887.	2.2	5
1305	Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. <i>Frontiers in Immunology</i> , 2019, 10, 1114.	2.2	41
1306	Molecular Mechanisms of Inflammation: Induction, Resolution and Escape by <i>Helicobacter pylori</i> . <i>Current Topics in Microbiology and Immunology</i> , 2019, , .	0.7	5
1307	Virus Control of Cell Metabolism for Replication and Evasion of Host Immune Responses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 95.	1.8	87
1308	PD1 pathway in immune-mediated myopathies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e558.	3.1	42
1310	Activation and Impaired Tumor Necrosis Factor- α Production of Circulating Mucosal-Associated Invariant T Cells in Patients with Trauma. <i>Journal of Innate Immunity</i> , 2019, 11, 506-515.	1.8	4
1311	An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of <i>Trypanosoma cruzi</i> That Depicts the Multifunctionality and Dysfunctionality of T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 918.	2.2	32
1312	Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells. <i>Journal of Immunology</i> , 2019, 203, 48-57.	0.4	53
1313	Translation of cancer immunotherapy from the bench to the bedside. <i>Advances in Cancer Research</i> , 2019, 143, 1-62.	1.9	28
1314	Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8 ⁺ T Cells in Murine Syngeneic Tumor Models. <i>Cancer Immunology Research</i> , 2019, 7, 963-976.	1.6	36
1315	Clinical significance of CD8 ⁺ T cell immunoreceptor with Ig and ITIM domains in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. <i>Oncolmmunology</i> , 2019, 8, e1593807.	2.1	35

#	ARTICLE	IF	CITATIONS
1316	Multiplex MHC Class I Tetramer Combined with Intranuclear Staining by Mass Cytometry. <i>Methods in Molecular Biology</i> , 2019, 1989, 147-158.	0.4	8
1317	Engineering immunomodulatory biomaterials for type 1 diabetes. <i>Nature Reviews Materials</i> , 2019, 4, 429-450.	23.3	89
1318	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
1319	Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction. <i>RSC Advances</i> , 2019, 9, 14944-14956.	1.7	23
1320	Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-stimulatory Signal Domain Exhibits High Functional Potency. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 27-37.	2.0	12
1321	Immunometabolism: A new target for improving cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 195-253.	1.9	30
1322	TCR activation mimics CD127 ^{low} PD-1 ^{high} phenotype and functional alterations of T lymphocytes from septic shock patients. <i>Critical Care</i> , 2019, 23, 131.	2.5	12
1323	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 896-909.	1.6	64
1324	T cell metabolism in chronic viral infection. <i>Clinical and Experimental Immunology</i> , 2019, 197, 143-152.	1.1	39
1325	Cholesterol Induces CD8 ⁺ T Cell Exhaustion in the Tumor Microenvironment. <i>Cell Metabolism</i> , 2019, 30, 143-156.e5.	7.2	460
1326	BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. <i>BMC Cancer</i> , 2019, 19, 387.	1.1	17
1327	CD8 ⁺ T cell exhaustion. <i>Seminars in Immunopathology</i> , 2019, 41, 327-337.	2.8	169
1328	CXCR5 ⁺ CD8 ⁺ T cells are a distinct functional subset with an antitumor activity. <i>Leukemia</i> , 2019, 33, 2640-2653.	3.3	40
1329	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
1330	A blood-based prognostic biomarker in IBD. <i>Gut</i> , 2019, 68, 1386-1395.	6.1	132
1331	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. <i>Cancer Immunology Research</i> , 2019, 7, 759-772.	1.6	235
1332	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	5.8	120
1333	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 453-470.	1.3	28

#	ARTICLE	IF	CITATIONS
1334	Generation and persistence of human tissue-resident memory T cells in lung transplantation. <i>Science Immunology</i> , 2019, 4, .	5.6	203
1335	From the "missing self" hypothesis to adaptive NK cells: Insights of NK cell-mediated effector functions in immune surveillance. <i>Journal of Leukocyte Biology</i> , 2019, 105, 955-971.	1.5	23
1336	Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation. , 2019, 7, 55.		16
1337	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. <i>Cancers</i> , 2019, 11, 272.	1.7	15
1338	Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 151.	1.3	43
1339	Towards multiscale modeling of the CD8 ⁺ T cell response to viral infections. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2019, 11, e1446.	6.6	16
1340	Tumor infiltrating lymphocytes: The regulator of melanoma evolution (Review). <i>Oncology Letters</i> , 2019, 17, 4155-4161.	0.8	66
1341	T-cell aging in end-stage renal disease: an evolving story with CMV. <i>Medical Microbiology and Immunology</i> , 2019, 208, 281-287.	2.6	5
1342	The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis. <i>Clinical Immunology</i> , 2019, 202, 18-28.	1.4	13
1343	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32
1344	Roles of NKT cells in cancer immunotherapy. <i>Archives of Pharmacal Research</i> , 2019, 42, 543-548.	2.7	72
1345	Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths. <i>Scientific Reports</i> , 2019, 9, 2899.	1.6	13
1347	CD8 ⁺ T Cell Response to <i>Trypanosoma cruzi</i> Antigens during Chronic Chagas Disease. <i>Methods in Molecular Biology</i> , 2019, 1955, 349-361.	0.4	3
1348	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. <i>Nature Neuroscience</i> , 2019, 22, 729-740.	7.1	327
1349	Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. <i>Cytotherapy</i> , 2019, 21, 593-602.	0.3	30
1350	Engineering an Artificial T _H Cell Stimulating Matrix for Immunotherapy. <i>Advanced Materials</i> , 2019, 31, e1807359.	11.1	74
1351	Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 960-973.	3.7	24
1352	A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. <i>Nature Communications</i> , 2019, 10, 1668.	5.8	78

#	ARTICLE	IF	CITATIONS
1353	Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 931.	2.2	15
1354	T cell anergy in perinatal mice is promoted by T reg cells and prevented by IL-33. <i>Journal of Experimental Medicine</i> , 2019, 216, 1328-1344.	4.2	27
1355	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. <i>Structure</i> , 2019, 27, 829-836.e3.	1.6	13
1356	Location, location, location: Tissue resident memory T cells in mice and humans. <i>Science Immunology</i> , 2019, 4, .	5.6	406
1357	The Microbiome Associated with Lung Cancer. <i>Current Cancer Research</i> , 2019, , 151-166.	0.2	0
1358	Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. <i>Scientific Reports</i> , 2019, 9, 2447.	1.6	116
1359	Complexities of Type I Interferon Biology: Lessons from LCMV. <i>Viruses</i> , 2019, 11, 172.	1.5	22
1360	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
1361	Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4 ⁺ and CD8 ⁺ T _{RM} Cells Associated with Protection against Recurrent Genital Herpes. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
1362	Acute Traumatic Brain Injury Induces CD4 ⁺ and CD8 ⁺ T Cell Functional Impairment by Upregulating the Expression of PD-1 via the Activated Sympathetic Nervous System. <i>NeuroImmunoModulation</i> , 2019, 26, 43-57.	0.9	20
1363	Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection. <i>Science Immunology</i> , 2019, 4, .	5.6	57
1364	Accumulation of exhausted CD8 ⁺ T cells in extramammary Paget's disease. <i>PLoS ONE</i> , 2019, 14, e0211135.	1.1	12
1365	Chronic virus infection compromises memory bystander T cell function in an IL-6/STAT1-dependent manner. <i>Journal of Experimental Medicine</i> , 2019, 216, 571-586.	4.2	17
1366	The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T Cells During Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2019, 10, 169.	2.2	66
1367	Sustained Type I Interferon Reinforces NK Cell-Mediated Cancer Immunosurveillance during Chronic Virus Infection. <i>Cancer Immunology Research</i> , 2019, 7, 584-599.	1.6	27
1368	Influenza Vaccination Induces NK-Cell-Mediated Type-II IFN Response that Regulates Humoral Immunity in an IL-6-Dependent Manner. <i>Cell Reports</i> , 2019, 26, 2307-2315.e5.	2.9	51
1369	NR4A transcription factors limit CAR T cell function in solid tumours. <i>Nature</i> , 2019, 567, 530-534.	13.7	519
1370	Neutrophil Dysfunction in the Airways of Children with Acute Respiratory Failure Due to Lower Respiratory Tract Viral and Bacterial Coinfections. <i>Scientific Reports</i> , 2019, 9, 2874.	1.6	39

#	ARTICLE	IF	CITATIONS
1371	Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. <i>Nature Immunology</i> , 2019, 20, 326-336.	7.0	1,148
1372	A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRP1± expression. <i>Nature Communications</i> , 2019, 10, 794.	5.8	46
1373	Epstein-Barr Virus in Multiple Sclerosis. , 2019, , .		1
1374	A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17393-17398.	3.3	33
1375	Prognostic and Therapeutic Implications of Lymphocytes in Hematological Disorders and Solid Malignancies. , 0, , .		0
1376	Immunology of <i>Mycobacterium tuberculosis</i> <i>Infections</i> . , 2019, , 1056-1086.		15
1377	Assessment of TCR signal strength of antigen-specific memory CD8+ T cells in human blood. <i>Blood Advances</i> , 2019, 3, 2153-2163.	2.5	10
1378	Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20070-20076.	3.3	39
1379	Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 776-776.	0.7	29
1380	Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. <i>Cancers</i> , 2019, 11, 2024.	1.7	12
1381	Immunotherapy using anti-PD-1 and anti-PD-L1 in <i>Leishmania amazonensis</i> -infected BALB/c mice reduce parasite load. <i>Scientific Reports</i> , 2019, 9, 20275.	1.6	27
1382	Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. <i>Scientific Reports</i> , 2019, 9, 17252.	1.6	20
1383	Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7981-8000.	4.6	106
1384	Prolonged Antiretroviral Therapy in Adolescents With Vertical HIV Infection Leads to Different Cytokine Profiles Depending on Viremia Persistence. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1115-1120.	1.1	6
1385	Tâ€cell exhaustion in HIV infection. <i>Immunological Reviews</i> , 2019, 292, 149-163.	2.8	217
1386	Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. <i>Frontiers in Immunology</i> , 2019, 10, 2832.	2.2	34
1387	Helminth-induced Th2 cell dysfunction is distinct from exhaustion and is maintained in the absence of antigen. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007908.	1.3	21
1388	Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. <i>Cell Reports</i> , 2019, 29, 3916-3932.e5.	2.9	69

#	ARTICLE	IF	CITATIONS
1389	PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. <i>Nature Immunology</i> , 2019, 20, 1335-1347.	7.0	142
1390	PD-1 Expression and Function of T-Cell Subsets in TILs From Human Lung Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 297-308.	1.2	9
1391	Enforcing the checkpoints. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 213-218.	1.2	25
1392	<p>Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9757-9765.	1.0	10
1393	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1237.	1.3	106
1394	<p>Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10791-10800.	0.9	8
1395	In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1). <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 436.	1.8	7
1396	Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	4
1397	Altered Tâ€cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. <i>Journal of Cellular Physiology</i> , 2019, 234, 4924-4933.	2.0	45
1398	Submicroscopic <i>Plasmodium</i> infection during pregnancy is associated with reduced antibody levels to tetanus toxoid. <i>Clinical and Experimental Immunology</i> , 2018, 195, 96-108.	1.1	7
1399	PI3KÎ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1427-1438.	3.3	51
1400	Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 49.	1.8	35
1401	Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. <i>Gastroenterology</i> , 2019, 156, 325-337.	0.6	140
1402	A novel approach to candidemia? The potential role of checkpoint inhibition. <i>Medical Mycology</i> , 2019, 57, 151-154.	0.3	9
1403	IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. <i>Oncolmmunology</i> , 2019, 8, e1515058.	2.1	14
1404	HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. <i>Journal of Virology</i> , 2019, 93, .	1.5	48
1405	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
1406	Immunological cure of HBV infection. <i>Hepatology International</i> , 2019, 13, 113-124.	1.9	38

#	ARTICLE	IF	CITATIONS
1407	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
1408	Malaria vaccines in the eradication era: current status and future perspectives. <i>Expert Review of Vaccines</i> , 2019, 18, 133-151.	2.0	30
1409	Immunotherapy With Antiprogrammed Cell Death 1 Antibody Improves Outcome in a Mouse Model of Spinal Cord Injury Followed by <i>Staphylococcus aureus</i> Pneumonia. <i>Critical Care Medicine</i> , 2019, 47, e28-e35.	0.4	2
1410	TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 632-641.	1.9	39
1411	T cell Subsets in Peripheral Blood of Women with Recurrent Implantation Failure. <i>Journal of Reproductive Immunology</i> , 2019, 131, 21-29.	0.8	48
1412	Hepatitis C: Is eradication possible?. <i>Liver International</i> , 2019, 39, 416-426.	1.9	78
1413	Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets. <i>British Journal of Pharmacology</i> , 2019, 176, 3558-3584.	2.7	17
1414	Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8 ⁺ effector memory T cells. <i>Gut</i> , 2019, 68, 2032-2043.	6.1	22
1415	Cellular Senescence: Aging, Cancer, and Injury. <i>Physiological Reviews</i> , 2019, 99, 1047-1078.	13.1	641
1416	LIN28 ^{hi} /let-7 ^{hi} /PD-L1 Pathway as a Target for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 487-497.	1.6	71
1417	Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8 ⁺ T Cells. <i>Cancer Immunology Research</i> , 2019, 7, 476-486.	1.6	59
1418	Sepsis erodes CD8 ⁺ memory T cell-protective immunity against an EBV homolog in a 2B4-dependent manner. <i>Journal of Leukocyte Biology</i> , 2019, 105, 565-575.	1.5	13
1419	Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 378-398.	2.6	66
1420	The E ^{1/4} -TCL1 Mouse Model of Chronic Lymphocytic Leukemia. , 2019, , 1-29.		0
1421	A SERS microfluidic platform for targeting multiple soluble immune checkpoints. <i>Biosensors and Bioelectronics</i> , 2019, 126, 178-186.	5.3	48
1422	SLAMF6 in health and disease: Implications for therapeutic targeting. <i>Clinical Immunology</i> , 2019, 204, 3-13.	1.4	9
1423	T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. <i>Journal of Medical Genetics</i> , 2019, 56, 22-28.	1.5	12
1424	Î±-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8 ⁺ T-cell infiltration. <i>Immunotherapy</i> , 2019, 11, 101-118.	1.0	15

#	ARTICLE	IF	CITATIONS
1425	Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. <i>Oncolimmunology</i> , 2019, 8, e1535730.	2.1	57
1426	mTORC2 deficiency in cutaneous dendritic cells potentiates CD8+ effector T cell responses and accelerates skin graft rejection. <i>American Journal of Transplantation</i> , 2019, 19, 646-661.	2.6	9
1427	Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , 2019, 33, 625-637.	3.3	55
1428	Genomic and epigenomic perspectives of T-cell exhaustion in cancer. <i>Briefings in Functional Genomics</i> , 2019, 18, 113-118.	1.3	6
1429	MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity. <i>Journal of Proteomics</i> , 2019, 191, 48-57.	1.2	11
1430	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 3-22.	6.6	44
1431	Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients. <i>Pathology and Oncology Research</i> , 2020, 26, 499-505.	0.9	43
1432	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 77-85.	1.3	4
1433	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
1434	CD8 ⁺ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. <i>Leukemia and Lymphoma</i> , 2020, 61, 351-356.	0.6	17
1435	Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 195-218.	2.3	35
1436	The role of DNA-demethylating agents in cancer therapy. , 2020, 205, 107416.		26
1437	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. <i>Modern Pathology</i> , 2020, 33, 603-615.	2.9	34
1439	Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury. <i>Gut</i> , 2020, 69, 133-145.	6.1	14
1440	Targeting B7 ϵ 1 in immunotherapy. <i>Medicinal Research Reviews</i> , 2020, 40, 654-682.	5.0	44
1441	Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells <i>in vivo</i> . <i>Haematologica</i> , 2020, 105, 796-807.	1.7	17
1442	Determinants of response and resistance to CAR T cell therapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 80-90.	4.3	59
1443	ATM activity in T cells is critical for immune surveillance of lymphoma <i>in vivo</i> . <i>Leukemia</i> , 2020, 34, 771-786.	3.3	13

#	ARTICLE	IF	CITATIONS
1444	Differential Expression of Immune Checkpoint Molecules on CD8 ⁺ T Cells Specific for Immunodominant and Subdominant Herpes Simplex Virus 1 Epitopes. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
1445	Metformin Effects on FOXP3 + and CD8 + T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2020, 130, E490-E498.	1.1	24
1446	7-oxo-DHEA enhances impaired M. tuberculosis-specific T cell responses during HIV-TB coinfection. <i>Journal of Biomedical Science</i> , 2020, 27, 20.	2.6	4
1447	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. <i>Immunological Medicine</i> , 2020, 43, 10-15.	1.4	3
1448	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. <i>Nanoscale</i> , 2020, 12, 413-436.	2.8	49
1449	Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. <i>Oral Oncology</i> , 2020, 101, 104554.	0.8	18
1450	Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 27-35.	4.8	168
1451	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.	2.5	92
1452	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111876.	2.6	98
1453	The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 1652-1664.	2.6	52
1454	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	58
1455	Immuno-Oncology. <i>Methods in Pharmacology and Toxicology</i> , 2020, , .	0.1	4
1456	Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 1763-1772.	3.2	64
1457	Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells. <i>Journal of Immunotherapy</i> , 2020, 43, 79-88.	1.2	14
1458	An Introduction to CAR Immunotherapy. , 2020, , 1-11.		1
1459	Challenges and Opportunities to Improve CAR T-Cell Therapy. , 2020, , 63-80.		1
1460	HTLV infected individuals have increased B-cell activation and proinflammatory regulatory T-cells. <i>Immunobiology</i> , 2020, 225, 151878.	0.8	2
1461	Stem, Effector, and Hybrid States of Memory CD8+ T Cells. <i>Trends in Immunology</i> , 2020, 41, 17-28.	2.9	65

#	ARTICLE	IF	CITATIONS
1462	T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. <i>Aids</i> , 2020, 34, 15-24.	1.0	21
1463	CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer. , 2020, , 199-208.		0
1464	Single-Cell RNA Sequencing Reveals the Diversity of the Immunological Landscape following Central Nervous System Infection by a Murine Coronavirus. <i>Journal of Virology</i> , 2020, 94, .	1.5	19
1465	EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e876.	3.1	6
1466	Chemokine Signatures of Pathogen-Specific T Cells II: Memory T Cells in Acute and Chronic Infection. <i>Journal of Immunology</i> , 2020, 205, 2188-2206.	0.4	7
1467	A Hydrogel-Integrated Culture Device to Interrogate T Cell Activation with Physicochemical Cues. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 47355-47367.	4.0	27
1468	Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary. <i>Frontiers in Immunology</i> , 2020, 11, 2046.	2.2	25
1469	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094748.	0.8	3
1470	Identification of Interleukin β as an Amplifier of Interferon alpha-induced Antiviral Responses. <i>PLoS Pathogens</i> , 2020, 16, e1008461.	2.1	5
1471	Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. <i>Pathogens</i> , 2020, 9, 850.	1.2	16
1472	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
1473	Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export. <i>Oncotarget</i> , 2020, 9, 1831153.	2.1	28
1474	Tumor Fibroblast-Derived FGF2 Regulates Expression of SPRY1 in Esophageal Tumor-Infiltrating T Cells and Plays a Role in T-cell Exhaustion. <i>Cancer Research</i> , 2020, 80, 5583-5596.	0.4	22
1475	TNF contributes to T-cell exhaustion in chronic <i>L. mexicana</i> infections of mice through PD-L1 up-regulation. <i>Cellular Immunology</i> , 2020, 358, 104196.	1.4	4
1476	Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. <i>Nature Immunology</i> , 2020, 21, 1552-1562.	7.0	167
1477	Pro-tumor β T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 2186.	2.2	29
1478	Immunological approaches to HIV cure. <i>Seminars in Immunology</i> , 2021, 51, 101412.	2.7	39
1479	Immunotherapy for Localized Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 443-456.	0.8	9

#	ARTICLE	IF	CITATIONS
1480	MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy. <i>Biomolecules</i> , 2020, 10, 1040.	1.8	51
1481	Hybrid spherical nucleotide nanoparticles can enhance the synergistic anti-tumor effect of CTLA-4 and PD-1 blockades. <i>Biomaterials Science</i> , 2020, 8, 4757-4766.	2.6	9
1482	PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma. <i>Pathology Research and Practice</i> , 2020, 216, 153096.	1.0	2
1483	Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 761-767.	1.3	7
1484	Chagas Disease. , 2020, , .		6
1485	PD1 expression on bone marrow T cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy. <i>EJHaem</i> , 2020, 1, 51-57.	0.4	0
1486	Effect of age and sex on immune checkpoint expression and kinetics in human T cells. <i>Immunity and Ageing</i> , 2020, 17, 32.	1.8	8
1487	Complement and Cancer—A Dysfunctional Relationship?. <i>Antibodies</i> , 2020, 9, 61.	1.2	10
1488	Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. , 2020, 8, e001478.		22
1489	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. , 2020, 8, e001392.		27
1490	Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 134.	2.2	12
1491	Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. <i>Genes and Development</i> , 2020, 34, 1577-1598.	2.7	19
1492	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <i>Frontiers in Microbiology</i> , 2020, 11, 588409.	1.5	19
1493	Mitochondrial Damage and the Road to Exhaustion. <i>Cell Metabolism</i> , 2020, 32, 905-907.	7.2	13
1494	PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer. , 2020, 8, e000422.		22
1495	Immunology of sarcoidosis: old companions, new relationships. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 535-543.	1.2	10
1496	T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	17
1497	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205

#	ARTICLE	IF	CITATIONS
1498	TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 6694-6709.	1.3	34
1499	Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer. <i>Journal of Theoretical Biology</i> , 2020, 505, 110403.	0.8	5
1500	A generalizable data-driven multicellular model of pancreatic ductal adenocarcinoma. <i>GigaScience</i> , 2020, 9, .	3.3	20
1501	Novel cucurmosinâ€based immunotoxin targeting programmed cell death 1â€ligand 1 with high potency against human tumor in vitro and in vivo. <i>Cancer Science</i> , 2020, 111, 3184-3194.	1.7	10
1502	NRP1 cripples immunological memory. <i>Nature Immunology</i> , 2020, 21, 972-973.	7.0	4
1503	NF-ÎB in the New Era of Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 677-687.	3.8	49
1504	Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection. <i>Molecular Therapy</i> , 2020, 28, 1795-1805.	3.7	4
1505	Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 677-694.	2.4	6
1506	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. <i>Cells</i> , 2020, 9, 1727.	1.8	8
1507	Host Transcriptional Response to Persistent Infection with a Live-Attenuated Porcine Reproductive and Respiratory Syndrome Virus Strain. <i>Viruses</i> , 2020, 12, 817.	1.5	6
1508	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. <i>Cell</i> , 2020, 182, 1341-1359.e19.	13.5	464
1509	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020, 10, 1061.	1.8	59
1510	The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVIDâ€19. <i>Clinical and Translational Medicine</i> , 2020, 10, e200.	1.7	115
1511	Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway. <i>Oncolmmunology</i> , 2020, 9, 1824643.	2.1	24
1512	Differential gene expression of tumor-infiltrating CD4 ⁺ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. <i>Oncolmmunology</i> , 2020, 9, 1825178.	2.1	6
1513	High Abundance of Intratumoral Î³ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 573920.	2.2	22
1514	Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. <i>Scientific Reports</i> , 2020, 10, 16060.	1.6	16
1515	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. <i>Cell</i> , 2020, 183, 1479-1495.e20.	13.5	449

#	ARTICLE	IF	CITATIONS
1516	Prevalence of <i>Mycobacterium avium</i> subspecies paratuberculosis (MAP) infection in suspected diarrhoeic buffaloes and cattle reporting at Veterinary University in India. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2020, 73, 101533.	0.7	4
1517	Resident Memory T Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 39-68.	0.8	3
1518	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. <i>Scientific Reports</i> , 2020, 10, 18336.	1.6	6
1519	Study and analysis of antitumor resistance mechanism of PD1/PD-1 immune checkpoint blocker. <i>Cancer Medicine</i> , 2020, 9, 8086-8121.	1.3	95
1520	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. <i>Nature</i> , 2020, 585, 277-282.	13.7	280
1521	Rewiring Mitochondrial Metabolism for CD8+ T Cell Memory Formation and Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1834.	2.2	26
1522	Immune Checkpoints in Viral Infections. <i>Viruses</i> , 2020, 12, 1051.	1.5	33
1523	Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. <i>Cancer Cell</i> , 2020, 38, 551-566.e11.	7.7	86
1524	An atlas of immune cell exhaustion in HIV-infected individuals revealed by single-cell transcriptomics. <i>Emerging Microbes and Infections</i> , 2020, 9, 2333-2347.	3.0	48
1525	T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. <i>Nature Communications</i> , 2020, 11, 4227.	5.8	23
1526	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	8
1527	Dysfunction of CD8+PD-1+T cells in type 2 diabetes caused by the impairment of metabolism-immune axis. <i>Scientific Reports</i> , 2020, 10, 14928.	1.6	28
1528	Role of Immunomodulators in Functional Cure Strategies for HBV. <i>Current Hepatology Reports</i> , 2020, 19, 337-344.	0.4	2
1529	Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 425.	1.8	51
1530	Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways. <i>Frontiers in Immunology</i> , 2020, 11, 1906.	2.2	65
1531	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. <i>Frontiers in Immunology</i> , 2020, 11, 1689.	2.2	63
1532	Palliative Radiofrequency Ablation Accelerates the Residual Tumor Progression Through Increasing Tumor-Infiltrating MDSCs and Reducing T-Cell-Mediated Anti-Tumor Immune Responses in Animal Model. <i>Frontiers in Oncology</i> , 2020, 10, 1308.	1.3	17
1533	Preclinical Progress of Subunit and Live Attenuated <i>Mycobacterium tuberculosis</i> Vaccines: A Review following the First in Human Efficacy Trial. <i>Pharmaceutics</i> , 2020, 12, 848.	2.0	8

#	ARTICLE	IF	CITATIONS
1534	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13
1535	A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. ACS Nano, 2020, 14, 12679-12696.	7.3	116
1536	Anti-cancer Immune-modulatory Activities of Panax Genus Extracts and Bioactive Compounds. Food Reviews International, 2022, 38, 1461-1484.	4.3	1
1537	Chronic Hepatitis B Infection Is Associated with Increased Molecular Degree of Inflammatory Perturbation in Peripheral Blood. Viruses, 2020, 12, 864.	1.5	7
1538	Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes. Frontiers in Endocrinology, 2020, 11, 569.	1.5	39
1539	Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Advances, 2020, 4, 3927-3942.	2.5	16
1540	Higher TIGIT ⁺ CD226 ⁻ T cells in Patients with Acute Myeloid Leukemia. Immunological Investigations, 2022, 51, 40-50.	1.0	25
1541	Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer. Journal of Translational Medicine, 2020, 18, 471.	1.8	15
1542	Function and evolution of the prototypic CD28 ⁺ and 4-1BB ⁺ chimeric antigen receptors. Immuno-Oncology Technology, 2020, 8, 2-11.	0.2	8
1543	Engineering better chimeric antigen receptor T cells. Experimental Hematology and Oncology, 2020, 9, 34.	2.0	64
1544	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-“PD-1 therapy. Science Translational Medicine, 2020, 12, .	5.8	133
1545	Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. BioMed Research International, 2020, 2020, 1-9.	0.9	10
1546	Airway Microbiota as a Modulator of Lung Cancer. International Journal of Molecular Sciences, 2020, 21, 3044.	1.8	35
1547	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702.	6.5	53
1548	Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion. OncoImmunology, 2020, 9, 1747349.	2.1	11
1549	A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy. Vaccine, 2020, 38, 4336-4345.	1.7	3
1550	The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy. Cancers, 2020, 12, 1230.	1.7	74
1551	Early Inflammatory Signatures Predict Subsequent Cognition in Long-Term Virally Suppressed Women With HIV. Frontiers in Integrative Neuroscience, 2020, 14, 20.	1.0	8

#	ARTICLE	IF	CITATIONS
1552	Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!. <i>Journal of Cellular Physiology</i> , 2020, 235, 9080-9097.	2.0	19
1553	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
1554	Update on Biology of Cutaneous T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 765.	1.3	20
1555	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
1556	Collagen-binding IL-12 inflames "cold" tumours. <i>Nature Biomedical Engineering</i> , 2020, 4, 483-484.	11.6	8
1557	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	1.9	15
1558	T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. <i>Leukemia</i> , 2020, 34, 2012-2024.	3.3	70
1559	Maternal and fetal T cells in term pregnancy and preterm labor. <i>Cellular and Molecular Immunology</i> , 2020, 17, 693-704.	4.8	52
1560	Tumor Endothelial Cell-Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway. <i>Molecular Cancer Research</i> , 2020, 18, 1427-1440.	1.5	22
1561	Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors. , 2020, 2, e0141.		18
1562	Influences of preoperative metformin on immunological factors in early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 55-63.	1.1	12
1563	Homeostatic Cytokines Drive Epigenetic Reprogramming of Activated T Cells into a "Naive-Memory" Phenotype. <i>IScience</i> , 2020, 23, 100989.	1.9	15
1564	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25
1565	HBV-specific CD8 T cells present higher TNF- α expression but lower cytotoxicity in hepatocellular carcinoma. <i>Clinical and Experimental Immunology</i> , 2020, 201, 289-296.	1.1	8
1566	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3088-3094.	0.8	61
1567	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	2.2	45
1568	Regulation of PD-1 in T cells for cancer immunotherapy. <i>European Journal of Pharmacology</i> , 2020, 881, 173240.	1.7	27
1569	Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. <i>Diagnostic Pathology</i> , 2020, 15, 69.	0.9	25

#	ARTICLE	IF	CITATIONS
1570	Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling. <i>Frontiers in Immunology</i> , 2020, 11, 898.	2.2	5
1571	Upregulation of Multiple CD8+ T Cell Exhaustion Pathways Is Associated with Recurrent Ocular Herpes Simplex Virus Type 1 Infection. <i>Journal of Immunology</i> , 2020, 205, 454-468.	0.4	8
1572	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
1573	Expression of immune checkpoints in active nonsegmental vitiligo: a pilot study. <i>International Journal of Dermatology</i> , 2020, 59, 982-988.	0.5	5
1574	Profiling Virus-Specific Tcf1+ T Cell Repertoires During Acute and Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2020, 11, 986.	2.2	12
1575	Oligomeric Forms of Human Amyloid-Beta(1 β) Inhibit Antigen Presentation. <i>Frontiers in Immunology</i> , 2020, 11, 1029.	2.2	6
1576	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
1577	T β cells expressing a chimeric β PD1 β ap10 β CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer. <i>Immunology</i> , 2020, 160, 280-294.	2.0	21
1578	High frequencies of PMN-MDSCs are associated with low suppressive capacity in advanced stages of HIV-1 infection. <i>Translational Medicine Communications</i> , 2020, 5, .	0.5	0
1579	Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN- β by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in <i>Mycoplasma bovis</i> Infection. <i>Frontiers in Veterinary Science</i> , 2020, 7, 12.	0.9	22
1580	Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 309-311.	0.5	10
1581	c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes. <i>Frontiers in Immunology</i> , 2020, 11, 206.	2.2	39
1582	Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. <i>Molecular Therapy</i> , 2020, 28, 1251-1262.	3.7	89
1583	Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood. <i>Frontiers in Immunology</i> , 2020, 11, 611.	2.2	23
1584	Contribution of <i>Leishmania braziliensis</i> antigen-specific CD4+ T, CD8+ T, NK and CD3+CD56+NKT cells in the immunopathogenesis of cutaneous leishmaniasis patients: Cytotoxic, activation and exhaustion profiles. <i>PLoS ONE</i> , 2020, 15, e0229400.	1.1	8
1585	Redox regulation of regulatory T-cell differentiation and functions. <i>Free Radical Research</i> , 2020, 54, 947-960.	1.5	10
1586	Selective inhibition of TGF β 1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	153
1587	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, S100-S119.	1.3	43

#	ARTICLE	IF	CITATIONS
1588	Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 732-742.	1.6	16
1589	Galectin-9 and VISTA Expression Define Terminally Exhausted T Cells in HIV-1 Infection. <i>Journal of Immunology</i> , 2020, 204, 2474-2491.	0.4	49
1590	T cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. <i>Journal of Pathology</i> , 2020, 251, 147-159.	2.1	25
1591	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <i>Hepatology</i> , 2020, 72, 315-329.	3.6	131
1592	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	24
1593	Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. <i>Genome Medicine</i> , 2020, 12, 22.	3.6	98
1594	T Cell Dysfunction and Exhaustion in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 17.	1.8	226
1595	Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 49.	1.8	122
1596	Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. <i>Frontiers in Oncology</i> , 2020, 10, 137.	1.3	53
1597	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. <i>Frontiers in Immunology</i> , 2020, 11, 1350.	2.2	13
1598	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. <i>Cellular and Molecular Immunology</i> , 2020, 17, 807-821.	4.8	1,136
1599	HIV-1 Persistence and Chronic Induction of Innate Immune Responses in Macrophages. <i>Viruses</i> , 2020, 12, 711.	1.5	17
1600	Targeting cellular senescence in cancer and aging: roles of p53 and its isoforms. <i>Carcinogenesis</i> , 2020, 41, 1017-1029.	1.3	43
1601	TOX is expressed by exhausted and polyfunctional human effector memory CD8 ⁺ T cells. <i>Science Immunology</i> , 2020, 5, .	5.6	125
1602	CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State. <i>Frontiers in Immunology</i> , 2020, 11, 1364.	2.2	83
1603	Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions. <i>Molecules</i> , 2020, 25, 3017.	1.7	11
1604	Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 428-445.	1.8	42
1605	Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers. <i>Molecular Therapy</i> , 2020, 28, 2394-2405.	3.7	19

#	ARTICLE	IF	CITATIONS
1606	Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. <i>Genes</i> , 2020, 11, 703.	1.0	14
1607	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 665-675.	2.9	42
1608	Molecular Mechanisms Controlling Foxp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation. <i>Frontiers in Immunology</i> , 2019, 10, 3136.	2.2	74
1609	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	1.2	42
1610	Characterizing Hepatitis C Virus-Specific CD4+ T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. <i>Hepatology</i> , 2020, 72, 1541-1555.	3.6	15
1611	Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment. <i>Frontiers in Oncology</i> , 2019, 9, 1556.	1.3	27
1612	Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody. <i>RSC Advances</i> , 2020, 10, 8074-8079.	1.7	13
1613	Prophylactic donor lymphocyte infusion for relapse prevention: a meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 661-670.	0.6	0
1614	Alterations of T-cell-mediated immunity in acute myeloid leukemia. <i>Oncogene</i> , 2020, 39, 3611-3619.	2.6	52
1615	miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 951-967.	2.0	36
1616	Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. <i>Cell Reports</i> , 2020, 30, 2075-2082.e4.	2.9	50
1617	Non-coding RNAs in CD8 T cell biology. <i>Molecular Immunology</i> , 2020, 120, 67-73.	1.0	24
1618	Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine. <i>Vaccine</i> , 2020, 38, 3369-3377.	1.7	11
1619	Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?. <i>Frontiers in Immunology</i> , 2020, 11, 275.	2.2	101
1620	Revisiting cellular immune response to oncogenic Marek's disease virus: the rising of avian T-cell immunity. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3103-3116.	2.4	17
1621	The Biology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 25-38.	0.8	52
1622	Altered distribution and enhanced osteoclastogenesis of mucosal-associated invariant T cells in gouty arthritis. <i>Rheumatology</i> , 2020, 59, 2124-2134.	0.9	13
1623	Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma. <i>Cellular Immunology</i> , 2020, 351, 104069.	1.4	15

#	ARTICLE	IF	CITATIONS
1624	The balancing act: Immunology of leishmaniasis. <i>Research in Veterinary Science</i> , 2020, 130, 19-25.	0.9	44
1625	Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoeeding in papillary thyroid carcinoma. <i>Experimental and Molecular Pathology</i> , 2020, 113, 104379.	0.9	13
1626	PD-1 blockade promotes immune memory following <i>Plasmodium berghei</i> ANKA reinfection. <i>International Immunopharmacology</i> , 2020, 80, 106186.	1.7	4
1627	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	5.7	129
1628	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
1629	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020, 146, 2305-2314.	2.3	44
1630	Methods to edit T cells for cancer immunotherapy. <i>Methods in Enzymology</i> , 2020, 631, 107-135.	0.4	5
1631	Prediction of cancer neoepitopes needs new rules. <i>Seminars in Immunology</i> , 2020, 47, 101387.	2.7	19
1632	Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. <i>Bioconjugate Chemistry</i> , 2020, 31, 404-415.	1.8	31
1633	Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. <i>Immunology Letters</i> , 2020, 220, 32-37.	1.1	14
1634	Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans. <i>Molecular Therapy</i> , 2020, 28, 747-757.	3.7	23
1635	Dynamic Post-Transcriptional Events Governing CD8+ T Cell Homeostasis and Effector Function. <i>Trends in Immunology</i> , 2020, 41, 240-254.	2.9	39
1636	Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. <i>Advanced Therapeutics</i> , 2020, 3, 1900136.	1.6	23
1637	CD8+ T Cells Form the Predominant Subset of NKG2A+ Cells in Human Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 3002.	2.2	30
1638	Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. <i>Journal of Genetics and Genomics</i> , 2020, 47, 1-15.	1.7	15
1639	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 636.	1.3	24
1640	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	0.6	130
1641	The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 526.	2.2	30

#	ARTICLE	IF	CITATIONS
1642	Programmed T cell differentiation: Implications for transplantation. <i>Cellular Immunology</i> , 2020, 351, 104099.	1.4	4
1643	A new dawn in the late stage of alveolar echinococcosis – parasite cancer. <i>Medical Hypotheses</i> , 2020, 142, 109735.	0.8	9
1644	Comparison of silver nanoparticle-induced inflammatory responses between healthy and metabolic syndrome mouse models. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2020, 83, 249-268.	1.1	20
1645	PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN- γ production, but lose cytotoxic activity in ovarian cancer. <i>International Immunology</i> , 2020, 32, 397-405.	1.8	22
1646	Chikungunya Virus Evades Antiviral CD8 + T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues. <i>Journal of Virology</i> , 2020, 94, .	1.5	21
1647	Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. , 2020, 8, e000317.		82
1648	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
1649	Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1781-1799.	2.0	56
1650	Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. <i>Cell</i> , 2020, 181, 728-744.e21.	13.5	131
1651	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. <i>Anticancer Research</i> , 2020, 40, 983-990.	0.5	17
1652	JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B. <i>Life Sciences</i> , 2020, 252, 117663.	2.0	25
1653	Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. <i>Immunological Investigations</i> , 2020, 49, 726-743.	1.0	11
1654	Dysregulation of humoral immunity in chronic infection. <i>Immunology and Cell Biology</i> , 2020, 98, 456-466.	1.0	14
1655	Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response. <i>BMC Immunology</i> , 2020, 21, 22.	0.9	14
1656	CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 912-925.	1.6	53
1657	Modulators of MicroRNA Function in the Immune System. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2357.	1.8	44
1658	Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2378.	1.8	48
1659	Anti-inflammatory effect of photodynamic therapy using guaiazulene and red lasers on peripheral blood mononuclear cells. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 31, 101747.	1.3	14

#	ARTICLE	IF	CITATIONS
1660	An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45â€”Years and Younger. <i>Laryngoscope</i> , 2021, 131, 304-311.	1.1	14
1661	Ectopic Tcf1 expression instills a stem-like program in exhausted CD8+ T cells to enhance viral and tumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1262-1277.	4.8	49
1662	Dietary fat and male sex increase histopathological changes in a mouse model of oral cancer. <i>Oral Diseases</i> , 2021, 27, 215-225.	1.5	5
1663	Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resistance. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 173-193.	2.4	72
1664	The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1343-1350.	2.0	11
1665	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 384-407.	7.7	64
1666	Programmed Cell Death-1 Inhibition Therapy in Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e105-e111.	0.2	2
1667	CD8 ⁺ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis. <i>Liver International</i> , 2021, 41, 470-481.	1.9	7
1668	Targeting metabolism to reverse T cell exhaustion in chronic viral infections. <i>Immunology</i> , 2021, 162, 135-144.	2.0	23
1669	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?. <i>Clinical Rheumatology</i> , 2021, 40, 1687-1695.	1.0	15
1670	Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey. <i>Nature Reviews Immunology</i> , 2021, 21, 257-267.	10.6	122
1671	Pathogenesis-directed therapy of 2019 novel coronavirus disease. <i>Journal of Medical Virology</i> , 2021, 93, 1320-1342.	2.5	40
1672	A risk signature of three autophagy-related genes for predicting lower grade glioma survival is associated with tumor immune microenvironment. <i>Genomics</i> , 2021, 113, 767-777.	1.3	13
1673	IL-21 treatment recovers follicular helper T cells and neutralizing antibody production in respiratory syncytial virus infection. <i>Immunology and Cell Biology</i> , 2021, 99, 309-322.	1.0	9
1674	Macrophage-Based Approaches for Cancer Immunotherapy. <i>Cancer Research</i> , 2021, 81, 1201-1208.	0.4	327
1675	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188483.	3.3	7
1676	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 919-935.	4.8	11
1677	A Whole Blood Enzyme-Linked Immunospot Assay for Functional Immune Endotyping of Septic Patients. <i>Journal of Immunology</i> , 2021, 206, 23-36.	0.4	20

#	ARTICLE	IF	CITATIONS
1678	Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?. <i>International Journal of Cancer</i> , 2021, 149, 31-41.	2.3	23
1679	TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. <i>Cancer Letters</i> , 2021, 499, 137-147.	3.2	42
1680	Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. <i>Biomaterials</i> , 2021, 268, 120584.	5.7	40
1681	Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103164.	2.0	40
1682	T Cells: Warriors of SARS-CoV-2 Infection. <i>Trends in Immunology</i> , 2021, 42, 18-30.	2.9	142
1683	Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity. <i>Cancer Research</i> , 2021, 81, 658-670.	0.4	15
1684	Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease. <i>Ophthalmology and Therapy</i> , 2021, 10, 5-12.	1.0	5
1685	MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. <i>Nature Immunology</i> , 2021, 22, 53-66.	7.0	95
1686	Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. <i>Advances in Cancer Research</i> , 2021, 149, 171-255.	1.9	13
1687	Origin and fine-tuning of effector CD8 T cell subpopulations in chronic infection. <i>Current Opinion in Virology</i> , 2021, 46, 27-35.	2.6	4
1688	UV α -induced DNA damage response in blood cells for cancer detection. <i>Medical Devices & Sensors</i> , 2021, 4, e10146.	2.7	0
1689	Role, function and regulation of the thymocyte selection-associated high mobility group box protein in CD8+ T cell exhaustion. <i>Immunology Letters</i> , 2021, 229, 1-7.	1.1	9
1690	Counteracting CAR T cell dysfunction. <i>Oncogene</i> , 2021, 40, 421-435.	2.6	76
1691	The Peptide Vaccine of the Future. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100022.	2.5	94
1692	Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis. <i>Clinical and Experimental Immunology</i> , 2021, 204, 78-95.	1.1	10
1693	Human Lung-Resident Macrophages Colocalize with and Provide Costimulation to PD1 ^{hi} Tissue-Resident Memory T Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1230-1244.	2.5	28
1694	Recent advances in immunotherapies against infectious diseases. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	28
1695	The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2020, 11, 615371.	2.2	12

#	ARTICLE	IF	CITATIONS
1696	Early change in peripheral CD4 ⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. <i>Immunotherapy</i> , 2021, 13, 55-66.	1.0	15
1697	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. <i>Neuro-Oncology</i> , 2021, 23, 240-250.	0.6	31
1698	Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. <i>Nature Immunology</i> , 2021, 22, 41-52.	7.0	110
1699	HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes. <i>International Journal of Infectious Diseases</i> , 2021, 102, 163-169.	1.5	37
1700	Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. <i>Modern Pathology</i> , 2021, 34, 314-326.	2.9	9
1701	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9
1702	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
1703	Balancing Inflammation and Central Nervous System Homeostasis: T Cell Receptor Signaling in Antiviral Brain TRM Formation and Function. <i>Frontiers in Immunology</i> , 2020, 11, 624144.	2.2	4
1704	Combining radiation therapy and immunotherapy for lung cancers: a narrative review. <i>Shanghai Chest</i> , 2021, 5, 10-10.	0.3	4
1705	Engineering advanced dynamic biomaterials to optimize adoptive T-cell immunotherapy. <i>Engineered Regeneration</i> , 2021, 2, 70-81.	3.0	11
1706	Microbiota Metabolites Can be Effective at Tuberculosis: Pneumatization of Lung Tissue Damaged by Tuberculosis Process. , 2021, , 95-95.		0
1707	T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. <i>Frontiers in Immunology</i> , 2020, 11, 612244.	2.2	31
1708	Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8+ T Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 640224.	1.8	13
1709	Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. <i>MedComm</i> , 2021, 2, 175-206.	3.1	24
1710	Expression profile analysis reveals hub genes that are associated with immune system dysregulation in primary myelofibrosis. <i>Hematology</i> , 2021, 26, 478-490.	0.7	0
1711	T cells in the brain enhance neonatal mortality during peripheral LCMV infection. <i>PLoS Pathogens</i> , 2021, 17, e1009066.	2.1	2
1712	A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 337-347.	1.6	10
1713	Intranasal Immunization with Peptide-based Immunogenic Complex Enhances BCG Vaccine Efficacy in murine model of Tuberculosis. <i>JCI Insight</i> , 2021, 6, .	2.3	6

#	ARTICLE	IF	CITATIONS
1714	Single-cell immune checkpoint landscape of PBMCs stimulated with <i>Candida albicans</i> . <i>Emerging Microbes and Infections</i> , 2021, 10, 1272-1283.	3.0	10
1715	The enhancement of Th1 immune response by anti-PD-L1 antibody in cattle infected with <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> . <i>Journal of Veterinary Medical Science</i> , 2021, 83, 162-166.	0.3	7
1716	Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2021, 28, 1075-1087.	2.2	23
1717	Inflammation in Pulmonary Arterial Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1303, 351-372.	0.8	17
1718	Systemic Inflammation Associated with Immune Reconstitution Inflammatory Syndrome in Persons Living with HIV. <i>Life</i> , 2021, 11, 65.	1.1	11
1719	PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100437.	0.7	0
1720	Programmed Death Ligand 1-Expressing Classical Dendritic Cells Mitigate -Induced Gastritis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 715-739.	2.3	9
1721	Venoarterial extracorporeal membrane oxygenation induces early immune alterations. <i>Critical Care</i> , 2021, 25, 9.	2.5	22
1722	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. <i>Cancer Research</i> , 2021, 81, 3079-3091.	0.4	27
1723	Prognostic and immunological role of Fam20C in pan-cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	19
1724	Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer. <i>Journal of Cancer</i> , 2021, 12, 2000-2009.	1.2	1
1725	Latest Developments in Cellular Therapy for Multiple Myeloma. <i>Oncology & Hematology Review</i> , 2021, 16, 111.	0.2	1
1726	Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: A case report. <i>Thoracic Cancer</i> , 2021, 12, 699-702.	0.8	8
1727	Blocking IL-10 signaling with soluble IL-10 receptor restores in vitro specific lymphoproliferative response in dogs with leishmaniasis caused by <i>Leishmania infantum</i> . <i>PLoS ONE</i> , 2021, 16, e0239171.	1.1	3
1728	Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence. , 2021, 9, e001660.		10
1729	Lipid Metabolism in Tumor-Infiltrating T Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1316, 149-167.	0.8	4
1730	Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 15591-15600.	1.3	0
1731	SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage. <i>Journal of Clinical Immunology</i> , 2021, 41, 515-525.	2.0	87

#	ARTICLE	IF	CITATIONS
1733	The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis. <i>Faculty Reviews</i> , 2021, 10, 4.	1.7	12
1734	Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 622509.	2.2	148
1736	Immunity in Space: Prokaryote Adaptations and Immune Response in Microgravity. <i>Life</i> , 2021, 11, 112.	1.1	13
1737	Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancerâ€T cell coculture models. <i>Gastric Cancer</i> , 2021, 24, 611-623.	2.7	32
1738	COVID-19: Molecular and Cellular Response. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 563085.	1.8	31
1739	Core Role of Hydrophobic Core of Polymeric Nanomicelle in Endosomal Escape of siRNA. <i>Nano Letters</i> , 2021, 21, 3680-3689.	4.5	58
1740	Exhausted T cells in systemic lupus erythematosus patients in long-standing remission. <i>Clinical and Experimental Immunology</i> , 2021, 204, 285-295.	1.1	14
1741	Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. <i>Scientific Reports</i> , 2021, 11, 4030.	1.6	10
1742	Biomechanics of T Cell Dysfunctions in Chronic Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 600829.	2.2	11
1743	Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection. <i>MSphere</i> , 2021, 6, .	1.3	31
1744	Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 346-360.	0.8	3
1745	Enabling single-cell trajectory network enrichment. <i>Nature Computational Science</i> , 2021, 1, 153-163.	3.8	5
1746	T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. <i>Cancers</i> , 2021, 13, 598.	1.7	19
1747	T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	35
1748	Terminally Differentiated CD4+ T Cells Promote Myocardial Inflammaging. <i>Frontiers in Immunology</i> , 2021, 12, 584538.	2.2	21
1749	Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion. <i>Experimental and Molecular Medicine</i> , 2021, 53, 202-209.	3.2	51
1750	Combined antiâ€PDâ€1 and antiâ€CTLAâ€4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	1.6	71
1751	Dampening antiviral immunity can protect the host. <i>FEBS Journal</i> , 2022, 289, 634-646.	2.2	5

#	ARTICLE	IF	CITATIONS
1753	Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation. <i>Frontiers in Immunology</i> , 2020, 11, 592328.	2.2	3
1754	Mucosal-Associated Invariant T (MAIT) Cells Are Highly Activated and Functionally Impaired in COVID-19 Patients. <i>Viruses</i> , 2021, 13, 241.	1.5	31
1755	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 448-458.	0.8	15
1756	Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	29
1757	TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2781-2793.	2.0	34
1758	Involvement of CD95 and ligand in CD4+ T-cell and CD8+ T-cell depletion and hepatic cytolysis in patients with chronic viral hepatitis B. <i>African Journal of Laboratory Medicine</i> , 2021, 10, 1224.	0.2	0
1759	Modeling the tumor immune microenvironment for drug discovery using 3D culture. <i>APL Bioengineering</i> , 2021, 5, 010903.	3.3	14
1760	PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis. <i>Frontiers in Immunology</i> , 2021, 12, 632667.	2.2	16
1761	Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 869-880.	2.5	16
1763	Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 608890.	2.2	8
1765	Biomarkers for Targeting the HIV-1 Reservoirs. <i>Journal of Bacteriology and Virology</i> , 2021, 51, 28-36.	0.0	0
1766	IFNAR1 signaling in NK cells promotes persistent virus infection. <i>Science Advances</i> , 2021, 7, .	4.7	10
1767	Effects of cellular senescence on metabolic pathways in non-immune and immune cells. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111428.	2.2	14
1768	Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. <i>Neoplasia</i> , 2021, 23, 281-293.	2.3	18
1769	Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. <i>Cancers</i> , 2021, 13, 1471.	1.7	6
1770	Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 616837.	2.2	72
1771	Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C. <i>Cells</i> , 2021, 10, 538.	1.8	4
1772	Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients. <i>Annals of Translational Medicine</i> , 2021, 9, 397-397.	0.7	0

#	ARTICLE	IF	CITATIONS
1773	Melanoma-reactive T cells take up residence. <i>Nature Cancer</i> , 2021, 2, 253-255.	5.7	1
1774	Mitochondrial Inhibition: a Treatment Strategy in Cancer?. <i>Current Oncology Reports</i> , 2021, 23, 49.	1.8	11
1775	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 589680.	1.3	23
1776	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. <i>Haematologica</i> , 2021, 106, 1234-1243.	1.7	18
1777	Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy. <i>Annals of Palliative Medicine</i> , 2021, 10, 30-30.	0.5	6
1778	Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2021, 9, 651-664.	1.6	43
1779	Complete Spontaneous Regression of Lung Metastases after Resection of CIC-Rearranged Sarcoma: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 152-159.	0.3	1
1781	Reduced <i>Trypanosoma cruzi</i> -specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1580-1592.	1.3	5
1782	A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1700-1715.	7.7	86
1783	Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response. <i>Frontiers in Oncology</i> , 2021, 11, 626463.	1.3	30
1784	Chapter 9: Selenium and immunity. , 2021, , 261-347.		2
1785	Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	19
1786	Expanded antigen-experienced CD160 ⁺ CD8 ⁺ effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. , 2021, 9, e002189.		23
1787	Connecting Timescales in Biology: Can Early Dynamical Measurements Predict Long-Term Outcomes?. <i>Trends in Cancer</i> , 2021, 7, 301-308.	3.8	4
1788	Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. <i>Drug Discovery Today</i> , 2021, 26, 951-967.	3.2	25
1789	Expression of Exhaustion Markers on CD8+ T-Cell Patterns Predict Outcomes in Septic Patients Admitted to the ICU*. <i>Critical Care Medicine</i> , 2021, 49, 1513-1523.	0.4	12
1790	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. <i>Biomedicines</i> , 2021, 9, 373.	1.4	55
1791	CAR-T cell persistence in the treatment of leukemia and lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2587-2599.	0.6	13

#	ARTICLE	IF	CITATIONS
1792	A systematic review and meta-analysis on the regulation of programmed cell death-1 on T-cells in type 2 diabetes. <i>Medicine (United States)</i> , 2021, 100, e25488.	0.4	3
1793	Lower IL-7 Receptor Expression of Monocytes Impairs Antimycobacterial Effector Functions in Patients with Tuberculosis. <i>Journal of Immunology</i> , 2021, 206, 2430-2440.	0.4	10
1794	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
1795	Pronounced expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients. <i>Microbial Pathogenesis</i> , 2021, 153, 104779.	1.3	19
1796	Perforin and granzymes in neurological infections: From humans to cattle. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2021, 75, 101610.	0.7	2
1798	T Cell-Mediated Immune Responses to AAV and AAV Vectors. <i>Frontiers in Immunology</i> , 2021, 12, 666666.	2.2	37
1799	Interleukin-10 counteracts T-helper type 1 responses in B-cell lymphoma and is a target for tumor immunotherapy. <i>Cancer Letters</i> , 2021, 503, 110-116.	3.2	3
1800	Obesity results in adipose tissue T cell exhaustion. <i>JCI Insight</i> , 2021, 6, .	2.3	55
1802	Expression of Senescence Marker TIGIT Identifies Polyfunctional Donor-Reactive CD4+ T Cells Preferentially Lost After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 656846.	2.2	15
1803	Identification of key genes and immune profile in limited cutaneous systemic sclerosis-associated pulmonary arterial hypertension by bioinformatics analysis. <i>Life Sciences</i> , 2021, 271, 119151.	2.0	7
1804	Multifunctionality of CD8 ⁺ T cells and PD-1 expression as a biomarker of anti-PD-1 antibody efficacy in advanced melanoma. <i>Journal of Dermatology</i> , 2021, 48, 1186-1192.	0.6	4
1805	Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 642316.	2.2	32
1806	Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 648925.	1.8	1
1807	Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center. <i>Journal of Dermatology</i> , 2021, 48, 979-988.	0.6	2
1808	Role of TCF-1 in differentiation, exhaustion, and memory of CD8 ⁺ T cells: A review. <i>FASEB Journal</i> , 2021, 35, e21549.	0.2	24
1810	Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications. <i>Frontiers in Immunology</i> , 2021, 12, 626172.	2.2	34
1811	Disease Progression in Children With Perinatal Human Immunodeficiency Virus Correlates With Increased PD-1+ CD8 T Cells That Coexpress Multiple Immune Checkpoints. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	2
1812	Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 547-570.	1.0	14

#	ARTICLE	IF	CITATIONS
1813	TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. <i>Cell Death and Disease</i> , 2021, 12, 400.	2.7	9
1814	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
1815	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 670088.	2.2	10
1816	Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL). <i>Cells</i> , 2021, 10, 1165.	1.8	7
1817	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. <i>Nutrients</i> , 2021, 13, 1718.	1.7	10
1818	The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells. <i>Cancer Letters</i> , 2021, 506, 55-66.	3.2	20
1819	Temporal and Epigenetic Control of Plasticity and Fate Decision during CD8 ⁺ T-Cell Memory Differentiation. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037754.	2.3	11
1820	Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. <i>Cells</i> , 2021, 10, 1293.	1.8	20
1821	Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7507-7532.	2.9	18
1822	Regulatory KIR ⁺ RA ⁺ T cells accumulate with age and are highly activated during viral respiratory disease. <i>Aging Cell</i> , 2021, 20, e13372.	3.0	12
1823	PD-1 blockade prevents the progression of oral carcinogenesis. <i>Carcinogenesis</i> , 2021, 42, 891-902.	1.3	14
1824	The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. <i>Cancer Research</i> , 2021, 81, 3876-3889.	0.4	21
1825	ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies. <i>BMC Cancer</i> , 2021, 21, 584.	1.1	6
1826	Immune modulation underpins the anti-cancer activity of HDAC inhibitors. <i>Molecular Oncology</i> , 2021, 15, 3280-3298.	2.1	18
1827	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 347-363.	1.5	25
1828	Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity. <i>Viruses</i> , 2021, 13, 916.	1.5	7
1829	Stimuli responsive and receptor targeted iron oxide based nanoplatfoms for multimodal therapy and imaging of cancer: Conjugation chemistry and alternative therapeutic strategies. <i>Journal of Controlled Release</i> , 2021, 333, 188-245.	4.8	31
1830	Immune and metabolic checkpoints blockade: Dual wielding against tumors. <i>International Immunopharmacology</i> , 2021, 94, 107461.	1.7	13

#	ARTICLE	IF	CITATIONS
1831	The role of CD47-SIRP α immune checkpoint in tumor immune evasion and innate immunotherapy. <i>Life Sciences</i> , 2021, 273, 119150.	2.0	45
1832	Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. <i>Clinical Cancer Research</i> , 2021, 27, 4325-4337.	3.2	58
1833	Regulation of Th1 T Cell Differentiation by Iron via Upregulation of T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3). <i>Frontiers in Immunology</i> , 2021, 12, 637809.	2.2	12
1834	From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. <i>Advanced Materials</i> , 2021, 33, e2008094.	11.1	60
1835	Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2021, 19, .	0.4	0
1836	Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion. <i>Frontiers in Immunology</i> , 2021, 12, 671743.	2.2	9
1837	Acute Myeloid Leukemia: Is It T Time?. <i>Cancers</i> , 2021, 13, 2385.	1.7	8
1838	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 346-359.	4.2	70
1839	Kaposi sarcoma in antiretroviral therapy-treated people with HIV: a wake-up call for research on human herpesvirus-8. <i>Aids</i> , 2021, 35, 1695-1699.	1.0	2
1840	CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3603-3616.	2.0	11
1841	Asymmetric cell division shapes naive and virtual memory T-cell immunity during ageing. <i>Nature Communications</i> , 2021, 12, 2715.	5.8	19
1842	Stromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 658984.	1.8	8
1843	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
1844	Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer. <i>Journal of Pancreatology</i> , 2021, 4, 106-114.	0.3	3
1845	WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. <i>Nature Communications</i> , 2021, 12, 3500.	5.8	28
1846	Exploiting the obesity-associated immune microenvironment for cancer therapeutics. , 2022, 229, 107923.		10
1848	Arrangement of V _L and V _H Domains in VRC01-Based Chimeric Antigen Receptor (CAR) Affects Functions and Exhaustion Status of CAR-T Cells. <i>Re:GEN Open</i> , 2021, 1, 26-39.	0.7	0
1849	Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2021, 22, 809-819.	7.0	113

#	ARTICLE	IF	CITATIONS
1850	The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 635623.	2.2	10
1851	Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 428-434.	0.4	4
1852	Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma. <i>Cancers</i> , 2021, 13, 3211.	1.7	4
1853	Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 557994.	2.2	10
1854	Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. <i>JCI Insight</i> , 2021, 6, .	2.3	19
1855	T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3255.	1.7	6
1856	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. <i>PLoS ONE</i> , 2021, 16, e0251731.	1.1	9
1857	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
1858	Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review. <i>Cancer Medicine</i> , 2021, 10, 4206-4220.	1.3	8
1859	A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6371.	1.8	8
1860	Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy. <i>Internal Medicine</i> , 2021, 60, 1743-1746.	0.3	9
1861	Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2021, 12, 669456.	2.2	38
1862	Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. <i>Cells</i> , 2021, 10, 1429.	1.8	5
1863	Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 773-784.	1.9	8
1864	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 685139.	2.2	13
1865	CD4+ Memory Stem T Cell in Peripheral Blood: A Promising Immune Index for Early Screening and Auxiliary Diagnosis of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 701738.	1.3	3
1867	Mechanisms of Immune Modulation by Radiation. <i>Seminars in Radiation Oncology</i> , 2021, 31, 205-216.	1.0	5
1868	Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4913-4928.	3.3	13

#	ARTICLE	IF	CITATIONS
1870	BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. <i>Nature Immunology</i> , 2021, 22, 983-995.	7.0	147
1871	Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	5
1872	Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8011.	1.8	18
1873	Improving T cell therapy: in vivo CRISPR-Cas9 screens tell us how to do. <i>Precision Clinical Medicine</i> , 2021, 4, 176-178.	1.3	1
1874	Natural killer cell exhaustion in lung cancer. <i>International Immunopharmacology</i> , 2021, 96, 107764.	1.7	7
1875	Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. <i>Nature Immunology</i> , 2021, 22, 1030-1041.	7.0	63
1877	Instruction of Immunometabolism by Adipose Tissue: Implications for Cancer Progression. <i>Cancers</i> , 2021, 13, 3327.	1.7	4
1878	Targeting Aging: Lessons Learned From Immunometabolism and Cellular Senescence. <i>Frontiers in Immunology</i> , 2021, 12, 714742.	2.2	14
1879	Comparative Characterization and Risk Stratification of Asymptomatic and Presymptomatic Patients With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 700449.	2.2	2
1880	Viewing Cancer Through the Lens of Corruption: Using Behavioral Ecology to Understand Cancer. <i>Frontiers in Ecology and Evolution</i> , 2021, 9, .	1.1	3
1881	CD8 ⁺ T Cells Exhibit an Exhausted Phenotype in Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1794-1803.	2.0	5
1882	Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection. <i>PLoS Biology</i> , 2021, 19, e3001387.	2.6	20
1883	Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies. <i>Cells</i> , 2021, 10, 2227.	1.8	17
1884	A peptide-based vaccine ACP derived from antigens of <i>Mycobacterium tuberculosis</i> induced Th1 response but failed to enhance the protective efficacy of BCG in mice. <i>Indian Journal of Tuberculosis</i> , 2022, 69, 482-495.	0.3	13
1885	Autophagy controls programmed death ligand 1 expression on cancer cells (Review). <i>Biomedical Reports</i> , 2021, 15, 84.	0.9	12
1886	iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma. <i>Cancer Immunology Research</i> , 2021, 9, 1175-1186.	1.6	8
1887	Tutorial: using nanoneedles for intracellular delivery. <i>Nature Protocols</i> , 2021, 16, 4539-4563.	5.5	47
1888	Obesity Has a Systemic Effect on Immune Cells in Naïve and Cancer-Bearing Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8803.	1.8	5

#	ARTICLE	IF	CITATIONS
1889	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8996.	1.8	73
1890	The Multifaceted Role of TGF- β in Gastrointestinal Tumors. <i>Cancers</i> , 2021, 13, 3960.	1.7	18
1891	p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 698565.	2.2	16
1892	Distinct Immune Profiles of Exhausted Effector and Memory CD8+ T Cells in Individuals With Filarial Lymphedema. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 680832.	1.8	9
1895	PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells. <i>Cancers</i> , 2021, 13, 4148.	1.7	22
1896	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. <i>Frontiers in Pharmacology</i> , 2021, 12, 720692.	1.6	20
1897	A structural perspective on the design of decoy immune modulators. <i>Pharmacological Research</i> , 2021, 170, 105735.	3.1	0
1899	Downregulation of Programmed Death-1 Pathway Promoting CD8+ T Cell Cytotoxicity in Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2981-2993.	1.1	3
1900	PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression. <i>Clinica Chimica Acta</i> , 2021, 519, 70-75.	0.5	8
1901	Case Report: FOXP3 Mutation in a Patient Presenting With ALPS. <i>Frontiers in Immunology</i> , 2021, 12, 692107.	2.2	3
1902	Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-Seq. <i>Cardiovascular Research</i> , 2021, 117, 2537-2543.	1.8	39
1903	Dynamic Network Biomarker of Pre-Exhausted CD8+ T Cells Contributed to T Cell Exhaustion in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 691142.	2.2	19
1904	Pembrolizumab Treatment-Induced Liver Toxicity. <i>Case Reports in Gastroenterology</i> , 2021, 15, 742-750.	0.3	5
1905	Single-Cell Analysis Reveals Spatial Heterogeneity of Immune Cells in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 638374.	1.8	11
1906	Schrödinger's T Cells: Molecular Insights Into Stemness and Exhaustion. <i>Frontiers in Immunology</i> , 2021, 12, 725618.	2.2	22
1907	Counting on You: How MHC Tetramers Revolutionized the Study of T Cell Memory and CD8+ T Cell Exhaustion. <i>Journal of Immunology</i> , 2021, 207, 1225-1227.	0.4	1
1908	TIM-3 as a potential exhaustion marker in CD4 ⁺ T cells of COVID-19 patients. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1707-1715.	1.3	22
1909	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. <i>Applied Materials Today</i> , 2021, 24, 101149.	2.3	7

#	ARTICLE	IF	CITATIONS
1910	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. <i>Nature Cancer</i> , 2021, 2, 1071-1085.	5.7	57
1911	Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. <i>EClinicalMedicine</i> , 2021, 40, 101125.	3.2	53
1912	Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma. <i>Translational Oncology</i> , 2021, 14, 101170.	1.7	5
1913	Imaging Changes and Immune-Checkpoint Expression on T Cells in Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis. <i>Biomedicines</i> , 2021, 9, 1231.	1.4	1
1914	A Novel Immunomodulator Delivery Platform Based on Bacterial Biomimetic Vesicles for Enhanced Antitumor Immunity. <i>Advanced Materials</i> , 2021, 33, e2103923.	11.1	19
1915	In vivo kinetics of peripheral cellular immune responses in <i>Mycobacterium avium</i> subspecies paratuberculosis (MAP) infected and vaccinated goats. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2021, 79, 101710.	0.7	3
1916	Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. <i>BMC Cancer</i> , 2021, 21, 1007.	1.1	6
1917	Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance. <i>Frontiers in Immunology</i> , 2021, 12, 714842.	2.2	10
1918	The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells. <i>Journal of Biological Chemistry</i> , 2021, 297, 101042.	1.6	11
1919	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 5086-5097.	2.5	16
1920	CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2â€infecte d patients. <i>JCI Insight</i> , 2021, 6, .	2.3	16
1922	The MAPK dual specific phosphatase (DUSP) proteins: A versatile wrestler in T cell functionality. <i>International Immunopharmacology</i> , 2021, 98, 107906.	1.7	14
1923	Irradiation Suppresses IFNÎ³-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity. <i>Cells</i> , 2021, 10, 2515.	1.8	3
1924	Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 4616.	1.7	13
1925	NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton. <i>Frontiers in Immunology</i> , 2021, 12, 734551.	2.2	13
1926	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
1927	PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. <i>Immunology Letters</i> , 2021, 240, 15-23.	1.1	19
1928	CytoF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 726428.	2.2	16

#	ARTICLE	IF	CITATIONS
1929	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. <i>Translational Oncology</i> , 2021, 14, 101153.	1.7	5
1930	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	0.7	5
1931	Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis. <i>Nutrition</i> , 2021, 90, 111345.	1.1	26
1932	Reduction and exhausted features of T lymphocytes under serological changes, and prognostic factors in COVID-19 progression. <i>Molecular Immunology</i> , 2021, 138, 121-127.	1.0	32
1933	Local delivery strategies to restore immune homeostasis in the context of inflammation. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113971.	6.6	17
1934	Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. <i>Materials and Design</i> , 2021, 209, 109958.	3.3	8
1935	Epigenetic programming of the immune responses in cancer. , 2022, , 197-235.		1
1936	Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression. <i>Gene</i> , 2022, 806, 145935.	1.0	2
1937	Improving the safety of iPSC-derived TÂcell therapy. , 2022, , 95-115.		3
1938	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. <i>JCI Insight</i> , 2021, 6, .	2.3	64
1939	Immunopathogenesis of Hepatitis B Virus Infection. , 2021, , 73-97.		0
1940	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 11-11.	0.4	8
1941	Current state of chemotherapy and immunotherapy regimens in gastric cancer. , 2021, , 289-316.		0
1942	The Potential of T Cell Factor 1 in Sustaining CD8+ T Lymphocyte-Directed Anti-Tumor Immunity. <i>Cancers</i> , 2021, 13, 515.	1.7	3
1943	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. <i>Cancers</i> , 2021, 13, 213.	1.7	6
1944	Hirsutella Sinensis Fungus Regulates CD8+ T Cell Exhaustion Through Involvement of T-Bet/Eomes in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2020, 11, 612620.	1.6	8
1945	Contribution of resident and circulating precursors to tumor-infiltrating CD8 ⁺ T cell populations in lung cancer. <i>Science Immunology</i> , 2021, 6, .	5.6	82
1946	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22

#	ARTICLE	IF	CITATIONS
1947	A Human In Vitro T Cell Exhaustion Model for Assessing Immuno-Oncology Therapies. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 89-101.	0.1	15
1948	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
1949	Monitoring Multifunctionality of Immune-Exhausted CD8 T Cells in Cancer Patients. <i>Methods in Molecular Biology</i> , 2014, 1142, 11-17.	0.4	9
1950	Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes. <i>Methods in Molecular Biology</i> , 2015, 1218, 163-186.	0.4	42
1951	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. <i>Methods in Molecular Biology</i> , 2020, 2055, 23-60.	0.4	12
1952	The Role of Exhaustion in Tumor-Induced T-Cell Dysfunction in Cancer. , 2020, , 117-132.		4
1953	Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 121-147.	0.8	14
1954	Drivers of EMT and Immune Evasion. , 2017, , 221-239.		1
1955	The Role of Exhaustion in Tumor-Induced T Cell Dysfunction in Cancer. , 2015, , 61-75.		2
1956	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 618-622.	2.0	13
1957	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. <i>Cellular and Molecular Immunology</i> , 2020, 17, 576-586.	4.8	12
1958	Interleukin-23 engineering improves CAR T cell function in solid tumors. <i>Nature Biotechnology</i> , 2020, 38, 448-459.	9.4	145
1959	Hepatic Stellate Cell- Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. <i>Seminars in Liver Disease</i> , 2020, 40, 307-320.	1.8	76
1960	Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma. <i>Oncimmunology</i> , 2018, 7, e1502129.	2.1	7
1961	SARS-CoV-2 reinfection and implications for vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3061-3073.	1.4	54
1962	The current landscape of single-cell transcriptomics for cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	35
1963	Computational modelling in single-cell cancer genomics: methods and future directions. <i>Physical Biology</i> , 2020, 17, 061001.	0.8	2
1964	Food Insecurity and T-cell Dysregulation in Women Living With Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 72, e112-e119.	2.9	7

#	ARTICLE	IF	CITATIONS
1965	Operative Trauma and Blood Loss â€” Impact on Tumor Growth and Recurrence. <i>Shock</i> , 2021, 55, 455-464.	1.0	13
1966	Immune Checkpoint Inhibitors in Transplantationâ€”A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	0.5	21
1967	Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors. <i>Journal of General Virology</i> , 2017, 98, 374-384.	1.3	14
1978	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , 2020, 5, e000689.	2.0	11
1979	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	123
1980	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3â€”CD8+ T cells. <i>JCI Insight</i> , 2020, 5, .	2.3	30
1981	Allergen-encoding bone marrow transfer inactivates allergic T cell responses, alleviating airway inflammation. <i>JCI Insight</i> , 2017, 2, .	2.3	12
1982	Transient stimulation expands superior antitumor T cells for adoptive therapy. <i>JCI Insight</i> , 2017, 2, e89580.	2.3	37
1983	An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. <i>Journal of Clinical Investigation</i> , 2018, 128, 5549-5560.	3.9	193
1984	Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. <i>Journal of Clinical Investigation</i> , 2019, 130, 480-490.	3.9	99
1985	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3051-3068.	3.9	90
1986	Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 1073-1083.	3.9	53
1987	Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. <i>Journal of Clinical Investigation</i> , 2013, 123, 1032-1043.	3.9	42
1988	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 3766-3776.	3.9	80
1989	Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. <i>Journal of Clinical Investigation</i> , 2014, 124, 2425-2440.	3.9	203
1990	Sprouty-2 regulates HIV-specific T cell polyfunctionality. <i>Journal of Clinical Investigation</i> , 2014, 124, 198-208.	3.9	49
1991	CD4+ and CD8+ T cellâ€”dependent antiviral immunity requires STIM1 and STIM2. <i>Journal of Clinical Investigation</i> , 2014, 124, 4549-4563.	3.9	50
1992	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81

#	ARTICLE	IF	CITATIONS
1993	TGF- β 2 receptor maintains CD4 T helper cell identity during chronic viral infections. <i>Journal of Clinical Investigation</i> , 2016, 126, 3799-3813.	3.9	31
1994	PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. <i>Journal of Clinical Investigation</i> , 2018, 128, 4669-4681.	3.9	98
1995	Role of the adaptive immune response in sepsis. <i>Intensive Care Medicine Experimental</i> , 2020, 8, 20.	0.9	58
1996	Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 2065-2074.	0.3	17
1997	Evaluation of CD8 T cell killing models with computer simulations of 2-photon imaging experiments. <i>PLoS Computational Biology</i> , 2020, 16, e1008428.	1.5	6
1998	Transient Loss of Protection Afforded by a Live Attenuated Non-typhoidal Salmonella Vaccine in Mice Co-infected with Malaria. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004027.	1.3	21
1999	Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct States of Infection of Humans with <i>Leishmania infantum</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005123.	1.3	52
2000	Phenotypic and Functional Profiling of CD4 T Cell Compartment in Distinct Populations of Healthy Adults with Different Antigenic Exposure. <i>PLoS ONE</i> , 2013, 8, e55195.	1.1	27
2001	The Ikaros Transcription Factor Regulates Responsiveness to IL-12 and Expression of IL-2 Receptor Alpha in Mature, Activated CD8 T Cells. <i>PLoS ONE</i> , 2013, 8, e57435.	1.1	9
2002	Re-Evaluation of PD-1 Expression by T Cells as a Marker for Immune Exhaustion during SIV Infection. <i>PLoS ONE</i> , 2013, 8, e60186.	1.1	65
2003	Activation Associated ERK1/2 Signaling Impairments in CD8+ T Cells Co-Localize with Blunted Polyclonal and HIV-1 Specific Effector Functions in Early Untreated HIV-1 Infection. <i>PLoS ONE</i> , 2013, 8, e77412.	1.1	13
2004	Direct Infection of Dendritic Cells during Chronic Viral Infection Suppresses Antiviral T Cell Proliferation and Induces IL-10 Expression in CD4 T Cells. <i>PLoS ONE</i> , 2014, 9, e90855.	1.1	10
2005	Increased Frequency of Tim-3 Expressing T Cells Is Associated with Symptomatic West Nile Virus Infection. <i>PLoS ONE</i> , 2014, 9, e92134.	1.1	17
2006	Phenotypic T Cell Exhaustion in a Murine Model of Bacterial Infection in the Setting of Pre-Existing Malignancy. <i>PLoS ONE</i> , 2014, 9, e93523.	1.1	20
2007	The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity. <i>PLoS ONE</i> , 2014, 9, e97495.	1.1	57
2008	Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes. <i>PLoS ONE</i> , 2014, 9, e106241.	1.1	58
2009	Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e112556.	1.1	22
2010	Attrition of T-Cell Functions and Simultaneous Upregulation of Inhibitory Markers Correspond with the Waning of BCG-Induced Protection against Tuberculosis in Mice. <i>PLoS ONE</i> , 2014, 9, e113951.	1.1	36

#	ARTICLE	IF	CITATIONS
2011	Parasite Load Induces Progressive Spleen Architecture Breakage and Impairs Cytokine mRNA Expression in Leishmania infantum-Naturally Infected Dogs. PLoS ONE, 2015, 10, e0123009.	1.1	57
2012	CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0128607.	1.1	19
2013	Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0130464.	1.1	13
2014	TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS ONE, 2015, 10, e0140694.	1.1	58
2015	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS ONE, 2015, 10, e0144594.	1.1	13
2016	Transcriptomic Analysis of Persistent Infection with Foot-and-Mouth Disease Virus in Cattle Suggests Impairment of Apoptosis and Cell-Mediated Immunity in the Nasopharynx. PLoS ONE, 2016, 11, e0162750.	1.1	23
2017	Src-family kinases negatively regulate NFAT signaling in resting human T cells. PLoS ONE, 2017, 12, e0187123.	1.1	9
2018	Association between preoperative peripheral blood mononuclear cell gene expression profiles, early postoperative organ function recovery potential and long-term survival in advanced heart failure patients undergoing mechanical circulatory support. PLoS ONE, 2017, 12, e0189420.	1.1	13
2019	CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathogens, 2015, 11, e1005177.	2.1	296
2020	PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathogens, 2015, 11, e1005224.	2.1	58
2021	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens, 2016, 12, e1005349.	2.1	271
2022	Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence. PLoS Pathogens, 2016, 12, e1005356.	2.1	49
2023	Nonclassical MHC Ib-restricted CD8+ T Cells Recognize Mycobacterium tuberculosis-Derived Protein Antigens and Contribute to Protection Against Infection. PLoS Pathogens, 2016, 12, e1005688.	2.1	20
2024	Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine. PLoS Pathogens, 2017, 13, e1006489.	2.1	13
2025	Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice. Journal of Clinical Medicine Research, 2020, 12, 300-306.	0.6	12
2026	IL-10: Expanding the Immune Oncology Horizon. Receptors & Clinical Investigation, 0, , .	0.9	4
2027	Taurine Chloramine decreases cell viability and cytokine production in blood and spleen lymphocytes from septic rats. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20191311.	0.3	4
2028	CD40 Signaling to the Rescue: A CD8 Exhaustion Perspective in Chronic Infectious Diseases. Critical Reviews in Immunology, 2013, 33, 361-378.	1.0	8

#	ARTICLE	IF	CITATIONS
2029	Cholesterol induces T cell exhaustion. <i>Aging</i> , 2019, 11, 7334-7335.	1.4	6
2030	miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. <i>Oncotarget</i> , 2016, 7, 53735-53750.	0.8	105
2031	PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. <i>Oncotarget</i> , 2016, 7, 72961-72977.	0.8	258
2032	Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition. <i>Oncotarget</i> , 2017, 8, 4520-4529.	0.8	9
2033	PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. <i>Oncotarget</i> , 2017, 8, 50782-50791.	0.8	10
2034	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 21177-21186.	0.8	20
2035	MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. <i>Oncotarget</i> , 2017, 8, 28125-28134.	0.8	49
2036	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. <i>Oncotarget</i> , 2017, 8, 41242-41255.	0.8	89
2037	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44418-44433.	0.8	95
2038	Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells. <i>Oncotarget</i> , 2017, 8, 82740-82753.	0.8	17
2039	Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 89802-89810.	0.8	54
2040	Chronic activation profile of circulating CD8+ T cells in SÃ©zary syndrome. <i>Oncotarget</i> , 2018, 9, 3497-3506.	0.8	21
2041	Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. <i>Oncotarget</i> , 2020, 11, 347-361.	0.8	26
2042	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. <i>Oncotarget</i> , 2015, 6, 3479-3492.	0.8	146
2043	Good syndrome presenting with CD8+ T-Cell large granular lymphocyte leukemia. <i>Oncotarget</i> , 2015, 6, 36577-36586.	0.8	11
2044	Identification of TIM3 2â€²-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 4522-4530.	0.8	44
2045	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. <i>Oncotarget</i> , 2016, 7, 1168-1184.	0.8	103
2046	Prognostic significance of PDâ€¹1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 553-559.	0.3	21

#	ARTICLE	IF	CITATIONS
2047	Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Research, 2020, 2020, .	0.6	6
2048	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
2049	Exhausted T cells and epigenetic status. Cancer Biology and Medicine, 2020, 17, 923-936.	1.4	32
2050	Immunotherapy for nasopharyngeal cancerâ€™a review. Chinese Clinical Oncology, 2016, 5, 22-22.	0.4	60
2051	Immune checkpoint regulator: a new assignment proposed for the classic adhesion molecule P-selectin glycoprotein ligand-1. Translational Cancer Research, 2016, 5, S668-S671.	0.4	1
2052	Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry, 2019, 26, 3009-3025.	1.2	286
2053	Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. Current Medicinal Chemistry, 2019, 26, 5244-5261.	1.2	8
2054	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Current Drug Targets, 2017, 18, 315-331.	1.0	39
2055	Innate and Adaptive Immune Responses in Chronic HCV Infection. Current Drug Targets, 2017, 18, 826-843.	1.0	53
2056	Immune Checkpoint Inhibitors in AML-A New Frontier. Current Cancer Drug Targets, 2020, 20, 545-557.	0.8	5
2057	Dysfunctional Adaptive Immunity During Parasitic Infections. Current Immunology Reviews, 2014, 9, 179-189.	1.2	14
2058	Parasites: What are They Good for?. Current Immunology Reviews, 2014, 9, 120-128.	1.2	1
2059	Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2269-2274.	0.5	26
2060	Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy, 2020, 12, 1341-1357.	1.0	3
2061	Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model. Frontiers in Immunology, 2019, 10, 3074.	2.2	6
2062	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. Journal of Clinical Medicine, 2021, 10, 88.	1.0	19
2063	Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries. Viruses, 2019, 11, 106.	1.5	16
2064	Between Scylla and Charybdis: The role of the human immune system in the pathogenesis of hepatitis C. World Journal of Gastroenterology, 2013, 19, 7852.	1.4	9

#	ARTICLE	IF	CITATIONS
2065	Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. <i>World Journal of Gastroenterology</i> , 2015, 21, 3480.	1.4	17
2066	Progress in the development of vaccines for hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2015, 21, 11984.	1.4	33
2067	Role of Tim-3 in hepatitis B virus infection: An overview. <i>World Journal of Gastroenterology</i> , 2016, 22, 2294-2303.	1.4	33
2068	Transforming growth factor- β^2 and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 2733-2740.	1.4	15
2069	Immunotherapy and Complexity: Overcoming Barriers to Control of Advanced Cancer. <i>MEDICC Review</i> , 2014, 16, 65.	0.5	7
2070	Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3150-3158.	0.8	5
2071	HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. <i>Oncology Letters</i> , 2017, 14, 4415-4427.	0.8	60
2072	High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 18, 4691-4702.	0.8	5
2073	Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion. <i>Oncology Letters</i> , 2020, 19, 3827-3838.	0.8	7
2074	MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	11
2075	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 30.	0.4	6
2076	Hepatitis B virus large surface protein: function and fame. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 1-10.	0.7	26
2077	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	0.7	27
2078	Peptide immunotherapy in experimental autoimmune encephalomyelitis. <i>Biomedical Journal</i> , 2015, 38, 206.	1.4	10
2079	Signaling Mechanisms that Balance Anti-viral, Auto-reactive, and Antitumor Potential of Low Affinity T Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 01, .	1.5	29
2080	The Emerging Role of Interleukin-21 in Transplantation. <i>Journal of Clinical & Cellular Immunology</i> , 2012, Suppl 9, 1-7.	1.5	8
2081	MUC1 Antigen-Specific CD8 T Lymphocytes Targeting MCF7 and MDA-MB-231 Human Breast Adenocarcinoma Cell Lines. <i>Journal of Cancer Therapy</i> , 2019, 10, 495-509.	0.1	5
2082	Transgene IL-21-Engineered T Cell-Based Vaccine Potently Converts CTL Exhaustion via the Activation of the mTORC1 Pathway in Chronic Infection. <i>World Journal of Vaccines</i> , 2019, 09, 1-21.	0.8	2

#	ARTICLE	IF	CITATIONS
2083	The Expression of Programmed Death-1 in Circulating CD4 ⁺ and CD8 ⁺ T Cells during Hepatitis B Virus Infection Progression and Its Correlation with Clinical Baseline Characteristics. <i>Gut and Liver</i> , 2014, 8, 186-195.	1.4	27
2084	Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1374-1391.	2.3	86
2085	CoViD-19 Immunopathology & Immunotherapy. <i>Bioinformatics</i> , 2020, 16, 219-222.	0.2	109
2086	Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. <i>ELife</i> , 2020, 9, .	2.8	44
2087	Cancer systems immunology. <i>ELife</i> , 2020, 9, .	2.8	14
2088	A perspective on HPK1 as a novel immuno-oncology drug target. <i>ELife</i> , 2020, 9, .	2.8	31
2089	PD-1 checkpoint blockade enhances adoptive immunotherapy by human V β 2V γ 2 T cells against human prostate cancer. <i>Oncolmmunology</i> , 2021, 10, 1989789.	2.1	15
2090	Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4/Pten mutant mice. <i>International Journal of Biological Sciences</i> , 2021, 17, 4176-4191.	2.6	7
2091	The immune landscape in BCR α CABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. <i>British Journal of Haematology</i> , 2022, 196, 1149-1158.	1.2	11
2092	Altered T-Cell Subsets are Associated with Dysregulated Cytokine Secretion of CD4+ T Cells During HIV Infection. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 5149-5163.	1.6	0
2093	Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer. <i>Cells</i> , 2021, 10, 2672.	1.8	5
2094	Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 153-163.	2.4	13
2095	Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. , 2021, 9, e003217.		29
2096	An overview of multiplexed analyses of CAR T-cell therapies: insights and potential. <i>Expert Review of Proteomics</i> , 2021, 18, 767-780.	1.3	2
2097	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. <i>Cancer Cell</i> , 2021, 39, 1578-1593.e8.	7.7	275
2098	CD8+ T Cell Response Quality Is Related to Parasite Control in an Animal Model of Single and Mixed Chronic <i>Trypanosoma cruzi</i> Infections. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 723121.	1.8	2
2099	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. <i>Science Translational Medicine</i> , 2021, 13, eaba6006.	5.8	33
2100	Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFN γ , Following Recognition of Autologous Tumor-Antigens. <i>Frontiers in Immunology</i> , 2021, 12, 705422.	2.2	10

#	ARTICLE	IF	CITATIONS
2101	Hodgkin Lymphoma: A Special Microenvironment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4665.	1.0	11
2102	Cellular Markers of Immunosuppression in Sepsis. <i>Archives of Medical Research</i> , 2021, 52, 828-835.	1.5	7
2103	Metabolic Profile of Adaptive Immune Cells. , 2022, , 115-132.		0
2104	A Dynamic Transcriptome Map of Different Tissue Microenvironment Cells Identified During Gastric Cancer Development Using Single-Cell RNA Sequencing. <i>Frontiers in Immunology</i> , 2021, 12, 728169.	2.2	16
2105	An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine. <i>Drug Safety</i> , 2021, 44, 1341-1353.	1.4	5
2107	Targeted Anti-CTumor Immunotherapy Using Tumor Infiltrating Cells. <i>Advanced Science</i> , 2021, 8, e2101672.	5.6	36
2108	Involvement of PD-L1-mediated tumor-intrinsic signaling and immune suppression in tumorigenic effect of Î±-tocopherol. <i>Carcinogenesis</i> , 2022, 43, 243-253.	1.3	2
2109	Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. <i>Molecular Therapy</i> , 2022, 30, 534-549.	3.7	20
2110	Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4+ T Cells in HIV-Infected Immunological Non-Responders. <i>Frontiers in Immunology</i> , 2021, 12, 744155.	2.2	3
2111	Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. <i>Future Oncology</i> , 2021, 17, 4971-4982.	1.1	5
2112	The tumor immune microenvironments of ⁺ and ^{â€™} head and neck cancers. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1539.	1.5	13
2113	Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis. <i>Scientific Reports</i> , 2021, 11, 20019.	1.6	1
2114	Anti-“PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. <i>Journal of Immunology</i> , 2021, 207, 2598-2607.	0.4	10
2115	Hepatocellular Carcinoma Immunotherapy. <i>Annual Review of Medicine</i> , 2022, 73, 267-278.	5.0	86
2116	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
2117	Expression of inhibitory receptors on CD4+ and CD8+ T cells from healthy Colombian donors. <i>Universitas Scientiarum</i> , 2013, 17, 35.	0.2	0
2119	Development of Antitumor Cellular Immunity. , 2013, , 107-133.		0
2121	Immune Cells Within the Tumor Microenvironment. , 2014, , 1-23.		2

#	ARTICLE	IF	CITATIONS
2122	HIV and SIV, CD4 T-Cell Responses to. , 2014, , 1-10.		0
2123	Tim-3 Regulation of Cancer Immunity. , 2014, , 239-261.		0
2124	Acute and Chronic Hepatitis B Virus Infection, Immune Response. , 2014, , 1-7.		0
2125	HIV-Associated Immune Exhaustion. , 2014, , 1-8.		0
2126	Immune Checkpoint Drug Goes Viral: Developing New Treatment Paradigm for Chronic Viral Infection. Journal of Human Virology & Retrovirology, 2014, 1, .	0.1	1
2127	PD-1,CTLA-4. Okayama Igakkai Zasshi, 2015, 127, 63-65.	0.0	0
2128	Fighting Fire with Fire in Cancer. , 2015, , 39-49.		1
2130	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. Cancer Drug Discovery and Development, 2015, , 231-244.	0.2	0
2131	Dendritic Cell Vaccine and its Application in Cancer Therapy. International Journal of Vaccines & Vaccination, 2015, 1, .	0.3	2
2133	Immunosenescence in Humans: Changes to the Aged T Lymphocyte Population in Response to Persistent Cytomegalovirus Infection. Journal of Immunology and Infectious Diseases, 2015, 2, .	0.0	0
2134	Brain Metastases from Cutaneous Melanoma. , 2016, , 237-254.		0
2135	Epstein-Barr Virus and Cytomegalovirus. , 0, , 563-577.		0
2136	Aiming the Immune System to Improve the Antitumor Efficacy of Radiation Therapy. , 2016, , 159-181.		0
2138	Immunotolerance and Immunoregulation. , 2017, , 39-47.		0
2139	Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. , 2017, , 225-241.		0
2141	Blimp-1 Expression as an Exhaustion Transcription Factor in Chronic Lymphocytic Leukemia. Research in Molecular Medicine, 2017, 5, 5-10.	0.1	0
2144	A Simple Method to Optimize the Effectiveness of Chemotherapy: Modulation of Glucose Intake During Chemotherapy. Anticancer Research, 2017, 37, 6199-6202.	0.5	6
2145	HIV and SIV, CD4 T-Cell Responses to. , 2018, , 661-669.		0

#	ARTICLE	IF	CITATIONS
2146	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Cancer Research</i> , 2018, , 365-396.	0.2	0
2147	HIV-Associated Immune Exhaustion. , 2018, , 1001-1008.		0
2154	Immune Checkpoint Inhibitors in the Treatment of Lymphomas. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018, 11, 303-312.	0.1	10
2155	The E1 $\frac{1}{4}$ -TCL1 Mouse Model of Chronic Lymphocytic Leukemia. , 2019, , 2213-2241.		0
2156	T Cell Senescence and Tumor Immunotherapy. , 2019, , 2091-2114.		0
2157	Ageing, Immunosenescence, and Transplantation Tolerance. , 2019, , 2169-2185.		0
2159	Complexities of the Lung Tumor Microenvironment. <i>Current Cancer Research</i> , 2019, , 179-194.	0.2	0
2160	Measuring Immunological Age: From T Cell Repertoires to Populations. , 2019, , 63-124.		0
2162	Current Status and Future Direction of Immune Checkpoint Inhibitors. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 217-223.	0.0	0
2165	Serum cytokine profile during disease progression stages in male and female hepatitis C patients. <i>Journal of Bioscience and Applied Research</i> , 2019, 5, 308-324.	0.1	0
2170	Dynamics of T Cells Repertoire During <i>Trypanosoma cruzi</i> Infection and its Post-Treatment Modulation. <i>Current Medicinal Chemistry</i> , 2019, 26, 6519-6543.	1.2	4
2172	Dental follicle mesenchymal stem cells regulate inflammatory responses in sepsis. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
2175	CD70 contributes to age-associated T cell defects and overwhelming inflammatory responses. <i>Ageing</i> , 2020, 12, 12032-12050.	1.4	9
2179	Pathologic findings and causes of death in bottlenose dolphins <i>Tursiops truncatus</i> stranded along the Georgia coast, USA (2007-2013). <i>Diseases of Aquatic Organisms</i> , 2020, 141, 25-38.	0.5	5
2180	Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2021, 19, 355.	4.2	33
2181	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10 \hat{c} IL-10R Pathways in Acute Myeloid Leukemia. <i>Pharmaceuticals</i> , 2021, 14, 1105.	1.7	6
2182	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. <i>Science Translational Medicine</i> , 2021, 13, eabf5264.	5.8	40
2183	Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 416.	0.8	24

#	ARTICLE	IF	CITATIONS
2184	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. <i>Frontiers in Immunology</i> , 2021, 12, 770390.	2.2	44
2185	Challenges in Response to Treatment Evaluation and Progression of the Disease. , 2020, , 173-191.		0
2186	Expression features of antigens involved in the formation of immunological synapse in splenic marginal zone lymphoma. <i>Oncogematologiya</i> , 2020, 15, 18-28.	0.1	0
2187	Thymosin $\hat{\pm}1$; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19. <i>Current Immunology Reviews</i> , 2020, 16, 55-57.	1.2	0
2188	Wnt signaling pathway in cancer immunotherapy. <i>Cancer Letters</i> , 2022, 525, 84-96.	3.2	60
2189	A 3D pancreatic tumor model to study T cell infiltration. <i>Biomaterials Science</i> , 2021, 9, 7420-7431.	2.6	17
2190	T Cell Exhaustion Could Be Regulating by Yangyin Fuzheng Decoction in Lewis Lung Cancer in a Tumor Burdened Mice. <i>World Journal of Cancer Research</i> , 2020, 10, 31-40.	0.1	0
2191	iPSC-derived Rejuvenated T-cell Therapy for Extranodal NK/T-cell Lymphoma, Nasal Type. <i>Juntendo Medical Journal</i> , 2020, 66, 200-205.	0.1	0
2192	Applications of Cutting-Edge Immunoproteomics Technology in Human Immunotherapy. , 2020, , 121-159.		0
2194	Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts. <i>Frontiers in Chemistry</i> , 2021, 9, 766107.	1.8	7
2195	Immunopotential of galangal (<i>Alpinia galanga</i> L.) when combined with T-cells against metastatic triple-negative breast cancer, MDA-MB 231. <i>Journal of Applied Pharmaceutical Science</i> , 0, , .	0.7	1
2196	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1333-1353.	1.1	9
2197	Comprehensive Analysis of CPA4 as a Poor Prognostic Biomarker Correlated with Immune Cells Infiltration in Bladder Cancer. <i>Biology</i> , 2021, 10, 1143.	1.3	4
2200	The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy. <i>BMC Cancer</i> , 2021, 21, 1183.	1.1	5
2201	Egr2 and 3 control inflammation, but maintain homeostasis, of PD-1 ^{high} memory phenotype CD4 T cells. <i>Life Science Alliance</i> , 2020, 3, e202000766.	1.3	7
2205	The DARC-null trait is associated with moderate modulation of NK cell profiles and unaltered cytolytic T cell profiles in black South Africans. <i>PLoS ONE</i> , 2020, 15, e0242448.	1.1	3
2206	Chapter 16: Vitagenes in gut health and immunity. , 2020, , 505-538.		0
2207	Immune response in glioma's microenvironment. <i>Innovative Surgical Sciences</i> , 2021, 5, 115-125.	0.4	16

#	ARTICLE	IF	CITATIONS
2208	Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells. Immunotherapy Advances, 2021, 1, ltaa001.	1.2	5
2210	Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale Journal of Biology and Medicine, 2011, 84, 409-21.	0.2	97
2211	Finding Balance: T cell Regulatory Receptor Expression during Aging. , 2011, 2, 398-413.		16
2215	Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. International Journal of Clinical and Experimental Pathology, 2014, 7, 6880-8.	0.5	31
2216	T-cell Exhaustion and Cancer Immunotherapy. Journal of International Oral Health, 2015, 7, i-ii.	0.0	0
2217	IL-10: Expanding the Immune Oncology Horizon. International Journal of Mechanical Engineering and Applications, 2015, 2, .	0.3	5
2218	Immunoregulation of hepatitis B virus infection--rationale and clinical application. Nagoya Journal of Medical Science, 2012, 74, 217-32.	0.6	5
2219	Preferential Tim-3 expression on Treg and CD8(+) T cells, supported by tumor-associated macrophages, is associated with worse prognosis in gastric cancer. American Journal of Translational Research (discontinued), 2016, 8, 3419-28.	0.0	11
2220	Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. Iranian Journal of Basic Medical Sciences, 2016, 19, 692-704.	1.0	11
2221	Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). Iranian Journal of Basic Medical Sciences, 2016, 19, 1201-1208.	1.0	28
2222	Tim-3 Up-regulation in Patients with Gastric Cancer and Peptic Ulcer Disease. Asian Pacific Journal of Cancer Prevention, 2017, 18, 765-770.	0.5	2
2223	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. Journal of Virus Eradication, 2017, 3, 236-241.	0.3	0
2224	Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer. American Journal of Cancer Research, 2018, 8, 1564-1575.	1.4	13
2225	The expression of PD-1 and LAG-3 in periapical lesions. American Journal of Translational Research (discontinued), 2018, 10, 2677-2684.	0.0	4
2226	Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy. Journal of Immunology Research and Therapy, 2017, 2, 100-113.	1.0	1
2229	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
2230	Expression Analysis of Fyn and Bat3 Signal Transduction Molecules in Patients with Chronic Lymphocytic Leukemia. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2615-2621.	0.5	0
2231	Role of kynurenine in promoting the generation of exhausted CD8 T cells in colorectal cancer. American Journal of Translational Research (discontinued), 2021, 13, 1535-1547.	0.0	3

#	ARTICLE	IF	CITATIONS
2232	CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV. <i>International Journal of Biological Sciences</i> , 2022, 18, 154-165.	2.6	8
2233	Towards effective beta-cell replacement through understanding and targeting of the autoreactive immune response during onset of type 1 diabetes. <i>Journal of Immunology and Regenerative Medicine</i> , 2022, 15, 100057.	0.2	2
2234	Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. <i>Journal of Advanced Research</i> , 2022, 40, 179-196.	4.4	75
2235	T-Cell Exhaustion in Mycobacterium tuberculosis and Nontuberculous Mycobacteria Infection: Pathophysiology and Therapeutic Perspectives. <i>Microorganisms</i> , 2021, 9, 2460.	1.6	21
2236	Quantitative contributions of TNF receptor superfamily members to CD8 ⁺ T cell responses. <i>Molecular Systems Biology</i> , 2021, 17, e10560.	3.2	7
2237	Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures. <i>Scientific Reports</i> , 2021, 11, 22244.	1.6	7
2238	A high OXPPOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
2239	Divergent fates of antigen-specific CD8 ⁺ T cell clones in mice with acute leukemia. <i>Cell Reports</i> , 2021, 37, 109991.	2.9	3
2240	Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. <i>EMBO Journal</i> , 2021, 40, e108662.	3.5	41
2241	Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 55890-55901.	4.0	16
2242	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 26-42.	2.0	26
2243	Anticancer natural products targeting immune checkpoint protein network. <i>Seminars in Cancer Biology</i> , 2022, 86, 1008-1032.	4.3	8
2244	Interleukin-10-Mediated Lymphopenia Caused by Acute Infection with Foot-and-Mouth Disease Virus in Mice. <i>Viruses</i> , 2021, 13, 2358.	1.5	5
2245	Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients. <i>PLoS Computational Biology</i> , 2021, 17, e1009587.	1.5	11
2246	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. <i>JCI Insight</i> , 2021, 6, .	2.3	11
2247	Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 706150.	2.2	2
2248	Cancer immunotherapy: Challenges and limitations. <i>Pathology Research and Practice</i> , 2022, 229, 153723.	1.0	53
2249	Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. <i>Nature Communications</i> , 2021, 12, 6742.	5.8	45

#	ARTICLE	IF	CITATIONS
2250	The role of the electron transport chain in immunity. <i>FASEB Journal</i> , 2021, 35, e21974.	0.2	49
2251	Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins. <i>Frontiers in Oncology</i> , 2021, 11, 761107.	1.3	20
2252	The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 779865.	1.8	11
2253	Sarcopenia's Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5329.	1.0	8
2254	Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 760031.	1.6	6
2255	A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy. <i>Journal of Biological Chemistry</i> , 2021, 297, 101420.	1.6	15
2256	T cells expressing multiple co-inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice. <i>European Journal of Immunology</i> , 2022, 52, 312-327.	1.6	8
2258	MAIT Cells in Respiratory Viral Infections in Mouse and Human. <i>Critical Reviews in Immunology</i> , 2021, 41, 19-35.	1.0	7
2259	Apolipoprotein E deficiency enhances the anti-tumor immunity via repressing T cell exhaustion. <i>International Journal of Transgender Health</i> , 2021, 14, 1054-1062.	1.1	0
2260	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
2261	The adaptation of SARS-CoV-2 to humans. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210127.	0.8	4
2262	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
2263	Filarial Lymphedema Patients Are Characterized by Exhausted CD4+ T Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 767306.	1.8	5
2264	High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. <i>Virus Research</i> , 2022, 309, 198660.	1.1	2
2265	A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 148-159.	2.0	14
2266	Expression Analysis of Fyn and Bat3 Signal Transduction Molecules in Patients with Chronic Lymphocytic Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2615-2621.	0.5	2
2267	Signal-Strength and History-Dependent Innate Immune Memory Dynamics in Health and Disease. <i>Handbook of Experimental Pharmacology</i> , 2021, , 1.	0.9	4
2268	Improving Therapeutic Vaccination against Hepatitis B—Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. <i>Vaccines</i> , 2021, 9, 1333.	2.1	4

#	ARTICLE	IF	CITATIONS
2269	Eomes and Tâ€bet, a dynamic duo regulating NK cell differentiation. <i>BioEssays</i> , 2022, 44, e2100281.	1.2	3
2271	Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV. <i>Cell Reports Medicine</i> , 2022, 3, 100487.	3.3	14
2272	Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. <i>Nature Communications</i> , 2022, 13, 440.	5.8	100
2273	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity. <i>Cancers</i> , 2022, 14, 285.	1.7	12
2274	Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome. <i>Thorax</i> , 2022, 77, 865-872.	2.7	5
2275	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Antiâ€Leukemia Efficacy of CARâ€T Cells via SOCEâ€Calcineurinâ€NFAT and Glycolysis Pathways. <i>Advanced Science</i> , 2022, 9, e2103508.	5.6	21
2276	Modulation of Host Immune Response during <i>Leishmania infantum</i> Natural Infection: A Whole-Transcriptome Analysis of the Popliteal Lymph Nodes in Dogs. <i>Frontiers in Immunology</i> , 2021, 12, 794627.	2.2	8
2277	Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development. <i>Npj Regenerative Medicine</i> , 2022, 7, 11.	2.5	10
2278	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. <i>Cancers</i> , 2022, 14, 299.	1.7	11
2279	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on â€œOff-the-Shelfâ€T Cell Therapy Using iPSC Technology and Gene Editing. <i>Cells</i> , 2022, 11, 269.	1.8	10
2280	Naturally acquired antibody response to a <i>Plasmodium falciparum</i> chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. <i>Malaria Journal</i> , 2022, 21, 6.	0.8	7
2281	B cellâ€derived IL-27 promotes control of persistent LCMV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
2282	The Interplay Between Epigenetic Regulation and CD8+ T Cell Differentiation/Exhaustion for T Cell Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 783227.	1.8	11
2283	Exhausted and Apoptotic BALF T Cells in Proinflammatory Airway Milieu at Acute Phase of Severe <i>Mycoplasma Pneumoniae</i> Pneumonia in Children. <i>Frontiers in Immunology</i> , 2021, 12, 760488.	2.2	6
2284	Differential expression of inhibitory receptor NKG2A distinguishes diseaseâ€specific exhausted CD8 + T cells. <i>MedComm</i> , 2022, 3, e111.	3.1	2
2285	TCR-T Immunotherapy: The Challenges and Solutions. <i>Frontiers in Oncology</i> , 2021, 11, 794183.	1.3	36
2286	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. <i>Cells</i> , 2022, 11, 410.	1.8	9
2287	An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 798683.	2.2	8

#	ARTICLE	IF	CITATIONS
2288	Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 558-567.	1.9	5
2289	Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. <i>Frontiers in Immunology</i> , 2021, 12, 788959.	2.2	9
2290	Metabolic Implications of Immune Checkpoint Proteins in Cancer. <i>Cells</i> , 2022, 11, 179.	1.8	15
2291	Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection. <i>Viruses</i> , 2022, 14, 198.	1.5	9
2292	Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	11
2293	Clonally Expanded Virus-Specific CD8 T Cells Acquire Diverse Transcriptional Phenotypes During Acute, Chronic, and Latent Infections. <i>Frontiers in Immunology</i> , 2022, 13, 782441.	2.2	7
2294	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. <i>Future Oncology</i> , 2022, , .	1.1	4
2295	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T ^A cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	2.9	45
2296	A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour CD8+ T cell immune response. <i>Journal of Theoretical Biology</i> , 2022, 538, 111028.	0.8	12
2297	Strategies for manufacturing cell therapy products aligned with patient needs. <i>Methods in Cell Biology</i> , 2022, 167, 203-226.	0.5	1
2298	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
2299	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 795463.	2.2	6
2300	Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma. <i>Hematological Oncology</i> , 2022, 40, 530-540.	0.8	2
2301	Novel low ^{avidity} glypican ³ specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. <i>Hepatology</i> , 2022, 76, 330-344.	3.6	11
2302	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 ^{int} TCF-1 ⁺ CD8 ⁺ T ^A cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
2303	Epigenetics and CD8 ⁺ T cell memory*. <i>Immunological Reviews</i> , 2022, 305, 77-89.	2.8	22
2304	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 ⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
2305	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. <i>Journal of Biosciences</i> , 2020, 45, .	0.5	6

#	ARTICLE	IF	CITATIONS
2306	Recent advances in biomaterial-boosted adoptive cell therapy. <i>Chemical Society Reviews</i> , 2022, 51, 1766-1794.	18.7	29
2307	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. <i>International Journal of Biological Sciences</i> , 2022, 18, 2775-2794.	2.6	27
2308	CAR T Cell Immunotherapy Beyond Haematological Malignancy. <i>Immune Network</i> , 2022, 22, e6.	1.6	11
2309	Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery. , 2022, , 129-161.		3
2310	Cell-based immunotherapy of glioblastoma multiforme (Review). <i>Oncology Letters</i> , 2022, 23, 133.	0.8	6
2311	Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
2312	Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective. <i>Current Treatment Options in Oncology</i> , 2022, 23, 268-294.	1.3	8
2313	Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2022, 15, 17.	6.9	46
2314	Neuroendocrine Regulation of Stress-induced T Cell Dysfunction during Lung Cancer Immunosurveillance via the Kisspeptin/GPR54 Signaling Pathway. <i>Advanced Science</i> , 2022, 9, e2104132.	5.6	9
2315	Treating CAR-T relapses: check not checkmate. <i>Blood</i> , 2022, 139, 955-957.	0.6	2
2316	Knowns and Unknowns about CAR-T Cell Dysfunction. <i>Cancers</i> , 2022, 14, 1078.	1.7	23
2317	Age-associated phenotypic imbalance in TCD4 and TCD8 cell subsets: comparison between healthy aged, smokers, COPD patients and young adults. <i>Immunity and Ageing</i> , 2022, 19, 9.	1.8	9
2318	Reactive oxygen species in cancer progression and its role in therapeutics. <i>Exploration of Medicine</i> , 0, , 43-57.	1.5	13
2319	New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. <i>Current Oncology Reports</i> , 2022, 24, 651-658.	1.8	21
2320	Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer. <i>Frontiers in Physiology</i> , 2022, 13, 819145.	1.3	8
2322	T-cells of invasive candidiasis patients show patterns of T-cell-exhaustion suggesting checkpoint blockade as treatment option. <i>Journal of Infection</i> , 2022, 84, 237-247.	1.7	12
2323	T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. <i>Nature Communications</i> , 2022, 13, 925.	5.8	104
2324	Cyclosporine A therapy of chronic lymphoblastic leukemia-related pancytopenia: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05538.	0.2	0

#	ARTICLE	IF	CITATIONS
2325	Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection. <i>Viruses</i> , 2022, 14, 581.	1.5	7
2326	Transcriptional switch of hepatocytes initiates macrophage recruitment and T-cell suppression in endotoxemia. <i>Journal of Hepatology</i> , 2022, 77, 436-452.	1.8	18
2327	CD8+ T-Cell Exhaustion Phenotype in Chronic Hepatitis C Virus Infection Is Associated With Epitope Sequence Variation. <i>Frontiers in Immunology</i> , 2022, 13, 832206.	2.2	4
2328	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
2329	Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer. <i>Frontiers in Immunology</i> , 2022, 10, e003667.		26
2330	Downregulation of TPX2 impairs the antitumor activity of CD8+ T cells in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 223.	2.7	11
2331	Tfh-cell-derived interleukin 21 sustains effector CD8+ T cell responses during chronic viral infection. <i>Immunity</i> , 2022, 55, 475-493.e5.	6.6	48
2332	Neutrophil Extracellular Traps in Cancer Therapy Resistance. <i>Cancers</i> , 2022, 14, 1359.	1.7	30
2333	The Role of Metabolic Dysfunction in T-Cell Exhaustion During Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2022, 13, 843242.	2.2	10
2334	CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-35.	1.9	15
2335	Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8+ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy. <i>Biomedicines</i> , 2022, 10, 805.	1.4	6
2336	Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. <i>Vaccines</i> , 2022, 10, 384.	2.1	3
2337	Cytokine-induced transient monocyte IL-7R α expression and the serum milieu in tuberculosis. <i>European Journal of Immunology</i> , 2022, 52, 958-969.	1.6	3
2338	Role of Senescence in Tumorigenesis and Anticancer Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-23.	0.6	3
2339	High Levels of CD244 Rather Than CD160 Associate With CD8+ T-Cell Aging. <i>Frontiers in Immunology</i> , 2022, 13, 853522.	2.2	3
2340	Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. <i>JCI Insight</i> , 2022, 7, .	2.3	7
2341	Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients. <i>Annals of Intensive Care</i> , 2022, 12, 21.	2.2	10
2342	Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. <i>Cells</i> , 2022, 11, 1015.	1.8	7

#	ARTICLE	IF	CITATIONS
2343	Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. <i>Journal of Hematology and Oncology</i> , 2022, 15, 38.	6.9	20
2344	Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. <i>EBioMedicine</i> , 2022, 77, 103941.	2.7	93
2345	Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 873834.	2.2	3
2346	Intratumoral genetic and immune microenvironmental heterogeneity in <sc>T4NOM0</sc> (diameterâ€‰%â€‰%¥â€‰%7Åcm) nonâ€‰small cell lung cancers. <i>Thoracic Cancer</i> , 2022, , .	0.8	2
2348	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
2349	Soluble Tim-3/Gal-9 as predictors of adverse outcomes after kidney transplantation: A cohort study. <i>Clinical Biochemistry</i> , 2022, 102, 19-25.	0.8	1
2350	Expression of Id3 represses exhaustion of anti-tumor CD8 T cells in liver cancer. <i>Molecular Immunology</i> , 2022, 144, 117-126.	1.0	5
2351	Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. , 2022, 10, e004114.		16
2352	Immunotherapeutic targeting of myeloid-derived suppressor cells (MDSCs) activity in obesity-associated cancer. <i>Advances in Cancer Biology Metastasis</i> , 2022, 4, 100036.	1.1	0
2353	A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. <i>Processes</i> , 2022, 10, 16.	1.3	13
2354	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
2355	Revisiting the Principles of Designing a Vaccine. <i>Methods in Molecular Biology</i> , 2022, 2410, 57-91.	0.4	1
2358	Single-Cell Transcriptome Analysis Reveals RGS1 as a New Marker and Promoting Factor for T-Cell Exhaustion in Multiple Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 767070.	2.2	29
2360	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793964.	2.2	13
2361	Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2022, 10, 146-153.	1.6	87
2362	CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development. <i>OncImmunology</i> , 2022, 11, 2010905.	2.1	12
2363	Cellular and Humoral Immune Responses Induced by an HLA Class Iâ€restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2022, 45, 56-66.	1.2	8
2365	Cardiac complications of cancer therapies. <i>Advances in Cancer Research</i> , 2022, , 167-214.	1.9	5

#	ARTICLE	IF	CITATIONS
2366	Androgen conspires with the CD8 ⁺ T cell exhaustion program and contributes to sex bias in cancer. <i>Science Immunology</i> , 2022, 7, .	5.6	74
2367	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
2368	Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies. <i>International Journal of Infectious Diseases</i> , 2022, 120, 77-82.	1.5	8
2369	Untangling the Web: The complex parenchymal-immune interface in endotoxemia. <i>Journal of Hepatology</i> , 2022, , .	1.8	0
2371	The Role of Immune Regulatory Molecules in COVID-19. <i>Viral Immunology</i> , 2022, 35, 359-364.	0.6	4
2372	Exhausted phenotype of circulating CD8 ⁺ T cell subsets in hepatitis B virus carriers. <i>BMC Immunology</i> , 2022, 23, 18.	0.9	12
2373	LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. <i>Nature Immunology</i> , 2022, 23, 757-767.	7.0	53
2374	Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. <i>Molecular Cancer</i> , 2022, 21, 98.	7.9	36
2375	Lymphocytic Thyroiditis Transcriptomic Profiles Support the Role of Checkpoint Pathways and B Cells in Pathogenesis. <i>Thyroid</i> , 2022, 32, 682-693.	2.4	4
2507	Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy. <i>Advanced Science</i> , 2022, 9, e2200999.	5.6	11
2508	A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy. <i>Journal of Controlled Release</i> , 2022, 346, 212-225.	4.8	17
2509	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 560-574.	0.9	3
2510	TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8 ⁺ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. <i>Immunology</i> , 2023, 168, 273-289.	2.0	12
2511	Preferential expansion of CD8 ⁺ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	2.5	20
2513	Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor γ towards B-Acute Myeloid Leukaemia Blasts.. <i>Cell Journal</i> , 2021, 23, 650-657.	0.2	2
2515	The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. <i>Chinese Clinical Oncology</i> , 2013, 2, 7.	0.4	9
2516	Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 451-468.	1.4	1
2517	TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 942-954.	0.0	0

#	ARTICLE	IF	CITATIONS
2518	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. <i>Frontiers in Immunology</i> , 2022, 13, 849515.	2.2	15
2519	The "Self-Sacrifice" of Immune Cells in Sepsis. <i>Frontiers in Immunology</i> , 2022, 13, 833479.	2.2	18
2520	Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases. <i>Cell Reports Medicine</i> , 2022, 3, 100620.	3.3	29
2521	The genetic influence of PD-1/PD-L1 axis single nucleotide polymorphisms on the incidence of type 1 diabetes mellitus in pediatric Egyptian patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	1
2522	Increase in Serum Soluble Tim-3 Level Is Related to the Progression of Diseases After Hepatitis Virus Infection. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
2523	A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. <i>Nature Communications</i> , 2022, 13, 2366.	5.8	26
2524	Plasticity of NK cells in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	11
2525	Changes in immune function and immunomodulatory treatments of septic patients. <i>Clinical Immunology</i> , 2022, 239, 109040.	1.4	3
2526	Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103707.	2.0	8
2527	Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2022, Volume 14, 1627-1639.	0.9	0
2528	A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy. <i>Materials Today Bio</i> , 2022, 14, 100284.	2.6	11
2529	NK Cells and ILC1s in Cancer Biology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1365, 41-55.	0.8	2
2530	Activation and increased production of interleukin-17 and tumour necrosis factor- α of mucosal-associated invariant T cells in patients with periodontitis. <i>Journal of Clinical Periodontology</i> , 2022, 49, 706-716.	2.3	5
2531	OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer. <i>International Immunopharmacology</i> , 2022, 108, 108813.	1.7	7
2533	CD4 ⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
2534	miR-146a Maintains Immune Tolerance of Kupffer Cells and Facilitates Hepatitis B Virus Persistence in Mice. <i>Journal of Immunology</i> , 2022, 208, 2558-2572.	0.4	3
2535	Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. <i>Cancer Cell</i> , 2022, 40, 674-693.e7.	7.7	41
2536	Perioperative Systemic Inflammation in Lung Cancer Surgery. <i>Frontiers in Surgery</i> , 2022, 9, .	0.6	3

#	ARTICLE	IF	CITATIONS
2537	Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
2539	Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3057-3070.	2.0	18
2540	Exhaustion of CAR T cells: potential causes and solutions. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	32
2541	The paradox of immune checkpoint inhibition re-activating tuberculosis. <i>European Respiratory Journal</i> , 2022, 60, 2102512.	3.1	8
2542	Epigenetic regulation of T cell exhaustion. <i>Nature Immunology</i> , 2022, 23, 848-860.	7.0	82
2543	RAB42 is a Potential Biomarker that Correlates With Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	2
2544	Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. <i>Cancer Medicine</i> , 2023, 12, 789-807.	1.3	5
2545	Zooming on T cells in cancer. <i>Science China Life Sciences</i> , 0, , .	2.3	2
2546	The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma. <i>BMC Immunology</i> , 2022, 23, .	0.9	4
2547	The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8 ⁺ cytotoxic T-cell response. <i>Genes and Development</i> , 2022, 36, 582-600.	2.7	9
2548	Exhausted PD-1+ TOX+ CD8+ T Cells Arise Only in Long-Term Experimental Trypanosoma cruzi Infection. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
2549	Clinical and Biological Significance of a Necroptosis-Related Gene Signature in Glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2550	The Influence of c-Kit and NRAS Mutation on Patients'™ Survival in Metastatic Melanoma Receiving Immune Checkpoint Inhibitors and Chemotherapy. <i>Dermato</i> , 2022, 2, 53-58.	0.6	1
2551	Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients With Herpes Zoster and Postherpetic Neuralgia. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
2552	Case Report: Immune Checkpoint Blockade Plus Interferon- γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
2553	An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 105-119.	2.0	12
2554	Decreased leukocyte exhaustion is associated with decreased IFN- γ and increased α -defensin-1 levels in type-2 diabetes. <i>Cytokine</i> , 2022, 156, 155918.	1.4	1
2556	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. <i>International Ophthalmology Clinics</i> , 2022, 62, 49-63.	0.3	6

#	ARTICLE	IF	CITATIONS
2557	Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2558	Impaired in vitro Interferon- γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010544.	1.3	3
2559	Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2560	Cytotoxic CD4+ T cells driven by T-cell intrinsic IL-18R/MyD88 signaling predominantly infiltrate <i>Trypanosoma cruzi</i> -infected hearts. <i>ELife</i> , 0, 11, .	2.8	7
2561	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
2562	High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4+ T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19. <i>Viruses</i> , 2022, 14, 1265.	1.5	5
2563	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2564	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. <i>Immunotherapy</i> , 0, , .	1.0	3
2565	Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1185-1203.	2.0	3
2566	Excessive immunosuppression by regulatory T cells antagonizes T cell response to schistosome infection in PD-1-deficient mice. <i>PLoS Pathogens</i> , 2022, 18, e1010596.	2.1	7
2567	Leukemia derived dendritic cell (DC _{leu}) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells. <i>Immunobiology</i> , 2022, 227, 152237.	0.8	8
2568	Immunological and Hemato-biochemical alterations in diarrhoeic buffaloes screened for <i>Mycobacterium avium</i> subspecies paratuberculosis infection using "indigenous ELISA kit". <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2022, 87, 101833.	0.7	1
2569	The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma. <i>Immunology Letters</i> , 2022, 248, 16-25.	1.1	2
2571	Chemical-induced lung tumor in Tg-rasH2 mice: a novel mouse tumor model to assess immune checkpoint inhibitors combined with a chemotherapy drug. <i>Journal of Toxicologic Pathology</i> , 2022, , .	0.3	0
2572	Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study. <i>Investigative and Clinical Urology</i> , 2022, 63, 415.	1.0	9
2573	Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
2574	The cellular and molecular basis of CD69 function in anti-tumor immunity. <i>International Immunology</i> , 2022, 34, 555-561.	1.8	11
2575	A Comparison of Pseudorabies Virus Latency to Other γ -Herpesvirinae Subfamily Members. <i>Viruses</i> , 2022, 14, 1386.	1.5	5

#	ARTICLE	IF	CITATIONS
2576	Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2577	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
2578	Microbial Metabolite 3-Indolepropionic Acid Mediates Immunosuppression. <i>Metabolites</i> , 2022, 12, 645.	1.3	5
2579	Mapping CAR T-Cell Design Space Using Agent-Based Models. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
2580	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
2581	Application of ATAC-seq in tumor-specific T cell exhaustion. <i>Cancer Gene Therapy</i> , 2023, 30, 1-10.	2.2	4
2583	Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
2584	Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma. <i>PLoS ONE</i> , 2022, 17, e0271205.	1.1	4
2585	Intersection of Inflammation and Senescence in the Aging Lung Stem Cell Niche. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	8
2586	Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8+ T Cells Are Associated With Increased Function Instead of Exhaustion. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2587	A novel <i>ZsGreen</i> knock-in melanoma cell line reveals the function of <i>CD11b</i> in tumor phagocytosis. <i>Immunology and Cell Biology</i> , 2022, 100, 691-704.	1.0	1
2589	LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade. <i>Journal of Immunology</i> , 2022, 209, 510-525.	0.4	5
2590	Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. <i>Cancer Discovery</i> , 2022, 12, 2098-2119.	7.7	24
2591	Chemoimmunotherapy Administration Protocol Design for the Treatment of Leukemia through Mathematical Modeling and In Silico Experimentation. <i>Pharmaceutics</i> , 2022, 14, 1396.	2.0	1
2592	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	0.7	2
2593	Stem cell like memory T cells: A new paradigm in cancer immunotherapy. <i>Clinical Immunology</i> , 2022, 241, 109078.	1.4	12
2594	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. <i>iScience</i> , 2022, 25, 104702.	1.9	15
2595	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	9

#	ARTICLE	IF	CITATIONS
2598	Radiogenomics to characterize the immune-related prognostic signature associated with biological functions in glioblastoma. <i>European Radiology</i> , 2023, 33, 209-220.	2.3	10
2599	T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. <i>Blood</i> , 2022, 140, 1104-1118.	0.6	60
2600	Resilient T-cell responses in patients with advanced cancers. <i>International Journal of Hematology</i> , 2023, 117, 634-639.	0.7	6
2601	A protein kinase D inhibitor suppresses AKT on T cells and antagonizes cancer immunotherapy by anti-PD-1. <i>International Immunology</i> , 2022, 34, 609-619.	1.8	3
2602	Effective Treatment of Patients Experiencing Primary, Acute HIV Infection Decreases Exhausted/Activated CD4+ T Cells and CD8+ T Memory Stem Cells. <i>Cells</i> , 2022, 11, 2307.	1.8	2
2603	Advances in Cutaneous Squamous Cell Carcinoma Management. <i>Cancers</i> , 2022, 14, 3653.	1.7	14
2604	Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. <i>EBioMedicine</i> , 2022, 82, 104179.	2.7	17
2605	Microbiota and lung cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 1-10.	4.3	23
2606	Mesenchymal stem cells-based therapy in liver diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	4
2607	Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade. <i>Cancers</i> , 2022, 14, 3679.	1.7	3
2608	A multi-omic approach reveals utility of CD45 expression in prognosis and novel target discovery. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
2609	BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	23
2610	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
2612	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	50
2613	A novel virotherapy encoding human interleukin-7 improves ex vivo T lymphocyte functions in immunosuppressed patients with septic shock and critically ill COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2614	Genome Engineering for Next-Generation Cellular Immunotherapies. <i>Biochemistry</i> , 0, , .	1.2	1
2615	Directly injected lentiviral vector-based T cell vaccine protects mice against acute and chronic viral infection. <i>JCI Insight</i> , 2022, 7, .	2.3	5
2616	Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. <i>Med</i> , 2022, 3, 538-564.	2.2	11

#	ARTICLE	IF	CITATIONS
2617	Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. <i>Science Immunology</i> , 2022, 7, .	5.6	8
2619	Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 885-894.	1.9	10
2620	A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. <i>Cancers</i> , 2022, 14, 3796.	1.7	3
2621	Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 5121-5135.	3.2	8
2622	Î³Î´ T cell exhaustion: Opportunities for intervention. <i>Journal of Leukocyte Biology</i> , 2022, 112, 1669-1676.	1.5	11
2623	CD4+ T-lymphocytes exhibit biphasic kinetics post-myocardial infarction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	47
2624	Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2625	CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 ⁺ T lymphocytes. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	9
2626	Pregnancy Imparts Distinct Systemic Adaptive Immune Function. <i>American Journal of Reproductive Immunology</i> , 0, , .	1.2	3
2627	VÎ²2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. , 2022, 10, e004880.		10
2628	Immunotherapeutic targets in nonâ€‘small cell lung cancer. <i>Immunology</i> , 2023, 168, 256-272.	2.0	5
2629	Effector Th1 cells under <sc>PD</sc>â€‘1 and <sc>CTLA</sc>â€‘4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and byâ€‘pass exhaustion. <i>Immunology</i> , 2022, 167, 640-650.	2.0	3
2630	Epigenetic engineering for optimal CARâ€‘T cell therapy. <i>Cancer Science</i> , 0, , .	1.7	4
2631	Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating nonâ€‘small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
2632	Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. <i>EBioMedicine</i> , 2022, 83, 104207.	2.7	43
2633	Defining and targeting patterns of T cell dysfunction in inborn errors of immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2634	An Ionâ€‘Enhanced Oncolytic Virusâ€‘Like Nanoparticle for Tumor Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	8
2635	Tuberculosis Immune Landscapes Revealed by a Single-Cell Transcriptome Atlas: An Omics Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
2636	Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. Computational and Structural Biotechnology Journal, 2022, 20, 5150-5161.	1.9	5
2637	Bioprospection and Clinical Investigations of Immunomodulatory Molecules. , 2022, , 53-81.		0
2638	CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 119-136.	1.2	15
2639	Infection chronique par le virus de l'herpès simple C. Medecine/Sciences, 2022, 38, 640-642.	0.0	0
2640	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers, 2022, 14, 4192.	1.7	6
2641	Distinct Immune Phenotypes and Cytokine Profiles in Children with Differing Severity of COVID-19. Pediatric Infectious Disease Journal, 2022, 41, 919-926.	1.1	2
2642	Contribution of skeletal muscle to cancer immunotherapy: A focus on muscle function, inflammation, and microbiota. Nutrition, 2023, 105, 111829.	1.1	3
2643	RAB6B is a potential prognostic marker and correlated with the remodeling of tumor immune microenvironment in hepatocellular carcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	1
2644	Tumor accomplice: T cell exhaustion induced by chronic inflammation. Frontiers in Immunology, 0, 13, .	2.2	9
2645	Impaired mitochondria of Tregs decreases OXPHOS-derived ATP in primary immune thrombocytopenia with positive plasma pathogens detected by metagenomic sequencing. Experimental Hematology and Oncology, 2022, 11, .	2.0	4
2646	Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas. Human Cell, 2022, 35, 1976-1992.	1.2	2
2647	Immune cells and their inflammatory mediators modify β^2 cells and cause checkpoint inhibitor-induced diabetes. JCI Insight, 2022, 7, .	2.3	17
2648	Prostaglandin E ₂ -Induced Immune Suppression via Cytotoxic T-Lymphocyte Antigen 4 in Paratuberculosis. Infection and Immunity, 2022, 90, .	1.0	3
2649	Metabolic plasticity and regulation of T cell exhaustion. Immunology, 2022, 167, 482-494.	2.0	14
2650	LAG3 blockade coordinates with microwave ablation to promote CD8+ T cell-mediated anti-tumor immunity. Journal of Translational Medicine, 2022, 20, .	1.8	9
2651	Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Frontiers in Immunology, 0, 13, .	2.2	11
2652	Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation. World Journal of Biological Chemistry, 0, 13, 72-82.	1.7	0
2653	Highly tailorable gellan gum nanoparticles as a platform for the development of T cell activator systems. Biomaterials Research, 2022, 26, .	3.2	1

#	ARTICLE	IF	CITATIONS
2655	Loss of CD47 alters CD8+ T cell activation <i>in vitro</i> and immunodynamics in mice. <i>Oncology</i> , 2022, 11, .	2.1	10
2657	An Ion-enhanced Oncolytic Virus-like Nanoparticle for Tumor Immunotherapy. <i>Angewandte Chemie</i> , 0, , .	1.6	0
2659	The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis. <i>Cancers</i> , 2022, 14, 4287.	1.7	9
2660	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2661	Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors. <i>PLoS ONE</i> , 2022, 17, e0274494.	1.1	3
2662	A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2663	Novel treatments in optic pathway gliomas. <i>Frontiers in Ophthalmology</i> , 0, 2, .	0.2	0
2664	Characterization of age-related immune features after autologous NK cell infusion: Protocol for an open-label and randomized controlled trial. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
2665	Non-coding RNAs: Key players in T cell exhaustion. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2666	Basics of immuno-oncology and immunotherapy in oncology. <i>Ekspierimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 129-139.	0.1	1
2667	PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer. <i>Liver Cancer</i> , 2023, 12, 129-144.	4.2	2
2668	Autoimmune disorders associated with common variable immunodeficiency: prediction, diagnosis, and treatment. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1265-1283.	1.3	1
2669	SLC7A5 is a lung adenocarcinoma-specific prognostic biomarker and participates in forming immunosuppressive tumor microenvironment. <i>Heliyon</i> , 2022, 8, e10866.	1.4	5
2670	Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
2671	Clinical characteristics, management, and outcome of gestational trophoblastic neoplasia patients with brain metastasis: A 10-year experience at the Philippine General Hospital. <i>Philippine Journal of Obstetrics & Gynecology: Official Publication, Philippine Obstetrical and Gynecological Society</i> , 2022, 46, 147.	0.0	1
2672	The Role of Tumor Microenvironment in Colon Cancer. , 2022, , 187-214.		0
2673	Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2023, 42, 11-30.	0.6	2
2674	Colorectal Cancer and Purinergic Signalling: An Overview. <i>Cancers</i> , 2022, 14, 4887.	1.7	6

#	ARTICLE	IF	CITATIONS
2675	Mitochondria in diseases: from cell power plants to DAMPs. Thorax, 0, , thoraxjnl-2022-219076.	2.7	1
2676	Neuroimmune Interactions in Severe COVID-19 Infection. Pathogens, 2022, 11, 1256.	1.2	1
2677	Cellular Senescence in Immunity against Infections. International Journal of Molecular Sciences, 2022, 23, 11845.	1.8	11
2680	The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell, 2022, 185, 4049-4066.e25.	13.5	89
2681	Immunometabolism in the tumor microenvironment and its related research progress. Frontiers in Oncology, 0, 12, .	1.3	7
2682	Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials. JCI Insight, 2022, 7, .	2.3	5
2683	Cross-Reactive T Cell Response Exists in Chronic Lymphocytic Choriomeningitis Virus Infection upon Pichinde Virus Challenge. Viruses, 2022, 14, 2293.	1.5	1
2684	Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells. Cellular Oncology (Dordrecht), 2022, 45, 1297-1309.	2.1	4
2685	Timely Leukapheresis May Interfere with the "Fitness" of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients. Cancers, 2022, 14, 5276.	1.7	3
2686	Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell, 2022, 40, 1407-1422.e7.	7.7	27
2687	The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	11
2688	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
2689	Current Status of Immune Checkpoint Inhibitors. Nihon Kikan Shokudoka Gakkai Kaiho, 2022, 73, 303-307.	0.0	0
2690	Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network. Vaccines, 2022, 10, 1764.	2.1	4
2691	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines, 2022, 10, 1673.	2.1	1
2692	Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. Cancers, 2022, 14, 5344.	1.7	11
2693	Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?. Cancers, 2022, 14, 4861.	1.7	1
2694	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. Frontiers in Immunology, 0, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
2696	Tâ€cell dysfunction as a potential contributing factor in <scp>postâ€COVID</scp>â€19 mucormycosis. <i>Mycoses</i> , 2023, 66, 202-210.	1.8	2
2697	BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13424.	1.8	4
2698	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. <i>International Immunopharmacology</i> , 2022, 113, 109300.	1.7	4
2699	The transcription factor IRF2 drives interferon-mediated CD8+ Tâ€cell exhaustion to restrict anti-tumor immunity. <i>Immunity</i> , 2022, 55, 2369-2385.e10.	6.6	29
2700	A case series report on successful management of patients with COVID-19-associated lymphopenia and potential application of PG2. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
2701	Combined mitoxantrone and anti-TGFÎ² treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
2702	Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. <i>Nature Communications</i> , 2022, 13, .	5.8	16
2703	The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer. <i>Biomedicines</i> , 2022, 10, 2826.	1.4	13
2704	Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. <i>Cells</i> , 2022, 11, 3626.	1.8	5
2705	The heterogeneity of fibrosis and angiogenesis in endometriosis revealed by single-cell RNA-sequencing. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166602.	1.8	6
2706	Immune Response Gaps Linked to SARS-CoV-2 Infection: Cellular Exhaustion, Senescence, or Both?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13734.	1.8	2
2707	Lipoproteins Are Potent Activators of Nuclear Factor Kappa B in Mammary Epithelial Cells and Virulence Factors in <i>Mycoplasma bovis</i> Mastitis. <i>Microorganisms</i> , 2022, 10, 2209.	1.6	2
2708	Tumor-Induced T Cell Polarization by Schwann Cells. <i>Cells</i> , 2022, 11, 3541.	1.8	5
2709	Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients. <i>Biology</i> , 2022, 11, 1633.	1.3	2
2710	In vivo gene immunotherapy for cancer. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	5
2711	Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction. , 2022, 19, 1347-1360.		9
2712	Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. <i>Cells</i> , 2022, 11, 3534.	1.8	1
2714	Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma. <i>Materials and Design</i> , 2023, 225, 111457.	3.3	2

#	ARTICLE	IF	CITATIONS
2715	T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy. <i>Biomaterials</i> , 2023, 293, 121972.	5.7	7
2716	Immunopathogenesis of Hepatitis B Virus Infection and Related Complications. <i>European Medical Journal Hepatology</i> , 0, , 84-92.	1.0	1
2717	Tumor Microenvironment Complexity: A Pathological Milieu that Innately Modulates Cancer Progression. , 2022, , 1-28.		0
2718	MONOCYTIC MYELOID-DERIVED SUPPRESSOR CELL EXPANSION AFTER CARDIAC SURGERY WITH CARDIOPULMONARY BYPASS INDUCES LYMPHOCYTE DYSFUNCTION. <i>Shock</i> , 2022, 58, 476-483.	1.0	1
2719	Nanoparticle-Delivered Transforming Growth Factor- β 21 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment. <i>Pharmaceuticals</i> , 2022, 15, 1487.	1.7	2
2720	Manipulation of diacylglycerol and ERK-mediated signaling differentially controls CD8+ T cell responses during chronic viral infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2721	Involvement in the tumor-infiltrating CD8+ T cell expression by the initial disease of remnant gastric cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	0
2722	Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-40.	2.4	5
2723	Multiplexed engineering and precision gene editing in cellular immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2724	Cancer immunosurveillance in respiratory diseases. , 2022, , 1-14.		2
2725	Immune predictors of hepatitis B surface antigen seroconversion in patients with hepatitis B reactivation. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 689-708.	1.9	6
2726	PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
2727	Mechanisms of colorectal liver metastasis development. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	7
2728	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
2729	Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2730	Identification of human progenitors of exhausted CD8+ T cells associated with elevated IFN- β 3 response in early phase of viral infection. <i>Nature Communications</i> , 2022, 13, .	5.8	8
2731	Study of epirubicin sustainedâ€‘release chemoablation in tumor suppression and tumor microenvironment remodeling. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2732	Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2023, 23, 173-188.	12.8	37

#	ARTICLE	IF	CITATIONS
2733	Age-related changes in CD4+ T and NK cell compartments may contribute to the occurrence of pregnancy loss in advanced maternal age. <i>Journal of Reproductive Immunology</i> , 2023, 155, 103790.	0.8	2
2734	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. <i>Cancers</i> , 2023, 15, 104.	1.7	14
2735	Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load. <i>IScience</i> , 2023, 26, 105867.	1.9	2
2737	Distinctive phenotype for HLA-E- versus HLA-A2-restricted memory CD8 $\hat{\pm}$ T cells in the course of HCMV infection discloses features shared with NKG2C+CD57+NK and $\hat{I}2\text{-}\hat{I}3\hat{I}$ T cell subsets. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2738	Cancer Immunology: Immune Escape of Tumorsâ€™ Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	2
2739	Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2740	Peptide vaccine against glioblastoma: from bench to bedside. , 2022, 1, .		5
2741	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5
2742	SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	5
2743	Single-cell profiling of T cells uncovers a tissue-resident memory-like T-cell subset associated with bidirectional prognosis for B-cell acute lymphoblastic leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2744	Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15973.	1.8	4
2745	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. <i>European Journal of Cell Biology</i> , 2023, 102, 151284.	1.6	8
2746	Development of therapeutic vaccines for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	11
2747	Roquin-dependent gene regulation in immune-mediated diseases and future therapies. <i>International Immunology</i> , 2023, 35, 159-170.	1.8	4
2748	Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5591-5602.	1.2	12
2749	Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2750	Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus. <i>Journal of Virology</i> , 2023, 97, .	1.5	1
2751	Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. <i>Journal of Clinical Medicine</i> , 2023, 12, 578.	1.0	8

#	ARTICLE	IF	CITATIONS
2752	Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. <i>OncoTargets and Therapy</i> , 0, Volume 16, 1-16.	1.0	1
2753	Non- SMC condensin I complex subunit H participates in anti-programmed cell death 1 resistance of clear cell renal cell carcinomas. <i>Cell Proliferation</i> , 2023, 56, .	2.4	3
2754	Epigenetics in T-cell driven inflammation and cancer. <i>Seminars in Cell and Developmental Biology</i> , 2024, 154, 250-260.	2.3	2
2755	Transcriptomic analysis for the retested positive COVID 19 patients with long-term persistent SARS CoV2 but without symptoms in Wuhan. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	0
2756	Trypanosoma cruzi-specific CD8+ T cells and other immunological hallmarks in chronic Chagas cardiomyopathy: Two decades of research. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
2759	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2
2760	Single-cell transcriptome analysis reveals heterogeneity and convergence of the tumor microenvironment in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2761	Advanced T and Natural Killer Cell Therapy for Glioblastoma. <i>Journal of Korean Neurosurgical Society</i> , 2023, 66, 356-381.	0.5	0
2763	Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. <i>International Immunopharmacology</i> , 2023, 115, 109638.	1.7	3
2764	MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. <i>Seminars in Immunology</i> , 2023, 66, 101710.	2.7	5
2765	PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. <i>Journal of Immunology</i> , 2022, 209, 621-628.	0.4	1
2766	Other Facets of SARS-CoV-2 Immunity, the Risk of Immune Tolerance and T Cell Exhaustion. , 2023, , 325-363.		0
2767	Present and Future Role of Immune Targets in Acute Myeloid Leukemia. <i>Cancers</i> , 2023, 15, 253.	1.7	2
2768	Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
2769	Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. <i>Nature Immunology</i> , 2023, 24, 148-161.	7.0	26
2770	IFN 3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. <i>Nature Communications</i> , 2023, 14, .	5.8	12
2771	Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection. <i>PLoS Biology</i> , 2023, 21, e3001983.	2.6	8
2772	Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	23

#	ARTICLE	IF	CITATIONS
2775	Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2776	Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	7
2777	<i>Infection and Immunity</i> , 2023, , 493-598.		1
2778	T cell exhaustion in malignant gliomas. <i>Trends in Cancer</i> , 2023, 9, 270-292.	3.8	23
2779	Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFN γ Responses of HIV-Infected Persons on Antiretroviral Therapy. <i>Vaccines</i> , 2023, 11, 211.	2.1	0
2780	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
2781	Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2782	Reprogramming the tumor microenvironment with biotechnology. <i>Biomaterials Research</i> , 2023, 27, .	3.2	7
2783	Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the "obesity paradox". <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2784	Immune Checkpoint Inhibitors Programmed Cell Death-1/Programmed Cell Death-Ligand1 (PD-1/PD-L1) for Cancer Therapy. , 0, , .		0
2785	Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses. , 2023, 2, .		3
2786	Immune checkpoint molecules in prevention and development of asthma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2787	IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model. <i>Cancer Immunology Research</i> , 2023, 11, 421-434.	1.6	14
2788	Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer. <i>Acta Biomaterialia</i> , 2023, 161, 184-200.	4.1	8
2789	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
2790	Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer. <i>International Immunopharmacology</i> , 2023, 118, 110038.	1.7	4
2791	Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes. <i>EBioMedicine</i> , 2023, 91, 104549.	2.7	3
2792	Train your T cells: How skeletal muscles and T cells keep each other fit during aging. <i>Brain, Behavior, and Immunity</i> , 2023, 110, 237-244.	2.0	4

#	ARTICLE	IF	CITATIONS
2793	Identification of shared characteristics in tumor-infiltrating T cells across 15 cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 32, 189-202.	2.3	3
2794	Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer. <i>European Journal of Pharmacology</i> , 2023, 949, 175718.	1.7	3
2795	Systems biology approaches to unravel lymphocyte subsets and function. <i>Current Opinion in Immunology</i> , 2023, 82, 102323.	2.4	0
2796	Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
2797	Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. <i>International Immunopharmacology</i> , 2023, 118, 110092.	1.7	5
2799	Prognostic Impact of Tumor Immune Microenvironment and Its Predictive Role in Salivary Gland Cancer. <i>Head and Neck Pathology</i> , 2023, 17, 515-527.	1.3	4
2800	IL18 Receptor Signaling Inhibits Intratumoral CD8+ T-Cell Migration in a Murine Pancreatic Cancer Model. <i>Cells</i> , 2023, 12, 456.	1.8	2
2802	Enhanced metabolic activation of and platelet response to clopidogrel in T cell-deficient mice through induction of Cyp2c and Cyp3a and inhibition of Ces1. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1322-1335.	1.9	0
2803	Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
2804	RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function. , 2023, 40, .		3
2805	Exhaustion-like dysfunction of T and NKT cells in a linked severe combined immunodeficiency patient with maternal engraftment by single-cell analysis. <i>International Journal of Molecular Medicine</i> , 2023, 51, .	1.8	0
2806	A systematic and comprehensive analysis of T cell exhaustion related to therapy in lung adenocarcinoma tumor microenvironment. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
2807	The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3226.	1.8	3
2808	TET2 guards against unchecked BATF3-induced CAR T cell expansion. <i>Nature</i> , 2023, 615, 315-322.	13.7	32
2809	T Cell Response to SARS-CoV-2 Coinfection and Comorbidities. <i>Pathogens</i> , 2023, 12, 321.	1.2	4
2810	TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
2811	Cancer immunotherapies: A hope for the incurable?. <i>Frontiers in Molecular Medicine</i> , 0, 3, .	0.6	3
2812	T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5

#	ARTICLE	IF	CITATIONS
2813	Hypercholesterolemia Influences the Progression of Cancer by Changing the Biomolecular and Immunological Status of the Tumor Microenvironment. , 2023, , 1-30.		0
2814	Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	22
2815	A necroptosis-independent function of RIPK3 promotes immune dysfunction and prevents control of chronic LCMV infection. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
2816	The role of m6A-mediated PD-1/PD-L1 in antitumor immunity. <i>Biochemical Pharmacology</i> , 2023, 210, 115460.	2.0	2
2817	Challenges of Anti-Mesothelin CAR-T-Cell Therapy. <i>Cancers</i> , 2023, 15, 1357.	1.7	8
2818	USP25 deficiency promotes T cell dysfunction and transplant acceptance via mitochondrial dynamics. <i>International Immunopharmacology</i> , 2023, 117, 109917.	1.7	0
2819	AP-1-independent NFAT signaling maintains follicular T cell function in infection and autoimmunity. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	1
2821	Effects of Low-Level Persistent Infection on Maintenance of Immunity by CD4 T Cell Subsets and Th1 Cytokines. <i>Infection and Immunity</i> , 2023, 91, .	1.0	1
2822	Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves. <i>Vaccines</i> , 2023, 11, 559.	2.1	0
2823	Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	5
2824	A Novel Vaccine Strategy to Prevent Cytauxzoonosis in Domestic Cats. <i>Vaccines</i> , 2023, 11, 573.	2.1	0
2825	Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
2826	The Function of Memory CD8+ T Cells in Immunotherapy for Human Diseases. <i>Immune Network</i> , 2023, 23, .	1.6	4
2827	Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. <i>Molecular Immunology</i> , 2023, 156, 31-38.	1.0	1
2828	Immunogen-Specific Strengths and Limitations of the Activation-Induced Marker Assay for Assessing Murine Antigen-Specific CD4+ T Cell Responses. <i>Journal of Immunology</i> , 2023, 210, 916-925.	0.4	0
2829	Exhausted CD8+ T cells face a developmental fork in the road. <i>Trends in Immunology</i> , 2023, 44, 276-286.	2.9	5
2830	B cell-related tertiary lymphoid structure may exert inhibitory effects on lung adenocarcinoma and SARS-COV-2. <i>Heliyon</i> , 2023, 9, e14334.	1.4	0
2831	OLFML3, as a potential predictor of prognosis and therapeutic target for glioma, is closely related to immune cell infiltration. <i>View</i> , 2023, 4, .	2.7	9

#	ARTICLE	IF	CITATIONS
2832	Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics. <i>Cancers</i> , 2023, 15, 1743.	1.7	4
2833	Landscape of Exhausted T Cells in Tuberculosis Revealed by Single-Cell Sequencing. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	4
2834	Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	19
2835	T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	43
2836	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
2837	The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
2838	T-cell exhaustion in CAR-T cell therapy and strategies to overcome it. <i>Immunology</i> , 2023, 169, 400-411.	2.0	7
2841	Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer. <i>IScience</i> , 2023, 26, 106484.	1.9	1
2842	CD83 expression characterizes precursor exhausted T cell population. <i>Communications Biology</i> , 2023, 6, .	2.0	2
2843	Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
2844	Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	10
2845	Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2023, 12, 406-424.	0.6	0
2846	Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlas. <i>Journal of Infection</i> , 2023, 86, 421-438.	1.7	9
2848	Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6520.	1.8	3
2849	IL-12 and IL-27 Promote CD39 Expression on CD8+ T Cells and Differentially Regulate the CD39+CD8+ T Cell Phenotype. <i>Journal of Immunology</i> , 2023, 210, 1598-1606.	0.4	4
2850	Establishment and validation of exhausted CD8+ T cell feature as a prognostic model of HCC. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2851	Regulation and function of poised mRNAs in lymphocytes. <i>BioEssays</i> , 2023, 45, .	1.2	4
2852	Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
2853	Regulatory Mechanisms and Reversal of CD8+T Cell Exhaustion: A Literature Review. <i>Biology</i> , 2023, 12, 541.	1.3	2
2854	The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 671-688.	1.3	0
2855	T _{STEM}-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	20
2857	Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer. <i>Immunology</i> , 2023, 169, 487-502.	2.0	5
2858	A closed, autologous bioprocess optimized for TCR- cell therapies. <i>Biotechnology and Bioengineering</i> , 2023, 120, 1809-1821.	1.7	0
2859	DNA architectural protein CTCF facilitates subset-specific chromatin interactions to limit the formation of memory CD8+ T cells. <i>Immunity</i> , 2023, 56, 959-978.e10.	6.6	5
2860	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. <i>Cell Reports</i> , 2023, 42, 112364.	2.9	0
2861	Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice. <i>Nature Communications</i> , 2023, 14, .	5.8	3
2862	Dynamics and specificities of T cells in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2023, 23, 295-316.	12.8	49
2863	Mathematical modeling identifies LAG3 and HAVCR2 as biomarkers of T cell exhaustion in melanoma. <i>IScience</i> , 2023, 26, 106666.	1.9	0
2864	Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
2865	Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy. <i>Oncologist</i> , 0, , .	1.9	0
2866	Immunotherapies against human bacterial and fungal infectious diseases: A review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	6
2867	Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
2868	Ovarian cancer-associated immune exhaustion involves SPP1+ T cell and NKT cell, symbolizing more malignant progression. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
2869	Current Medicinal Insights on Synthetic Small Molecules and Natural Origin Products as PD-1/PD-L1 Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	0
2870	CD19/CD22 bispecific chimeric antigen receptor- NK-92 cells are developed and evaluated. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
2872	Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2023, 29, 2110-2122.	3.2	3

#	ARTICLE	IF	CITATIONS
2873	Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	6
2874	Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. <i>Cancer Letters</i> , 2023, 563, 216192.	3.2	4
2895	Cancer immunotherapy. , 2023, , 681-741.		0
2921	T cells in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	36
2925	Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. <i>British Journal of Cancer</i> , 2023, 129, 572-585.	2.9	4
2971	Local Onco-Sphere: Tumorâ€™Immune Cells Interactions. , 2023, , 51-76.		0
2973	Adoptive Cellular Therapy. , 2023, , 713-725.		0
2985	Regulation of CD8+ T memory and exhaustion by the mTOR signals. , 2023, 20, 1023-1039.		4
2991	Immune suppression. , 2024, , 39-45.		0
3001	The kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
3020	IONPs-Based Treatment Methods. <i>Nanomedicine and Nanotoxicology</i> , 2023, , 129-240.	0.1	0
3022	T Cell Exhaustion and Activation Markers in Pancreatic Cancer: A Systematic Review. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	1
3033	In vitro re-challenge of CAR T cells. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
3052	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. <i>Experimental and Molecular Medicine</i> , 2023, 55, 2287-2299.	3.2	7
3054	Development of nano-immunotherapy for cancer treatment: achievements and scopes. <i>Journal of Pharmaceutical Investigation</i> , 2023, 53, 827-844.	2.7	0
3057	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. <i>3 Biotech</i> , 2023, 13, .	1.1	0
3067	Novel Targets in Development for Advanced Renal Cell Carcinoma. , 2023, , 309-342.		0
3069	Vitamin D and pancreatic cancer. , 2024, , 937-966.		0

#	ARTICLE	IF	CITATIONS
3087	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology, 0, , .	10.6	2
3094	Redirecting Human Conventional and Regulatory T Cells Using Chimeric Antigen Receptors. Methods in Molecular Biology, 2024, , 201-241.	0.4	0
3120	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0
3138	Roles of exosomes in immunotherapy for solid cancers. Cell Death and Disease, 2024, 15, .	2.7	0
3168	Lung Cancer Therapy: Synergistic Potential of PD-1/PD-L1 and CTLA-4 Inhibitors. , 2024, , 297-316.		0